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Abstract 
Acute myeloid leukemia (AML) involves the proliferation, abnormal survival and arrest of 
cells at a very early stage of myeloid cell differentiation. The biological and clinical 
heterogeneity of this disease complicates treatment and highlights the significance of 
understanding the underlying causes of AML, which may constitute potential therapeutic 
targets, as well as offer prognostic information. Tribbles homolog 2 (Trib2) is a potent 
murine oncogene capable of inducing transplantable AML with complete penetrance. The 
pathogenicity of Trib2 is attributed to its ability to induce proteasomal degradation of the 
full length isoform of the transcription factor CCAAT/enhancer-binding protein alpha 
(C/EBPα p42). The role of TRIB2 in human AML cells, however, has not been 
systematically investigated or targeted.  
Across human cancers, TRIB2 oncogenic activity was found to be associated with its 
elevated expression. In the context of AML, TRIB2 overexpression was suggested to be 
associated with the large and heterogeneous subset of cytogenetically normal AML 
patients. Based upon the observation that overexpression of TRIB2 has a role in cellular 
transformation, the effect of modulating its expression in human AML was examined in a 
human AML cell line that expresses high levels of TRIB2, U937 cells. Specific 
suppression of TRIB2 led to impaired cell growth, as a consequence of both an increase in 
apoptosis and a decrease in cell proliferation. Consistent with these in vitro results, TRIB2 
silencing strongly reduced progression of the U937 in vivo xenografts, accompanied by 
detection of a lower spleen weight when compared with mice transplanted with TRIB2-
expressing control cells. Gene expression analysis suggested that TRIB2 modulates 
apoptosis and cell-cycle sensitivity by influencing the expression of a subset of genes 
known to have implications on these phenotypes. Furthermore, TRIB2 was found to be 
expressed in a significant subset of AML patient samples analysed. To investigate whether 
increased expression of this gene could be afforded prognostic significance, primary AML 
cells with dichotomized levels of TRIB2 transcripts were evaluated in terms of their xeno-
engraftment potential, an assay reported to correlate with disease aggressiveness observed 
in humans. A small cohort of analysed samples with higher TRIB2 expression did not 
associate with preferential leukaemic cell engraftment in highly immune-deficient mice, 
hence, not predicting for an adverse prognosis. However, further experiments including a 
larger cohort of well characterized AML patients would be needed to clarify TRIB2 
significance in the diagnostic setting. Collectively, these data support a functional role for 
TRIB2 in the maintenance of the oncogenic properties of human AML cells and suggest 
TRIB2 can be considered a rational therapeutic target.  
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Proteasome inhibition has emerged as an attractive target for the development of novel 
anti-cancer therapies and results from translational research and clinical trials support the 
idea that proteasome inhibitors should be considered in the treatment of AML. The present 
study argued that proteasome inhibition would effectively inhibit the function of TRIB2 by 
abrogating C/EBPα p42 protein degradation and that it would be an effective 
pharmacological targeting strategy in TRIB2-positive AMLs. Here, a number of cell 
models expressing high levels of TRIB2 were successfully targeted by treatment with 
proteasome inhibitors, as demonstrated by multiple measurements that included increased 
cytotoxicity, inhibition of clonogenic growth and anti-AML activity in vivo. 
Mechanistically, it was shown that block of the TRIB2 degradative function led to an 
increase of C/EBPα p42 and that response was specific to the TRIB2-C/EBPα axis. 
Specificity was addressed by a panel of experiments showing that U937 cells (express 
detectable levels of endogenous TRIB2 and C/EBPα) treated with the proteasome inhibitor 
bortezomib (Brtz) displayed a higher cytotoxic response upon TRIB2 overexpression and 
that ectopic expression of C/EBPα rescued cell death. Additionally, in C/EBPα-negative 
leukaemia cells, K562 and Kasumi 1, Brtz-induced toxicity was not increased following 
TRIB2 overexpression supporting the specificity of the compound on the TRIB2-C/EBPα 
axis. Together these findings provide pre-clinical evidence that TRIB2- expressing AML 
cells can be pharmacologically targeted with proteasome inhibition due, in part, to 
blockage of the TRIB2 proteolytic function on C/EBPα p42.  
A large body of evidence indicates that AML arises through the stepwise acquisition of 
genetic and epigenetic changes. Mass spectrometry data has identified an interaction 
between TRIB2 and the epigenetic regulator Protein Arginine Methyltransferase 5 
(PRMT5). Following assessment of TRIB2‟s role in AML cell survival and effective 
targeting of the TRIB2-C/EBPα degradation pathway, a putative TRIB2/PRMT5 
cooperation was investigated in order to gain a deeper understanding of the molecular 
network in which TRIB2 acts as a potent myeloid oncogene. First, a microarray data set 
was interrogated for PRMT5 expression levels and the primary enzyme responsible for 
symmetric dimethylation was found to be transcribed at significantly higher levels in AML 
patients when compared to healthy controls. Next, depletion of PRMT5 in the U937 cell 
line was shown to reduce the transformative phenotype in the high expressing TRIB2 
AML cells, which suggests that PRMT5 and TRIB2 may cooperate to maintain the 
leukaemogenic potential. Importantly, PRMT5 was identified as a TRIB2-interacting 
protein by means of a protein tagging approach to purify TRIB2 complexes from 293T 
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cells. These findings trigger further research aimed at understanding the underlying 
mechanism and the functional significance of this interplay. 
In summary, the present study provides experimental evidence that TRIB2 has an 
important oncogenic role in human AML maintenance and, importantly in such a 
molecularly heterogeneous disease, provides the rational basis to consider proteasome 
inhibition as an effective targeting strategy for AML patients with high TRIB2 expression. 
Finally, the identification of PRMT5 as a TRIB2-interacting protein opens a new level of 
regulation to consider in AML. This work may contribute to our further understanding and 
therapeutic strategies in acute leukaemias. 
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1.1 Haemopoiesis 
Haemopoiesis describes the commitment and differentiation processes by which all blood 
cellular components are produced. In mammals, the anatomical sites of haemopoiesis 
change during development and sequentially include the yolk sac, an area surrounding the 
dorsal aorta termed the aorta-gonad mesonephros region, placenta, foetal liver and bone 
marrow (BM) – the primary adult haemopoietic centre (Orkin and Zon, 2008).The blood-
forming system is organized as a cellular hierarchy sustained at its apex by a rare 
population of haemopoietic stem cells (HSCs), which is defined by a dual capability of 
self-renewal and multilineage differentiation and has been isolated in both mice and human 
(Spangrude et al., 1988, Baum et al., 1992, Morrison and Weissman, 1994, Osawa et al., 
1996). The existence of the HSCs was firstly postulated by Arthur Pappenhein in 1917, as 
reviewed by (Huntly and Gilliland, 2005). In the 1950s, research evolved from 
experiments showing that an intravenous transplant of normal adult mouse BM cells could 
rescue irradiated mice from lethality by replacing the destroyed blood-forming system with 
a new and sustained source of lymphoid and myeloid cells (Jacobson et al., 1951, Ford et 
al., 1956). In 1961, Till and McCulloch demonstrated the existence of clonogenic BM cells 
that could give rise to multilineage haemopoietic colonies in the spleen of lethally 
irradiated mice. Some of these colonies contained a subset of clonogenic cells that could 
reconstitute haemopoiesis of irradiated mice in secondary transplants and thus where 
proposed to be HSCs (Till and McCulloch, 1961). The hallmarks of HSCs underlie the 
enormous utility of bone marrow transplantation as a clinical procedure (Weissman, 2000). 
During steady-state haemopoiesis, the BM HSCs are relatively quiescent (Bradford et al., 
1997, Cheshier et al., 1999) but upon cell cycle entry give rise to a hierarchy of 
differentiating progenitor populations that undergo the immense proliferative expansion 
required to replenish the mature and predominantly short-lived blood cells. HSCs can be 
divided into long-term reconstituting HSCs (LT-HSCs) and short-term reconstituting HSCs 
(ST-HSCs) (Figure 1.1). LT-HSCs maintain self-renewal and multilineage differentiation 
potential throughout life. ST-HSCs derive from LT-HSCs and exhibit more-limited self-
renewal potential, although preserving multipotency (Morrison and Weissman, 1994). ST-
HSCs differentiate into multipotent progenitors (MPPs) (Morrison et al., 1997) (Figure 
1.1), which do not or briefly self-renew and have the ability to differentiate into 
oligolineage-restricted progenitors that ultimately give rise to functionally mature cells of 
either lymphoid or myeloid lineage. The common lymphoid progenitors (CLPs) produce T 
lymphocytes, B lymphocytes and natural killer (NK) cells (Kondo et al., 1997) (Figure 
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1.1). On the other hand, common myeloid progenitors (CMPs) are responsible for 
generating granulocyte-macrophage progenitors (GMPs) - which undergo further 
restriction into granulocytes (basophil, neutrophil, eosinophil) and 
monocytes/macrophages- and megakaryocyte-erythroid progenitors (MEPs), which 
differentiate into megakaryocytes/platelets and erythrocytes (Akashi et al., 2000). Both 
lymphoid and myeloid differentiation can give rise to dendritic-cells (Manz et al., 2001) 
(Figure 1.1). Human and murine haemaopoiesis seem to be generally comparable, except 
for the unique combinations of cell surface markers that phenotypically identify HSCs and 
progenitor populations by fluorescence-activated cell sorting (FACS) (Doulatov et al., 
2012). 
 
Figure 1.1 The haemopoietic classic hierarchy 
HSCs, haemopoietic stem cells; LT-HSCs, long-term reconstituting HSCs; ST-HSCs, 
short-term reconstituting HSCs; MPPs, multipotent progenitors; CLPs, common lymphoid 
progenitors; NK, natural killer cells; CMPs, common myeloid progenitors; GMPs, 
granulocyte-macrophage progenitors; MEPs, megakaryocyte-erythroid progenitors; Pro-
DC, pro-dendritic cell; C/EBPα, CCAAT/enhancer binding protein-α.  
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Throughout the maturational pathways that direct transition from haemopoietic stem and 
progenitor cells to terminally differentiated blood cells, a tightly regulated network of 
transcription factors is highly important in defining cellular fates. Examples of these 
include Notch-1, GATA-3 and Pax5, which mediate T- and B-cell development; GATA-1 
and FOG-1, which are involved in the development of erythrocytes and megakaryocytes; 
and PU.1 and C/EBPα, which control the commitment of myeloid cells (Orkin, 2000, Xie 
and Orkin, 2007). The role of C/EBPα (further characterized in section 1.2.4) as a master 
regulator of granulopoiesis (Zhang et al., 1997) is highlighted in Figure 1.1, where it is 
shown to be expressed in HSCs and GMPs, downregulated as CMPs differentiate to MEPs 
and absent in precursors of lymphoid cells (Miyamoto et al., 2002). In addition to 
transcriptional regulation, signals from the BM niche (microenvironment), including the 
ones from cytokines and growth factors, are critical for the early cell fate decisions 
(Dorantes-Acosta and Pelayo, 2012). It was once considered that cellular differentiation 
was unidirectional, that is, once progenitors have committed to a particular linear pathway 
their fate is sealed due to precise combinations of lineage transcription factors and 
epigenetic modifications to the chromatin. However, the unidirectional and irreversible 
nature of the process has been questioned by a number of findings that, instead, support 
plasticity of early progenitor cells. Indeed, cells of one haemopoietic lineage can be 
redirected to another through forced expression of carefully chosen transcription factors or 
loss of these regulators, a process called cellular reprogramming (Orkin, 2000, Xie and 
Orkin, 2007). For example, introducing C/EBPα into B- or T-cells converts them into 
functional macrophages (Xie et al., 2004, Laiosa et al., 2006). Ectopic GATA-1 can also 
reprogram common B and T progenitor cells into megakaryocytic/erythroid cells (Iwasaki 
et al., 2003) while pro-B cells lacking Pax5 (Pax5
-/-
) are not restricted in their lineage fate 
(Nutt et al., 1999). 
The classical view of the blood hierarchy (Figure 1.1) has recently been challenged. In the 
murine system, the identification of lymphoid-primed multipotent progenitors (LMPP) 
argued that the megakaryocytic/erythroid lineage diverts earlier, without implicitly going 
through a shared CMP stage (Adolfsson et al., 2005, Mansson et al., 2007). Recently, 
Notta et al. added an additional layer of complexity by suggesting a developmental shift in 
the human progenitor cell architecture from the foetus, where many stem and progenitor 
cell types are multipotent, to the adult, where the stem cell compartment is multipotent but 
the progenitors are unipotent (Notta et al., 2015). While these and other studies challenge 
the classical view of haemopoiesis hierarchy, in the absence of a clear consensus on a 
revised model, the standard model is still used extensively as an operational paradigm. 
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Defects in the regulatory pathways that control haemopoiesis severely perturb normal 
development and lie at the root of haematological malignancies, such as leukaemia. 
1.2 Acute Myeloid Leukaemia  
Acute Myeloid Leukaemia (AML) is best understood by first describing the larger group of 
haemopoietic malignancies in which it is embedded, that is leukaemia. 
1.2.1 History and classification of leukaemia 
Reports from the early 19th century first establish the possibility that sustained 
leukocytosis could occur in the absence of infection. The first published description of a 
case of leukaemia in medical literature dates to 1827, when French physician Alfred 
Velpeau described a 63-year-old Parisian patient who was noted at post-mortem 
examination to have substantial enlargement of the liver and spleen, as well as blood 
resembling “gruel”. In 1845, a series of patients who died with enlarged spleens and 
changes in the "colours and consistencies of their blood" were reported by the Edinburgh-
based pathologist J.H. Bennett, who used the term "leucocythemia" to describe this 
pathological condition. In 1847, the German pathologist Virchow was credited with 
coining the term “leukaemia” (Greek for "white blood") to describe the abnormal excess of 
white blood cells in patients with the previously reported clinical syndrome (Beutler, 2001, 
Piller, 2001, Freireich et al., 2014). 
Leukaemia, nowadays a well-recognized distinct entity, is characterized by disruption of 
the processes directing self-renewal, differentiation and haemopoietic cell expansion, 
which leads to the accumulation of immature, non-functioning neoplastic cells. According 
to the American Cancer Society, an estimated 54,270 new cases of leukaemia were 
expected in 2015 (3% of total cancers) in the USA (American Cancer Society, 2015). 
Clinically and pathologically, the term leukaemia comprises a spectrum of haematological 
malignancies that are mainly subdivided in four categories: acute lymphocytic leukaemia 
(ALL), acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL) and 
chronic myeloid leukaemia (CML). According to progression of the untreated disease and 
maturity of the affected cells, leukaemia has traditionally been designated as acute or 
chronic. Acute forms of the disease progress rapidly and require prompt treatment. They 
target immature cells, causing symptoms to appear quickly. Chronic forms of leukaemia, 
on the other hand, target more mature cells and develop over long periods of time, with 
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symptoms arising often at later stages. The second factor in classifying leukaemia concerns 
the type of blood cells that are affected: lymphoblastic or myeloid, as outlined in Figure 
1.1. Symptoms are generally the same regardless of which cell is affected; the difference is 
mainly important for therapeutic-management of the patients. Some forms of leukaemia 
are far more common than others and rates of incidence also vary by age. In the USA, the 
majority (91%) of leukaemia cases are diagnosed in adults 20 years of age and older. 
Among adults, the most common types are CLL (36%) and AML (32%). In contrast, ALL 
is most common before age 20, accounting for 76% of cases. Overall leukaemia incidence 
rates have been slowly increasing over the past few decades; from 2007 to 2011, rates 
increased by 1.6% per year in males and 0.6% per year in females (American Cancer 
Society, 2015). 
1.2.2 Pathology, epidemiology and etiology of AML 
In AML, differentiation block and increased proliferation affect the myeloid lineage and 
result in the accumulation of abnormal immature cells (blasts) within the BM and blood, 
which are incapable of differentiating towards granulocytes or monocytes (Lowenberg et 
al., 1999). Infiltration of blasts, that replace normal cells in these tissues, causes the first 
clinical signs and symptoms usually found at presentation of AML - fatigue, haemorrhage 
or infections and fever due to decreases in red blood cells (anaemia), platelets 
(thrombocytopenia) or neutrophils (neutropenia), respectively. Leukaemic infiltration of 
other tissues, including the liver (hepatomegaly), spleen (splenomegaly), skin (leukaemia 
cutis), lymph nodes (lymphadenopathy), bone (bone pain) and central nervous system can 
produce a variety of other symptoms (Lowenberg et al., 1999). At least 20% of cells in a 
BM aspirate or circulating blood need to be blasts of myeloid lineage for disease diagnosis. 
Blast lineage is assessed by multiparameter flow cytometry with CD33 and CD13 being 
surface markers typically expressed by human myeloid blasts (Estey, 2012). 
While it can occur in children (usually during the first two years of life), the prevalence of 
AML increases with age and is generally a disease of elderly people with an average age at 
diagnosis of 70 years and more common in men than in women. The American Cancer 
Society estimated 20,830 new cases of AML (12,730 in men and 8,100 in women) to occur 
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in the USA in 2015, accounting for 32% of all leukaemia cases in adults 20 years of age 
and older (American Cancer Society, 2015)
1
.  
The vast majority of AML are sporadic and are the consequence of acquired somatic 
alterations in haemopoietic progenitor cells but association with risk factors has been 
reported. Congenital disorders such as Fanconi‟s anemia, Bloom‟s, Down‟s, Kostmann‟s 
and Diamond-Blackfan syndromes can increase the relative risk of developing AML. Risk 
is also increased in individuals with acquired haematologic disorders including the 
myeloproliferative and myelodysplastic syndromes and paroxysmal nocturnal 
haemoglobinuria. Therapy-related AML (t-AML) may develop as a consequence of 
exposure to chemotherapy, including alkylating agents, epipodophyllotoxins and ionizing 
radiation. Smoking is also reported as a risk factor to the development of AML associated 
with benzene exposure (Gilliland and Tallman, 2002, Estey and Dohner, 2006). 
1.2.3 AML classification  
AML comprises a group of disorders with great variability regarding clinical course and 
response to therapy. Diversity is also detected at the genetic and molecular basis of the 
pathology, which can be associated with chromosomal translocations, genetic mutations 
and transcription factors perturbations. Such heterogeneity has been used for disease 
stratification into specific subgroups to improve prognostication and support risk-adapted 
therapeutic management of AML patients. The first proposed standardized method of 
classification was that developed in 1976 by the French–American–British (FAB) 
Cooperative Group. The FAB system divides AML into seven distinct subtypes (M0 to 
M7) according to the myeloid lineage involved/degree of leukaemic-cell differentiation, 
and is based on conventional morphologic and histochemical analysis of peripheral blood 
(PB) and BM leukaemia blasts (Bennett et al., 1976, Bennett et al., 1985) (Table 1.1). 
While this method is still commonly used for morphologic diagnosis, progress made 
during recent years in deciphering the molecular basis of AML and in defining new 
diagnostic and prognostic markers, refined the classification approach. Hence, new 
standardized systems have been proposed, correlating cytogenetic and molecular genetic 
information with clinical data. Amongst them, the World Health Organization (WHO) 
                                         
1 Epidemiology of leukaemia and, in particular, AML here reported are based on the US population since the 
most recent and detailed data concerning this subject are provided by the American Cancer Society. 
However, information available from Cancer Research UK (www.cancerresearchuk.org) should be 
mentioned as well. According to this source, in 2013 AML accounted for 0.8% of all new cancer cases in the 
UK, and 32% of all leukaemia types combined. In the same year, there were 2,942 new cases of AML: 1,715 
(58%) in males and 1,227 (42%) in females. 
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classification for haematological malignancies is widely used by clinicians and categorizes 
the increasing number of acute leukaemias as distinctive clinico-pathologic-genetic 
entities. The 2008 revised fourth edition included AML with mutated nucleophosmin 
(NPM1) and AML with mutated CEBPA as provisional entities, and strongly 
recommended a routine mutational screen of NPM1, CEBPA and FMS-like tyrosine kinase 
3-ITD (FLT3-ITD) (Vardiman et al., 2009); genes afforded prognostic significance by 
other stratification models, such as the European Leukemia Net system (Dohner et al., 
2010). The 2016 edition (Table 1.1) represents a revision of the prior classification. 
Refinements in gene names are included as well as new provisional entities of AML (Arber 
et al., 2016). 
  Table 1.1 AML classification systems 
 
a APL, Acute Promyelocytic Leukaemia
b Further subdivided based on morphologic criteria similar to those of the FAB classification
M0
M1
M2
M3
M3v
M4
M4eo
M5a
M5b  Monocytic with differentiation
M6
M7
1  AML with recurrent cytogenetic abnormalities:
 -AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1
 -AML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBFβ-MYH11
 -APL
a
 with PML-RARα 
 -AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2A
 -AML with t(6;9)(p23;q34.1); DEK-NUP214
 -AML with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
 -AML (megakaryoblastic) with t(1;22)(p13.3;q13.3), RBM15-MKL1
 -provisional entities: AML with BCR-ABL1 , AML with mutated RUNX1
 -AML with mutated NPM1
 -AML with biallelic mutations of CEBPA
2  AML with myelodysplasia-related changes
3  Therapy-related myeloid neoplasm (t-AML)
4  Myeloid sarcoma
5  Myeloid proliferations associated with Down syndrome
6  Blastic plasmacytoid dendritic cell neoplasm
7  AML not otherwised specified (AML-NOS)
b
 Myelomonocytic 
 Myelomonocytic with eosinophilia
 Monocytic
 Erythroleukaemia
 Megakaryoblastic 
2016 release of the World Health Organization (WHO) Classification 
French-American-British (FAB) classification
 Undifferentiated 
 Myeloblastic without/with minimal maturation
 Myelobastic with maturation
 Promyelocitic-hypergranular; APL
a
 Promyelocitic-hypogranular variant; APL
a
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In addition, large collaborative studies have proposed risk stratification into favourable, 
intermediate or adverse groups based upon cytogenetic profile found at presentation 
(Grimwade et al., 1998, Grimwade et al., 2001). Non-random, clonal chromosome 
aberrations are detected in the leukaemic blasts of approximately 55% of adults with AML 
(Dohner and Dohner, 2008) and have long been recognized as important independent 
predictors for achievement of complete remission, risk of relapse and overall survival in 
AML (Mrozek et al., 2001). Patients carrying t(8;21)(q22;q22) leading to a fusion of 
RUNX1 gene to RUNX1T1 gene, inv(16)(p13.1q22) or t(16;16)(p13.1q22) both leading to 
the fusion of the CBF and MYH11 genes, or t(15;17) with the resulting PML-RARα 
rearrangement generally have a favourable prognosis. On the opposite side of the 
spectrum, patients with t(6;9), 11q23 (mixed lineage leukaemia (MLL) gene) 
abnormalities, monosomies of chromosomes 7 or 5 or showing complex karyotype 
(independent alterations of three or more chromosomes in the absence of t(8;21), inv(16) 
or t(16;16) and t(15;17)) have a distinctively poor prognosis (Löwenberg, 2001). The 
remaining large group of patients (~45%), with cytogenetically normal AML (CN-AML), 
are classified in the intermediate prognostic category (Walker and Marcucci, 2012). 
Specific mutations were also recently identified to predict AML outcome and improve risk 
stratification independent of historically recognized risk factors. That is the case of FLT3, 
NPM1, and C/EBPα recurrent molecular abnormalities, shown to improve risk 
stratification for patients with CN-AML (Walker and Marcucci, 2012), as further detailed 
below (section 1.2.4.2).  
1.2.4 Molecular pathogenesis of AML 
1.2.4.1 Two-hit model 
The observation that a single mutation appears generally insufficient for overt leukaemia to 
develop in mouse models supported the two-hit model of leukaemogenesis (Kelly and 
Gilliland, 2002, Speck and Gilliland, 2002). This hypothesis considers AML development 
to be a multistep process, requiring the collaboration of two classes (I and II) of mutations 
for transformation of a myeloid precursor. Class I mutations confer a survival/proliferation 
advantage and those that impair haemopoietic differentiation are included in class II 
(Figure 1.2). Survival or proliferative mutations typically involve activation of tyrosine 
kinase signaling (FLT3, c-KIT, RAS) or tyrosine phosphatase (PTPN11) pathways, while 
defects in myeloid differentiation often result from chromosomal translocations (e.g., 
generation of novel oncogenes such as RUNX1-RUNX1T1 or PML-RARα) or mutations in 
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CEBPA or NPM1 (Gilliland and Tallman, 2002, Renneville et al., 2008). However, not all 
the genetic aberrations that have been found in human AML fall within the two categories 
(Figure 1.2), implicating that the two-hit model may be an oversimplification. This is best 
exemplified by the growing evidence suggesting that changes in the epigenetic landscape 
have a role in leukaemia development and maintenance (Greenblatt and Nimer, 2014). 
Mutations affecting DNA (cytosine-5-) -methyltransferase 3 alpha (DNMT3A), additional 
sex combs like 1 (ASXL1), ten-eleven-translocated gene 2 (TET2) or isocitrate 
dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) genes were shown to be 
implicated in AML and could, therefore, be ascribed to a third important mechanistic 
pathway involving epigenetic regulators (O´Brien et al., 2014) (Figure 1.2). 
Modified from (O´Brien et al., 2014) 
Figure 1.2 Molecular pathogenesis of AML 
The Venn diagram depicts some of the key mutated genes found in AML. They are 
grouped according to the two-hit model classes (I and II) and are also included in new 
proposed classes.  
1.2.4.2 Recurrent genetic mutations 
1.2.4.2.1 Mutations in the epigenetic modifiers  
 
The use of next-generation sequencing techniques to sequence whole-genomes and exomes 
has identified several new molecular alterations in AML patients. Most of these mutations 
affect epigenetic regulation, as they involve genes encoding, IDH1 and IDH2, TET2, as 
well as DNMT3A. Mutations affecting IDH1 and its mitochondrial homolog, IDH2, occur 
in 15 to 20% of newly diagnosed AML patients, particularly in those with normal 
cytogenetics (Mardis et al., 2009, Abbas et al., 2010). The IDH metabolic enzymes convert 
isocitrate into α-ketoglutarate (α-KG), which is not only an intermediate in the Krebs 
cycle, but also affects normal function of several dioxygenases, including TET2. The IDH 
mutations are heterozygous and affect critical arginine (R) residues in the active site of the 
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enzyme: R132 in IDH1 and R140 and R172 in IDH2 (Chou et al., 2011). The subsequent 
amino acid substitution prevents the normal catalytic function of the enzyme and results in 
the conversion of α-KG to 2-Hydroxyglutarate (2-HG), which is a competitor inhibitor of 
dioxygenases (Dang et al., 2009). In AML it has been show that the accumulation of this 
putative oncogenic metabolite not only blocks the function of TET2 protein, leading to 
aberrant DNA methylation, but also impairs histone demethylation and interferes with 
normal differentiation of cells. IDH1/2 mutations and TET2 mutations, which lead to loss 
of function, are associated with similar epigenetic defects (Figueroa et al., 2010). 
Moreover, Chaturvedi and colleagues found that mutant IDH1 in combination with 
homeobox 9 (HoxA9) greatly accelerates leukaemogenesis in a murine model (Chaturvedi 
et al., 2013). While the prognostic impact of IDH-mutations is still controversial (Thiede, 
2012), the effect of mutations in the DNMT3A appears to be more consistent across studies. 
DNMT3A mutations are an unfavourable prognosis biomarker in AML (Renneville et al., 
2012, Shivarov et al., 2013). The overall prevalence is ~18-23% and is particularly higher 
in CN-AML (29-36%) (Thiede, 2012). The majority of DNMT3A somatic mutations are 
missense alterations in the R882 residue located near the carboxyl terminus of the 
DNMT3A protein. DNMT3A belongs to a family of DNA-methyltransferases whose role 
is to catalyse the addition of methyl groups onto the 5′-position of cytosine residues of 
CpG dinucleotides. However, the function and biological consequences of DNMT3A 
mutations in AML have yet to be fully elucidated (Im et al., 2014). Ferreira and colleagues 
have recently reported that in the absence of MLL-fusion proteins, an alternative pathway 
for engaging a leukaemogenic MEIS1-dependent transcriptional program can be mediated 
by DNMT3A mutations (Ferreira et al., 2015). 
1.2.4.2.2 NPM1 
 
NPM1 is the most common single gene mutated in AML (30-35%) (Thiede, 2012). 
Alterations in NPM1 gene encoding a nucleocytoplasmic shuttling protein with prominent 
nucleolar localization are almost exclusively detected in AML. They consist of a 4 base 
pair (bp)-frameshift mutation occurring in exon 12 that converts a nucleolar localization 
signal into a nuclear export signal, resulting in aberrant cytoplasmic localization in the 
AML blasts (Falini et al., 2005). 50% of the CN-AML patients are identified with a mutant 
NPM1, also frequently associated with alterations in FLT3, DNMT3A and IDH1/2 genes. 
As a result, NPM1-mutated AML was defined as a distinct leukaemia entity by the WHO 
classification (Table 1.1), shown to be a predictor for a favourable outcome in the absence 
of FLIT3-ITD mutations (Dohner et al., 2005, Schnittger et al., 2005, Thiede et al., 2006).  
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1.2.4.2.3 FLIT3 
 
Two major types of mutations affecting the FLIT3 receptor kinase have been described in 
AML patients. Internal tandem duplication (ITD) mutations of the juxtamembrane region 
are present in 15-20% of AML (Nakao et al., 1996), particularly in certain cytogenetically 
defined groups, as CN-AML, t(15;17) and t(6;9). Also, patients carrying NPM1 and 
DNMT3A mutations more often display FLIT3-ITD (Thiede, 2012). The other predominant 
type of mutations are missense single base pair exchanges in the second tyrosine kinase 
domain, typically involving codon D835. They are also more prevalent in patients with 
normal karyotype and are commonly detected in association with NPM1 and inv(16) 
(Thiede, 2012). Both lead to constitutive activation of the FLT3 protein, expressed on early 
haemopoietic progenitor cells, and while FLIT3-ITD mutations are generally associated 
with poor outcome (Estey, 2010), debate exists on whether mutations in the tyrosine kinase 
domain are either irrelevant for prognosis (Thiede et al., 2002) or associated with inferior 
outcome (Whitman et al., 2008).  
1.2.4.2.4 CEBPA 
 
CEBPA (19q13.1) encodes the transcription factor C/EBPα and is the most commonly 
studied gene in AML, with a mutational frequency of ~9% across this disease. Mutations 
are particularly higher in the M2 subtype (up to 20%) and in the CN-AML patients (15%) 
(Nerlov, 2004, Thiede, 2012). C/EBPα is a member of the basic-region leucine zipper (BR-
LZ) family of transcription factors and consists of highly homologous C-terminal DNA-
binding (basic-region) and dimerization (leucine zipper) motifs and two less conserved N-
terminal transactivation domains (TAD 1 and TAD 2), via which transcription is activated 
(Tenen et al., 1997) (Figure 1.3). C/EBPα was originally isolated as a rat liver transcription 
factor regulating hepatic and adipocyte genes (Cao et al., 1991, Watkins et al., 1996, 
Timchenko et al., 1996) and controls the proliferation and differentiation of various cell 
types (Hendricks-Taylor and Darlington, 1995). Within haemopoiesis, its expression is 
detected in early myeloid progenitors, specifically upregulated in myeloid cells undergoing 
granulocytic differentiation and rapidly downregulated during the alternative monocytic 
pathway (Scott et al., 1992, Radomska et al., 1998). Accordingly, C/EBPα knockout mice, 
which die at birth because of severe hypoglycemia, display a complete lack of mature 
granulocytes. Adult mice with induced loss of C/EBPα have normal numbers of CMPs but 
are devoid of GMPs and consecutive granulocytic stages but not monocytes, indicating that 
C/EBP is essential for the transition of CMPs to GMPs (depicted in Figure 1.1) (Wang et 
al., 1995, Zhang et al., 2004b). C/EBPα‟s critical role in lineage commitment during 
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haemopoietic differentiation is executed by coupling the direct transcriptional activation of 
myeloid-specific genes with the arrest of cell proliferation (Nerlov, 2004). CEBPA is an 
intronless gene whose mRNA can be differentially translated into two isoforms of 42 kDa 
(p42) and 30 kDa (p30) by usage of alternative start AUG codons within the same open 
reading frame. C/EBPα-p30 lacks the N-terminal transactivation domain TAD 1 that is 
only present on the full-length form (Lin et al., 1993). As a consequence, the p30 isoform 
lacks domains mediating the contact with the transcriptional apparatus, whereas other 
functions such as dimerization or regions involved in protein-protein interactions are 
preserved in both p30 and p42 proteins (Figure 1.3). Hence, only the p42 isoform of 
C/EBPα can promote proliferation arrest and is able to induce differentiation of 
granulocytes (Kirstetter et al., 2008).  
 
Figure 1.3 Diagram of C/EBPα 
Two transactivation domains (TAD1, TAD2) are depicted as well as a basic region (BR) 
mediating DNA binding and a leucine zipper region (LZ). The protein translated from the 
AUG at amino acid 1 encodes the p42 isoform whereas the 30 kDa form is translated from 
the AUG at amino acid 120. 
Regulation of the p42/p30 ratio controls cell proliferation and differentiation. Initially, the 
generation of truncated cellular C/EBP isoforms was proposed to occur via differential 
translation initiation from internal AUG codons through a mechanism called leaky 
scanning of ribosomes (Descombes and Schibler, 1991, Lin et al., 1993, Ossipow et al., 
1993). However, it has been suggested that instead cells regulate the p42/p30 ratio by 
responding to extracellular conditions. Under nutrient- or growth factor-rich conditions, 
proliferation is promoted by increasing the activity of eukaryotic translation initiation 
factors eIF-2α/eIF-4E, possibly through an increase in c-MYC activity (Rosenwald et al., 
1993). High eIF-2α/eIF-4E activity leads to an increased production of p30 at the expense 
of p42, as eIF-2α and eIF-4E promote the translation of a small upstream open reading 
frame (uORF) that results in a bypass of the p42 initiation codon. When levels of factors 
eIF2α and eIF4E are low, translation is primarily initiated from the p42 start codon 
(Calkhoven et al., 2000). 
NH2
p42
AUG
COOHBRTAD1 TAD2
p30
AUG
LZ
1                            70            97                127                    200                                    278  358         
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The spectrum of CEBPA mutations observed in AML patients includes two main 
categories affecting the N- or C-terminus. The N-terminal frame-shift mutations abolish 
p42 protein expression while retaining the truncated-C/EBPα isoform (p30), initiated 
further downstream from an internal translational start site. The C-terminal mutations 
generate in-frame insertions/deletions within the BR-LZ region that compromise DNA 
binding of both isoforms and may result in dominant-negative homodimers or 
heterodimers with other C/EBP family members (Nerlov, 2004). These two classes of 
mutations often co-occur in a biallelic manner and double mutations in CEBPA, but not 
single, have been identified as an independent favorable prognostic factor in 
cytogenetically normal AML patients by several studies (Wouters et al., 2009, Pabst et al., 
2009, Dufour et al., 2010, Taskesen et al., 2011, Fasan et al., 2014). 
Besides mutations in the N- and C-terminus, other molecular mechanisms are responsible 
for C/EBPα inactivation or modulation. These include inhibition of transcription due to the 
leukaemic fusion protein AML1-ETO (Pabst et al., 2001) or CEBPA promoter methylation 
(Wouters et al., 2007), and post-translational modifications, such as phosphorylation of 
serine 21 by ERK1/2 (Ross et al., 2004) and the p38 MAP kinase (Geest et al., 2009). 
Moreover, C/EBPα protein expression can also be modulated by proteasomal degradation 
mediated by Trib1 or Trib2, which are members of the Tribbles family of proteins.  
 
1.3 Tribbles 
1.3.1 Introduction to the Tribbles family 
The tribbles gene was first identified in the year 2000 in Drosophila mutational screens for 
genes that control cell division and migration. Drosophila tribbles was found to mediate 
degradation of the CDC25 homolog String, resulting in a protracted G2/M transition 
during gastrulation and morphogenesis (Grosshans and Wieschaus, 2000, Mata et al., 2000, 
Seher and Leptin, 2000). In addition, Drosophila tribbles was shown to regulate oogenesis 
by inducing ubiquitination and proteasomal degradation of the protein encoded by the gene 
slow border cells (slbo), the Drosophila homolog of C/EBP transcription factors (Rorth et 
al., 2000). Drosophila tribbles was named after the fictional animals featuring Star Trek 
television series that first appeared in the episode titled „„The Trouble with Tribbles”. 
Phenotype displayed by fly genes are in the origin of their names and Seher et al. (Seher 
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and Leptin, 2000) observed that the over-proliferating mesodermal cells seen in tribbles 
mutant embryos resembled these furry and fecund animals.  
Tribbles encodes an evolutionarily conserved protein family. Currently, there are three 
known mammalian homologs of the tribbles gene: TRIB1⁄C8FW⁄SKIP1, 
TRIB2⁄C5FW⁄SKIP2⁄SINK and TRIB3⁄NIPK⁄SKIP3. The first member of the mammalian 
Tribbles family to be discovered was TRIB2 as an mRNA upregulated in the dog thyroid 
upon stimulation by mitogens (Wilkin et al., 1996, Wilkin et al., 1997). The amino acid 
sequences of Tribbles are highly conserved among human and mouse (TRIB1, 97.5%; 
TRIB2, 99.2%; TRIB3, 81.2%) and also within the human family of sequences 
(TRIB1⁄TRIB2, 71.3%; TRIB1⁄ TRIB3, 53.3%; TRIB2⁄ TRIB3, 53.7%) (Yokoyama and 
Nakamura, 2011). The Tribbles family structurally shares three motifs that contribute to 
function:  an N-terminal region, a central  pseudokinase domain and a C-terminal region 
(Figure 1.4).  
 
Figure 1.4 The structure of Tribbles proteins 
 
The N-terminal regions are barely conserved between Drosophila and the three 
mammalian Tribbles. They are a relatively short sequence of the Tribbles protein (60 to 80 
amino acid), characterized by a high serine and proline content (PEST). PEST regions are 
indicative of proteins with short half-lives. A putative nuclear localization signal, 
[K⁄R]2X2[D⁄E]X[D⁄  E], has been proposed by Hegedus et al. and it is well conserved in the 
three mammalian  Tribbles  (Hegedus et al., 2007). Flanked by the N- and C-terminal 
sequences, the serine/threonine kinase-like domain is the defining feature of the Tribbles 
family and is highly conserved among orthologues throughout evolution (Hegedus et al., 
2006). A canonical kinase domain consists of 12 subdomains, many of which include 
conserved sequence patterns of functional importance. The family of Tribbles proteins 
retains an invariant lysine residue necessary for adenosine triphosphate (ATP) orientation 
in subdomain II and also a catalytic aspartate residue in the DLKLRKF sequence in 
subdomain VIB of canonical kinases (Hegedus et al., 2007). Moreover, the predicted 3D 
structure of Tribbles proteins is consistent with that of a protein kinase (SWISS-MODEL) 
NH2
N-terminal domain C-terminal domainPseudokinase domain
PEST motif
COOH
MEK1
binding
COP1
binding
Catalytic
loop
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(Hegedus et al., 2007). However, the consensus ATP-binding pocket is highly divergent 
between the conventional kinases and the kinase-like domain of Tribbles proteins (Seher 
and Leptin, 2000). The complete lack of GXGX2GXV motif in subdomain I, the loss of 
histidine and asparagine in HRDLKX2N in the catalytic cleft VIB and lack of the DFG 
(Asp-Phe-Gly) triplet in VII are important variations specific to Tribbles. They affect 
anchoring of ATP, phosphate transfer and Mg2+ chelation, which is necessary for catalysis 
and ATP orientation (Hegedus et al., 2007). Given these sequence characteristics that 
define Tribbles as pseudokinases (proteins which have a kinase-like domain lacking 
canonical motifs) it is believed that none of the Tribbles possess kinase activity and, 
indeed, specific Tribbles substrates are yet to be identified. However, such view has 
recently been challenged by Bailey and colleagues that reported a vestigial kinase activity 
in TRIB2 and TRIB3 pseudokinases (Bailey et al., 2015). With regards to the Tribbles C-
terminal domain, two important motifs have been identified within this region: an E3 
ubiquitin ligase  COP1  (constitutive photomorphogenic 1) binding motif [D/E]QXVP[D/E] 
that triggers the ubiquitin-proteasome machinery for targeted protein degradation, and a 
MEK1 [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated 
kinase) kinase 1] binding site, ILLHPWF. Both the COP1- and MEK1-binding motifs are 
highly conserved in mammalian Tribbles homologues (Qi et al., 2006, Yokoyama and 
Nakamura, 2011). The presence of these two distinct protein-binding sites (Figure 1.4) 
highlights the functionally diverse roles of Tribbles as scaffold proteins, mediating 
degradation and changes to signalling pathways. In support of that, X-Ray structures were 
reported for COP1 WD40 domains with the binding motif of TRIB1 (Uljon et al., 2016). 
Also, Murphy et al. described the first crystal structure of a Tribbles pseudokinase, that of 
TRIB1. Further functional studies showed that TRIB1 recognizes a conserved stretch 
within a transactivation domain of C/EBP proteins and a model was suggested by which 
TRIB1 acts as a dynamic adapter for recruiting C/EBPs to COP1 (Murphy et al., 2015). 
Any of the interaction motifs described in Tribbles can be potentially suitable for small 
molecule ligand targeting. Foulkes and colleagues have begun to analyse small molecules 
that bind to TRIB2 using differential scanning fluorimetry (DSF) analyses (Foulkes et al., 
2015). 
1.3.2 Tribbles in AML 
Both Trib2 and Trib1 overexpression can independently drive AML in mouse bone 
marrow transplantation (BMT) models (Keeshan et al., 2006, Dedhia et al., 2010). Trib2 
and Trib1 transduced cells were found to exhibit growth advantage in vitro, as 
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overexpression of both genes conveyed serial plating potential to murine BM cells (Dedhia 
et al., 2010). In the BMT model, Trib2 was found to drive the induction of murine AML 
with a robust and short latency. Trib2 promotes monocyte and inhibits granulocytic 
differentiation in mice thereby perturbing myeloid development in vivo. However, the 
leukaemias that Trib2 gives rise to are clonal and this suggests that a secondary hit is 
occurring in order to give rise to overt AML (Keeshan et al., 2006). Both Trib2 and Trib1 
can cooperate with other genes to induce murine AML. Trib1, by itself a transforming gene 
for myeloid cells, was first discovered as a cooperating gene in a murine model of 
HoxA9/Meis1 myeloid leukaemogenesis, in which it was shown to accelerated disease 
onset (Jin et al., 2007). Later, it was discovered that Trib2 also cooperates with HoxA9 in 
the induction of myeloid leukaemia, as mice reconstituted with HSCs co-transduced with 
Trib2 and HoxA9 have an accelerated onset of AML when compared to either gene alone 
(Keeshan et al., 2008). Trib2 has also been separately linked to Meis1 leukaemogenic 
activity. Trib2 was identified as a downstream target gene of Meis1 in Meis1 ⁄NUP98-
HOXD13 leukaemia cells, being suggested that Trib2 replaces Meis1 function in 
leukemogenesis (Argiropoulos et al., 2008). 
Unlike Trib2 and Trib1, ectopic expression of Trib3 cannot convey serial plating potential 
to transduced murine bone marrow nor can it induce murine AML (Dedhia et al., 2010). 
Trib2 and Trib1 differential capacity to induce leukaemia is linked to the ability of these 
proteins to degrade the full-length isoform of C/EBPα protein in hematopoietic cells, 
inducing a block of myeloid differentiation. Both Trib2 and Trib1 induce this degradation 
by complexing with the E3 ligase COP1 and this cooperation has been confirmed by in 
vivo experiments (Keeshan et al., 2010, Yoshida et al., 2013). Mutants of both proteins 
lacking a conserved COP1-binding site are unable to induce murine AML, indicating that 
this binding site is crucial for their leukaemic activity (Keeshan et al., 2010, Yokoyama et 
al., 2010).. Trib3, instead, links COP1 ligase to lipid metabolism. Trib3 stimulates lipolysis 
during fasting and loss of insulin signalling by triggering the degradation of the enzyme 
promoting fatty acid synthesis (acetyl-coenzyme A carboxylase) in adipose tissue (Qi et 
al., 2006). 
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1.3.3 TRIB2  
TRIB2 was identified as a direct NOTCH1-regulated transcript in a distinct subset of 
immature AML with silenced CEBPA and a mixed myeloid/T-lymphoid phenotype 
(Keeshan et al., 2006, Wouters et al., 2007). As described above, Trib2 was found to cause 
fatal transplantable AML when introduced in murine hematopoietic stem cells in vivo 
(Keeshan et al., 2006), but its tumorigenic activity is not limited to leukaemia. In fact, there 
is accumulating evidence indicating broad involvement of TRIB2 in both solid and non-
solid malignancies. In melanoma, TRIB2 mediates downregulation of the tumour 
suppressor FOXO3a by promoting its cytoplasmic sequestration and impairing its 
transcriptional control function (Zanella et al., 2010). In lung cancer, TRIB2 acts as a 
tumorigenic driver through a mechanism involving association with the E3 ligase TRIM21 
and downregulation of the C/EBPα transcription factor (Zhang et al., 2012, Grandinetti et 
al., 2011). TRIB2 was also identified as a critical downstream effecter of Wnt signalling in 
liver cancer cells (Wang et al., 2013a). TRIB2 was found to downregulate the Wnt 
signalling key factors β-catenin and transcription factor 4 (TCF4) through its associated E3 
ligases Smad ubiquitination regulatory factor 1 (Smurf1), βTrCP and COP1. The binding 
region of Smurf1 encompasses amino acids 1–5 in the N-terminal region of TRIB2 protein. 
The binding region of βTrCP encompasses TRIB2 amino acids 307–323, and the binding 
region of COP1 encompasses TRIB2 amino acids 324–343, both in the C-terminal domain. 
Deletion of the binding regions of these E3-ligases within the TRIB2 protein abolished its 
ability to decrease protein stability of β-catenin and TCF4 (Xu et al., 2014). In T-cell ALL 
(T-ALL), TRIB2 was identified as a direct target for upregulation by the oncogenic 
transcription factor TAL1 and found to be required for the survival of T-ALL cells (Sanda 
et al., 2012). 
It is noteworthy that TRIB2 expression was found to be elevated in the cancers in which it 
has an oncogenic role, highlighting the importance of understanding how its expression is 
governed. Indeed, several mechanisms underlying the regulatory network of TRIB2 have 
been identified in different cell contexts. These include the previously mentioned 
NOTCH1 (Wouters et al., 2007), MEIS1 (Argiropoulos et al., 2008) and TAL1 (Sanda et 
al., 2012), as well as GATA2, FOG1 (Mancini et al., 2012) and PITX1 (Nagel et al., 2011). 
A number of microRNAs also regulate the expression levels of TRIB2, including but not 
limited to miR-511, miR-1297 (Zhang et al., 2012), miR-99 (Zhang et al., 2013), miR-155 
(Palma et al., 2014), and let-7 (Wang et al., 2013c). Moreover, the E3 ligase Smurf1 is also 
involved in the ubiquitination and proteasomal degradation of TRIB2 in liver cells, that 
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requires the phosphorylation of TRIB2 at Serine 83 by P70 S6 kinase (P70S6K) (Wang et 
al., 2013b). Stability and ubiquitination of TRIB2 in liver cells is additionally thought to be 
negatively regulated by the E3 ligase complex SKIP1-CUL1 (Cullin)-F-box (SCF) βTrCP 
(Qiao et al., 2013).  
Collectively, the current knowledge on TRIB2 points towards a network of both regulatory 
molecules and binding partners in which TRIB2 acts as a powerful oncogene. This is an on-
going research, with new mechanisms yet to be identified. Significant for the current study, 
previous studies have connected TRIB2 with two protein arginine methyltransferases 
(PRMTs). Interaction with PRMT6 was reported by a yeast two-hybrid screening approach 
involving short-read second-generation sequencing (Weimann et al., 2013). TRIB2 was 
also recently associated with the post-translational modifier PRMT5 by a mass 
spectrometry assay (data from Prof Claire Eyers, University of Liverpool, further included 
in (Uljon et al., 2016)) and this will be detailed in Chapter 5. It is also significant that the 
tumorigenic role of TRIB2 is often associated with its ability to promote degradation of 
key substrates, whose stability and downstream targets are affected. This happens via 
association with E3 ubiquitin ligase enzymes and engagement of the ubiquitin proteasome 
system (UPS), hence considered an attractive therapeutic target and further discussed.  
 
1.4 The proteasome as a therapeutic target 
1.4.1 The UPS 
Two main routes have been identified for intracellular eukaryotic protein degradation 
involving either lysosomes or proteasomes. Transmembrane proteins and proteins that 
enter the cell from the extracellular milieu after endocytosis are degraded in lysosomes, a 
proteolytic pathway that occurs mostly under stressed conditions. Proteasomes, via the 
UPS, are in turn, responsible for the highly selective turnover of intracellular proteins that 
occurs either under basal metabolic conditions or stress (Ciechanover, 1994). This 
mechanism of proteolysis was discovered at the beginning of the 1980s by Aaron 
Ciechanover, Avram Hershko and Irwin Rose, which resulted in the three scientists from 
the Fox Chase Cancer Center (Philadelphia, USA) being jointly awarded with the 2004 
Nobel Prize in Chemistry for the discovery of “ubiquitin-mediated protein degradation”. 
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The UPS plays a central role in maintaining cellular protein homeostasis through the 
targeted degradation of approximately 80% of intracellular proteins. Selected targets are 
damaged, misfolded and short-lived regulatory proteins that control critical cellular 
functions, including cell cycle control, transcription, DNA damage repair, protein quality 
control and antigen presentation. Degradation via the UPS involves two distinct and 
consecutive steps: covalent attachment of multiple ubiquitin (Ub) molecules to a protein 
substrate and proteasomal degradation (Ciechanover, 1998). 
1.4.1.1 Ubiquitination and ubiquitin as a versatile cellular signalling 
Ub-labelling of proteins is known as ubiquitination and is mediated by a sequential series 
of enzymatic activities. An E1 Ub-activating enzyme, that can be either Ube1 or Ube1-L2, 
activates Ub in an ATP-dependent manner and connects it to one of several Ub-
conjugating enzymes (E2). The activated Ub is then transferred to a target protein by a 
member of the E3 Ub-ligase family (Hershko and Ciechanover, 1998, Jariel-Encontre et 
al., 2008). Anchoring of the Ub moiety to the substrate occurs by covalent attachment to 
the amino (-NH2) group of either the N-terminal residue (Breitschopf et al., 1998, Aviel et 
al., 2000, Reinstein et al., 2000) or internal lysine(s) (Glickman and Ciechanover, 2002). 
Replication of the three-step enzymatic cascade generates a poly-Ub chain that marks the 
protein for degradation in the proteasome (Figure 1.5A). Ubiquitination can be reversed 
through the action of deubiquitinating enzymes (DUBs). Balance between the opposing 
actions of ubiquitin ligases an DUBs plays a critical role in regulating protein turnover and 
function (Hochstrasser, 1995). 
Ub chains of at least four molecules that form through their lysine residues at position 48 
(K48) seem to invariably flag the protein for proteasome-mediated degradation (Thrower 
et al., 2000), even if some proteins enter this proteolytic route without the requirement of a 
Ub-tag, e.g., ornithine decarboxylase (Murakami et al., 1992), p21/Cip1 (Sheaff et al., 
2000), retinoblastoma (Rb) family of proteins (Kalejta and Shenk, 2003), hypoxia-
inducible factor 1 (Kong et al., 2007), calmodulin and troponin C (Benaroudj et al., 2001). 
Given that Ub has seven acceptor lysines, the highly evolutionarily conserved 76-amino-
acid molecule can also be conjugated via its K6, 11, 27, 29,33 and 63, forming chains with 
variable lengths and linkage types (Ikeda and Dikic, 2008). Ub can also modify substrate 
proteins in its monomeric form. Such different post-translational modifications serve, 
however, alternative purposes to proteolytic degradation. Mono-ubiquitination instead 
controls cellular processes such as regulation of transcription, DNA repair, cellular 
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localization, epigenetic events and protein trafficking in the endocytic pathway (Hicke, 
2001, Raiborg et al., 2006). Also the formation of K63-linked poly-ubiquitin chains seem 
to serve purposes that partially overlap those of the mono-ubiquitination, including 
intracellular trafficking, transcription, DNA repair and replication (Pickart and Eddins, 
2004, Haglund and Dikic, 2005).  
1.4.1.2 Proteasomal degradation 
Substrate proteins tagged with K48-linked Ub polymers are degraded to small peptides by 
the 26S proteasome. The 26S or constitutive proteasome is a multi-subunit complex 
localized in both the nucleus and the cytoplasm of eukaryotes. It combines two 19S 
regulatory caps, which contain ATPases and act as a recognition and entry site for proteins 
destined for proteolysis, with a central core termed the 20S proteasome (Figure 1.5B). In 
the 19S particle, free and recyclable Ub molecules are released and the target protein is 
unfolded, linearized and fed into the 20S proteasome (Groll et al., 2000, Navon and 
Goldberg, 2001), a cylindrical structure composed of four heptameric rings that create a 
chamber for proteolysis to occur. The two outer rings are composed of -subunits, whereas 
seven distinct -subunits form the two inner rings. At least 3 of the -subunits harbor the 
proteolytically active sites of the proteasome (Groll et al., 1997) that are classified upon 
preference to cleave after a particular amino acid residue. The three catalytic activities, 
chymotrypsin-like (CT-L), trypsin-like (T-L) and caspase-like (C-L) are encoded by 
separate polypeptides, 5, 2 and 1, respectively (Figure 1.5B).  
An alternative proteasome isoform known as the immunoproteasome can be formed 
predominantly in haemopoietic cells and in cells that have been exposed to gamma-
interferon (IFN-) or particular proinflammatory cytokines (Akiyama et al., 1994, 
Stohwasser et al., 1997, Sijts and Kloetzel, 2011). The immunoproteasome expresses 
subunits LMP7, MECL1 and LMP2 in place of 5, 2 and 1, altering the proteasome to 
favour the generation of antigenic peptides to be presented by the major histocompatibility 
complex (MHC) class 1 molecules and, thus, potentiating the immune system response 
(Rock et al., 1994). 
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Figure 1.5 The ubiquitin proteasome system (UPS) for protein degradation 
(A) The UPS is responsible for the degradation of poly-ubiquitinated proteins formed by a 
cascade of E1, E2 and E3 enzymes, which activate, conjugate and transfer multiple 
ubiquitin (Ub) moieties to protein substrates to be degraded, allowing tight regulation and 
high selectivity of degradation. (B) The functionally active 26S proteasome is a 2.4 MDa 
ATP-dependent proteolytic complex that consist of a 20S catalytic cylindrical complex 
capped at both ends by 19S regulatory subunits. Ub molecules are removed at the 19S cap 
through interaction with the outer α-rings and the protein is unfolded and fed into the inner 
catalytic chamber of the 20S proteasome, where the protein is cleaved into small peptides 
using 3 main catalytic activities, chymotripsin-like (CT-L), trypsin-like (T-L) and caspase-
like (C-L). 
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Given the important role that the UPS plays in regulating protein stability and thus normal 
cellular function, it is not surprising that aberrant activity of this system has been 
implicated in a variety of pathologies, including Alzheimer´s Disease (Keller et al., 2000a), 
ischaemic stress (Keller et al., 2000b), diabetes (Broca et al., 2014) and cancer (Arlt et al., 
2009, Yu et al., 2009), in which haematological malignancies are included (Crawford and 
Irvine, 2013). UPS abnormalities have been described as a result of deregulation in 
regulatory pathways that are mediated by proteasome substrates, rather than specific 
defects in proteasome structure or function (Adams, 2004). 
1.4.2 Targeting the UPS  
Targeting intracellular protein turnover by inhibiting the UPS has recently emerged as a 
rational strategy for cancer therapy. The catalytic molecular properties of the proteasome 
have been exploited chemically and pharmacological interference with UPS-mediated 
proteolysis has been validated by a class of compounds collectively referred to as 
proteasome inhibitors. 
The possibility of targeting the proteasome for cancer therapeutics, although initially 
doubted due to the essential role the UPS plays in critical biological processes, was well 
supported by a wealth of experimental data. Pre-clinical results showed proteasome 
inhibitors to be well tolerated with activity against in vivo models bearing human 
malignancies (Orlowski et al., 1998). Moreover, it has been demonstrated that malignant 
cells harbor elevated proteasome activity compared with normal cells (Arlt et al., 2009, Ma 
et al., 2009) and have been shown to be relatively more sensitive to the effects of 
proteasome inhibitors than their non-malignant counterparts. This differential susceptibility 
was suggested to be associated with a higher dependency of highly proliferative malignant 
cells on the proteasome system to remove aberrant proteins. Another explanation is that 
inhibition of the proteasome activity interferes with cell-cycle or apoptosis molecules that 
have caused the development or maintenance of the cancerous phenotype (Adams et al., 
1999)  
Most proteasome inhibitors are based on peptides that serve as active-site analogs, which 
bind to the proteasome subunits. Eight classes of proteasome inhibitors have been 
recognized across natural compounds and synthetic molecules (peptide aldehydes, peptide 
vinyl sulfones, syrbactins, peptide boronates, peptide epoxyketones, peptide 
ketoaldehydes, β-lactones and oxatiazol-2-ones). Only representative members of some 
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classes have reached the stage of clinical trials investigations in cancer. Many have failed 
due to the lack of specificity and/or toxicity in preclinical studies. Potent inhibition of the 
CT-L activity of the proteasome is a shared property of the clinically relevant proteasome 
inhibitors (Bennett and Kirk, 2008) and is suggested to be a necessary feature of these 
drugs to produce an anti-tumor response (Parlati et al., 2009).  
1.4.2.1 Bortezomib 
The modified dipeptidyl boronic acid bortezomib (Brtz, former name PS-341, brand name 
Velcade) (Palombella et al., 1998, Adams et al., 1999) was the first proteasome inhibitor to 
be introduced into medical practice. Supported by preclinical and clinical studies, the US 
Food and Drug Administration (FDA) approved in 2003 and 2006 the use of Brtz for the 
treatment of multiple myeloma and mantle cell lymphoma, respectively (Kane et al., 2003, 
Kane et al., 2007). Moreover, the selective and reversible inhibitor of the CT-L (β5 and 
LMP7) subunit has shown in vitro and in vivo activity against a variety of other 
haematological malignancies and solid tumours, either as a single agent or as a part of 
combination therapy (Chen et al., 2011). Therapeutic proteasome inhibition has shown, 
however, better results in blood cancers than in solid tumours (Orlowski and Kuhn, 2008) 
and this could be due to the fact that leukaemic cells express high levels of proteasomes 
(Kumatori et al., 1990). 
1.4.2.2 Other UPS inhibitors 
The development of Brtz has transformed the treatment of multiple myeloma and mantle 
cell lymphoma. Following on its success, efforts are focused on the development of 
second-generation proteasome inhibitors and small molecule inhibitors of other UPS 
components. The core aim is to extend the spectrum of Brtz efficacy, hampered by the 
appearance of dose-limiting toxicity (particularly peripheral neuropathy), limited activity 
in solid tumours and drug-resistance. Recently, the FDA approved the epoxyketone peptide 
carfilzomib for the treatment of relapsed/refractory multiple myeloma, while oprozomib, 
ixazomib, marizomib and delanzomib have already reached clinical trials investigation 
(Crawford and Irvine, 2013). The activity of immunoproteasome-specific inhibitors is also 
currently being investigated and thought to be particularly efficacious for the treatment of 
haematologic maliganacies. The immunoproteasomes are predominantly expressed in cells 
of haemopoietic origin. Targeting them alone can, therefore, provide a certain amount of 
specificity and an opportunity to overcome toxicities associated with proteasome 
inhibition. Enzymes upstream of the proteasome are also being actively explored as 
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selective targets. In this category, compounds directed at E1, E2, E3 and DUB enzymes 
have been developed to block aberrant pathways in malignant cells (Crawford and Irvine, 
2013). Other examples of therapeutic agents that interfere with UPS action include an 
inhibitor of the 19S ATPase reported to impair the degradation of folded proteins (Lim et 
al., 2007) and the Nutlins, which inhibit the interaction of the E3 ligase MDM2 with the 
tumour-suppressor protein p53 (Vassilev et al., 2004). 
1.4.3 Mechanisms of anti-cancer activity of proteasome inhibitors  
Although molecular mechanisms underlying proteasome inhibitors´ anti-cancer activity are 
not fully elucidated, it is clear that multiple pathways are involved, as detailed in several 
reviews (Almond and Cohen, 2002, Adams, 2004, Nencioni et al., 2007, Crawford and 
Irvine, 2013). One of the first mechanisms of action attributed to proteasome inhibitors 
was suppression of the nuclear factor kB (NF-kB) signaling pathway, which has a critical 
role in multiple myeloma pathogenesis, hence the first disease to be considered a target for 
proteasome inhibition therapy (Hideshima et al., 2001). While contradicted by recent 
studies (Dolcet et al., 2006, Hideshima et al., 2009), proteasome inhibition was shown to 
block activation of the inflammation-associated transcription factor NF-kB by preventing 
degradation of its inhibitory molecule IkB, which in response to stress (e.g. neoplasia and 
chemotherapy) becomes phosphorylated, ubiquitinated and deactivated by the 26S multi-
subunit complex. Association of stabilized IkB with NF-kB confines them to inactivity in 
the cytoplasm, thereby downregulating levels of NF-kB transcriptional targets (such as IL-
6) and promoting pro-survival pathways (Finco and Baldwin, 1995).  
Although the UPS is the predominant non-lysosomal pathway of proteolysis in eukaryotic 
cells, proteasome inhibition also has other known effects. Many of these contribute to anti-
tumour activity since proteasome substrates are often known mediators of proliferation and 
apoptotic signaling pathways that are deregulated in cancer. Proteasome inhibition has 
been proposed to induce apoptosis by stabilizing pro-apoptotic p53, Bax proteins and 
NOXA, while reducing levels of anti-apoptotic proteins such as Bcl-2 and inhibitor of 
apoptosis family of protein (Zhang et al., 2004a). Other mechanisms ascribed to 
proteasome inhibitors are disruption of the unfolded protein response (UPR) with pro-
apoptotic endoplasmic reticulum (ER) stress induction (Lee et al., 2003) and increase of 
intracellular reactive oxygen species and oxidative stress (Perez-Galan et al., 2006). 
Moreover, studies on the proteasome inhibition effect in multiple myeloma cells showed 
that it triggers a dual apoptotic pathway of mitochondrial cytochrome c release and 
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caspase-9 activation, as well as activation of Jun kinase and a Fas/caspase-8-dependent 
apoptotic pathway (Mitsiades et al., 2002). Proteasome inhibitors were also shown to cause 
G2/M cell cycle arrest in cell lines of different origins, namely, ovarian (Bazzaro et al., 
2006), prostate (Adams et al., 1999) and non-small lung cancer (Ling et al., 2002), multiple 
myeloma (Buzzeo et al., 2005) and AML (HEL cells) (Colado et al., 2008). The effect on 
cell cycle regulation is associated with stabilisation of the tumour suppressor molecule 
P27KIP1, which prevents activation of both cyclin D and cyclin E to negatively regulate 
progression through the G1/S phase of the cell cycle (Pagano et al., 1995). Furthermore, 
proteasome inhibition appears to regulate DNA repair (Motegi et al., 2009) and elicits anti-
angiogenic effects on the tumour microenvironment, including reduced multiple myeloma 
cells migratory capacity in response to vascular endothelial growth factor (VEGF) (Podar 
et al., 2004, Roccaro et al., 2006). Other effects of proteasome inhibitors appear to promote 
cellular survival, such as activating multiple heat-shock protein (HSP) family members, 
inducing the stress response protein MKP-1 and promoting activity of the protein kinase 
B/Akt pathway. Fortunately, on balance, the net effect is typically a pro-apoptotic one, as 
evidenced by the findings of the first study of Brtz (Orlowski and Kuhn, 2008).  
Given the central role of the proteasome in protein homeostasis and cellular physiology, 
discussion on the ultimate targets of proteasome inhibitors is ongoing and additional 
studies are needed to better understand the mechanisms of the apoptotic cascades mediated 
by this class of compounds. However, it seems clear that proteasome inhibition holds much 
promise as a new investigational avenue for treatment of haematological malignancies and 
cancer therapy in general.  
1.5 Aims 
The following thesis is an investigation on TRIB2 in the context of human AML, from 
both a biological and therapeutic angle. Experiments were designed to address the 
subsequent specific aims: 
1.To evaluate TRIB2 oncogenic properties in human AML cells; 
2.To investigate if high TRIB2 AML cells are responsive to proteasome inhibition 
treatment; 
3.To examine whether TRIB2 interacts with PMRT5.  
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Chapter 2: 
Materials and Methods 
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2.1 Tissue Culture 
Tissue culture was conducted using a laminar air flow hood. An aseptic technique was 
maintained with all materials sprayed in 70% alcohol prior to use. 
2.1.1 Culture of cell lines  
All cell lines were maintained at 37°C with 5% CO2, counted and passaged every two days 
with warm fresh medium to maintain a density of ~0.15x10
6
 cells/mL. Cell lines were 
passaged for a maximum of 2 months, after which new seed stocks were thawed and tested 
for mycoplasma contamination using the MycoAlert mycoplasma detection kit (Lonza, PN 
LT07-318) according to the manufacturer‟s instructions. 
Adult AML cell lines OCI-AML5 and MUTZ-2, paediatric AML cells SB1690CB and 
SBRes, and the human bladder carcinoma cell line 5637 were kindly provided by Dr. 
Stefan Meyer (University of Manchester). SBRes cell line was derived from SB1690CB 
after selection for resistance to mitomycin-c. All cells were cultured in Roswell Park 
Memorial Institute (RPMI) 1640 (Life Technologies, PN 12633-012) medium 
supplemented as described in Table 2.1. The 5637 cell line-conditioned media was used as 
a source of several functional cytokines, including G-CSF and GM-CSF. Dr. Stefan Meyer 
also provided CV1665, CV1785, CV1810 and CV1939 cells. These cell lines are derived 
from patients carrying Fanconi anaemia-associated defects and were used as a model of 
non-AML cells. The U937, NB4 and Kasumi-1 AML cells were available in-house and 
grown in suspension culture (Table 2.1). K562 leukaemic cells were also grown in RPMI 
1640 complete medium (Table 2.1). Human embryonic kidney cells 293T cells were used 
for lentiviral packaging and transient transfection, and mouse embryonic fibroblast 3T3 
cells were grown for virus titration. Both of these adherent cell lines were maintained in 
Dulbecco's modified eagle medium (DMEM, Life Technologies, PN 11966-025) complete 
media (Table 2.1).  
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Table 2.1 Cell lines and growth media 
 
FBS, foetal bovine serum (Life technologies); L-Glutammine (Life technologies); Pen/St, 
Penicillin/streptomycin solution, 10,000UmL
-1
/10,000gmL
-1
 (Life technologies); hIL-3 
(Peprotech). 
2.1.2 Culture of murine primary cells 
Primary murine cells collected from the BM were maintained in liquid culture in DMEM 
medium containing 15% FBS, 1% Pen/St, 1% L-Glutamine and supplemented with mIL-3 
(10 ng/mL), mIL-6 (10 ng/mL) and mSCF (10 ng/mL) (PeproTech). Cytokines were 
freshly added, prior to cell culture.  
2.1.3 Culture and recovery of human primary AML cells 
PB samples from AML patients were collected following protocol approved by the Local 
Research and Ethics Committee and those involved gave their informed consent in 
accordance with the Declaration of Helsinki. Cells were either obtained from 
cryopreserved samples or cultured immediately after processing of the AML patients PB. 
For recovery of the cryopreserved samples, AML mononuclear cells (MNCs) were thawed 
in a 37ºC water bath and transferred into sterile 50 mL falcon tubes. To ensure slow 
rehydration of cells and prevent or minimize cell clumping, thawing media (Table 2.2) was 
supplemented with DNAse I 10000 units/L (Stemcell Technologies, PN 7900). 10 mL of 
the supplemented media (1 mL in 20 mL final volume of thawing media per sample) were 
added dropwise to each sample over 20 min with gentle swirling of the tubes, followed by 
centrifugation at 192 x g for 15 min at 4 ºC. Cells were resuspended in additional 10 mL of 
supplemented thawing media. After centrifugation at 192 x g for 10 min 4ºC, pellets were 
Cell line Culture Media
293T DMEM, 10% FBS, 1% L-Glutamine 1% Pen/St
3T3 DMEM, 10% FBS, 1% L-Glutamine 1% Pen/St
CV1665 RPMI 1640, 15% FBS, 1% L-Glutamine 1% Pen/St
CV1785 RPMI 1640, 15% FBS, 1% L-Glutamine 1% Pen/St
CV1810 RPMI 1640, 15% FBS, 1% L-Glutamine 1% Pen/St
CV1939 RPMI 1640, 15% FBS, 1% L-Glutamine 1% Pen/St  
K562 RPMI 1640, 10%FBS 1% L-Glutamine 1% Pen/St 
Kasumi-1 RPMI 1640, 20% FBS, 1% L-Glutamine 1% Pen/St 
MUTZ-2  RPMI 1640, 20% FBS, 15% conditioned medium from 5637 cells, h IL-3 (10 ng/mL)
NB4 RPMI 1640, 10% FBS, 1% L-Glutamine 1% Pen/St
OCI-AML5  RPMI 1640, 20% FBS, 15% conditioned medium from 5637 cells, h IL-3 (10 ng/mL)
SB1690CB  RPMI 1640, 20% FBS, 15% conditioned medium from 5637 cells, h IL-3 (10 ng/mL)
SBRes  RPMI 1640, 20% FBS, 15% conditioned medium from 5637 cells, h IL-3 (10 ng/mL)
U937 RPMI 1640 10% FBS, 1% L-Glutamine 1% Pen/St
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resuspended in 1 mL of culture media supplemented with a freshly added growth factor 
cocktail for cell survival (Table 2.3). Cells were passed through sterile 70 µm cell strainers 
into new falcon tubes, seeded at a density of 1-2x10
6
 cells/mL and incubated for a few 
hours or overnight (O/N) for recovery prior to downstream experiments. MNCs 
immediately obtained after possessing of patient samples were directly cultured in the 
culture media (Table 2.3). MNCs were isolated by using Histopaque (Sigma-Aldrich) and 
density-gradient centrifugation. 
Table 2.2 Thawing media 
 
Table 2.3 Culture media 
 
 
2.1.4 Plasmid vectors 
The expression plasmids PHMA-mTRIB2-Myc and pcDNA3.1-PRMT5-HA were used for 
Co-Immunoprecipitation. The latter was kindly provided by Dr. Stephen Nimer, University 
of Miami/Sylvester Comprehensive Cancer Center. pLKO.1-puro-CMV- TurboGFP or 
pLKO.1-puro-CMV-TurboGFP-shTrib2 (shCtrl/shTRIB2, Sigma-Aldrich) were used for 
lentiviral-mediated downregulation of TRIB2 (target sequence: 
GCGTTTCTTGTATCGGGAAAT). For TRIB2 overexpression, PhrCtrl was used as 
control and PhrTRIB2 was made by subcloning murine Trib2 into the phr-SIN-BX-IRES-
EmGFP (Phr) lentiviral backbone. This is a a bicistronic (IRES - internal ribosome entry 
site) transfer vector expressing emerald green fluorescent protein (EmGFP) as a marker 
and generating self-inactivating (SIN) lentiviral particles for improved safety. 
shCtrl/shPRMT5#1/ShPRMT5#2 were used for PRMT5 knockdown and are expressed in 
pLKO.1-puro vector (kindly given by Dr. Xu Huang, University of Glasgow). The 
retroviral constructs produced for TRIB2 downregulation were the LMP control or LMP-
shTrib2 (target sequence: TCCTAATCTCTTCAATCAATAAA). For overexpression of 
FBS-ESC (Biosera, PN FB-10015/500-4253) 100 mL
Heparin (5000U/mL) 4 mL
L-Glutamine 5 mL
IMDM (Life Technologies, PN 12633-012) up to 500 mL
StemSpan (Stemcell Technologies, PN 9650) 45 mL
Myelocult (Stemcell Technologies, PN H5100) 5 mL
hIL-3 (100 µg/mL stock, Pepro Tech) 5 µL
hIL-6 (100 µg/mL stock, Pepro Tech) 5 µL
hSCF (100 µg/mL stock, Pepro Tech) 5 µL
hFLIT3-L (100 µg/mL stock, Pepro Tech) 5 µL
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full-length (42 kDa) C/EBPα, a bicistronic retrovirus (MigR1) was used, containing the 
IRES-GFP elements and carrying C/EBPα cDNA lacking the uORF. 
2.1.5 Virus production 
2.1.5.1 Lentivirus  
For lentiviral vectors production, 4.5x10
6
 293T cells were plated in 10 cm dishes 24 h 
before transfection (CaCl2 method). 3-4 h prior to transfection, 10 mL of fresh medium 
(Table 2.1) were added to the cells. The lentiviral transfer vector DNA (15 µg), together 
with psPAX2 packaging (10 µg) and VSVG envelope plasmid DNA (6 µg) were 
combined. Plasmids were previously verified by restriction enzyme digestion (psPAX2 
digested with EcoRI renders 1.7 and 4.3 kb fragments, and VSVG digested with BamHI 
results in two bands of 1.7 and 4.7 kb). The precipitate was formed by adding 31 μg of 
DNA to a final volume of 500 µL dH2O and 61 μL 2.5M CaCl2. The mixture was added 
dropwise to 500 µL 2X HEPES-buffered saline (280 mM NaCl, 50 mM HEPES, 1.5 mM 
Na2HPO4, pH 7.05) while vortexing the 15 mL falcon tube to vigorously bubble air 
through the DNA mix. The solution was incubated at room temperature (RT) for 5 min. 
Following this, the solution was added dropwise to the cells. Dishes were rocked gently in 
a circular motion to distribute the precipitates, and then returned to the incubator. 12 to 16 
h later, the medium was replaced with fresh growth medium supplemented with 2% FBS 
and incubated at 5% CO2 for 24 h prior to the initial collection of viral supernatant. A 
second collection was made after a further 24 h. The conditioned medium from the two 
harvests was centrifuged at 432 x g for 5 min at 4ºC to discard cell debris. Aliquots of viral 
supernatants were snap frozen on dry ice and stored at -80ºC.  
2.1.5.2 Retrovirus 
For retrovirus production, the same protocol described for lentivirus production was 
adopted, with the following changes: pCGP (digestion with HindIII renders 4.5 and 6.2 kb 
fragments) was used as packaging construct instead of psPAX2. Also, to prepare the DNA 
cocktail, CaCl2 was used at 2M and 50 µL 10X NTE buffer (2 M NaCl, 1 M Tris-HCl pH 
7.4, 0.25 M EDTA pH 8.0, dH20 up to 100 mL) were also included in the mixture. The 
DNA mixture was added to only 3 mL of fresh media and replaced after 6 h transfection 
with 4.5 mL of pre-warmed media. Supernatants containing packaged virus particles were 
collected after 24, 48 and 72 h.  
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2.1.6 Virus titration 
For constructs co-expressing GFP, titres were determined by transducing 3T3 cells. Cells 
were seeded the day before transduction at 2×10
5 
in 6 cm dishes. After 24 h, 1 mL of fresh 
growth media (Table 2.1) was added to each plate, supplemented with 8 μg/mL polybrene 
(Sigma-Aldrich, PN 107689, stock at 4 mg/mL). Titres were determined with 1:10 and 
1:100 dilutions of virus stocks added to the 3T3 cells plates. The following day, 2 mL of 
fresh growth medium were added to the plates. After further 24 h of incubation, cells were 
harvested and GFP expression was determined by flow cytometry using FITC channel on 
BD FACSCanto
TM
 II. Acquired data were analysed using FlowJo software (Treestar, v10). 
2.1.7 Transduction of suspension cells 
Cells were seeded at 0.2x10
6
/mL on the day before transduction so as to be in the 
logarithmic growth phase at the beginning of the experiment. Cells were transduced either 
with lentiviral or retroviral constructs. Briefly, cells were harvested and resuspended in 
complete culture medium supplemented with extra 10% FBS and polybrene (Sigma-
Aldrich, PN 107689, stock at 4 mg/mL) at 8 µg/mL. Cryopreserved aliquots with 1 mL of 
virus supernatant were thawed in a water bath and added into target cells. Cells were 
centrifuged for 60 min at 1250 x g and returned to the incubator. After 3-6 h, fresh media 
was added to the cells (up to a final volume of 10 mL) for O/N incubation. Selection of 
efficiently transduced cells was achieved by either sorting GFP+ cells or treatment with 2 
µg/mL puromycin (Sigma-Aldrich, PN P7255, 10 mg/mL stock) for 48 h to eliminate non-
infected cells. Non-transduced cells were included as a control for puromycin selection. 
2.1.8 Drugs 
Brtz (M.W. 384.24) was purchased from LC laboratories (PN B-1408) and prepared as a 
25 mg/mL (65 mM) stock. Peptido sulfonyl fluoride (SF; M.W. 656.85) was provided by 
Professor Robert M. Liskamp and Raik Artschwager (School of Chemistry, University of 
Glasgow). Drug was prepared as a 21.9 mg/mL (33 mM) stock. Carfilzomib (Cfz; M.W. 
719.91) was purchased from LC laboratories (PN C-3022). A 50 mg/mL (69 mM) stock 
was made. All drugs were prepared in dimethyl sulphoxide (DMSO) and stored as single 
use aliquots at -20ºC. 
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2.1.8.1 In vitro drug treatment 
Cells were plated at 0.2x10
6
/mL and were treated with 10 nM Brtz, 500 nM SF, 10 nM Cfz 
or DMSO only. After 6, 8, 16 or 24 h cytotoxicity was assessed as described in section 2.8. 
Treatment time points are indicated in the related Figure legends. 
2.1.8.2 Methylcellulose colony-forming assay of Brtz treated and untreated 
secondary Trib2 murine cells  
Primary Trib2 murine AML cells propagated in secondary transplanted recipients were 
collected and treated with Brtz at 10 nM or DMSO. After 24 h, cells were counted by the 
trypan blue exclusion. 1.4×10
4
 cells were then plated in duplicate in methylcellulose media 
(MethoCult™ GF M3434, Stem Cell Technologies). Colonies were scored at 7 days under 
an inverted microscope and analysed by FACS for detection of myeloid cell surface 
markers with CD11b-APC and Gr-1-PE or Gr-1-PECy7 antibodies (Table 2.13). 
2.1.8.3 In vivo drug treatment 
The 25 mg/mL stock of Brtz was diluted on day of treatment with sterile phosphate 
buffered saline (PBS). Treated mice were injected with Brtz at a dose of 0.5 mg/kg body 
weight. 
2.2 PCR-based assays 
2.2.1 Primer pair design 
Primers for SYBR Green detection and fluidigm assay were designed using Primer-
BLAST software available at NCBI website (http://www.ncbi.nlm.nih.gov/tools/primer-
blast) and following specific considerations. Forward and reverse primers have 
approximately 20 bp with similar melting temperature (Tm ; ~60ºC) and a GC content in 
the range of 40-60%. All selected primers amplify amplicons within the target genes of 
about 100 to 180 bp and were checked for absence of self-complementary capability or 
complementary to the other primer in the reaction mixture. This encourages formation of 
hairpin structures and primer-dimers that would compete with the template for the use of 
primer and reagents and could lower the amplification yield of the desired target region. In 
addition, primers are either spanning an intron or overlapping an exon-exon junction to 
allow a product obtained from the cDNA to be distinguished from unspliced genomic 
DNA contamination. Primers that were found to anneal to sequences other than the 
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intended target were re-designed using the NCBI´s primer designing tool. The primer 
sequences are shown in Table 2.4. Primers were synthesised commercially by Integrated 
DNA Technologies and reconstituted with the appropriate volume of nuclease-free H20 
(Qiagen, PN 129114) to attain a stock concentration of 100 μM. Dilutions were made to 
achieve the appropriate working concentration of 10 μM and aliquots were prepared to 
ensure sterility and stored at -20ºC. For detection of some genes, validated sequences were 
provided by Dr. Helen Wheadon (University of Glasgow), as depicted in Table 2.4. 
Table 2.4 Primer sequences 
 
a
 Sequences retrieved from (Beillard et al., 2003); 
b 
Reference gene; 
c
 Sequences provided 
by Dr. Helen Wheadon 
Gene Symbol Specie
forward TGGAGATAACACTCTAAGCATAACTAAAGGT
reverse GATGTAGTTGCTTGGGACCCA
forward TGTGTAACTACTGCTCCAGACC
reverse GCAGGTGGAGGGATTTGGTA
forward GCGCCACTGAATGAAACTGG
reverse ACGGCAGTCCTGTCACTCTA
forward GCTGACATGTTTTCTGACGG
reverse ATGATGGTTCTGATCAGTTCC
forward GAGAAATCAAACAGAGGCCG
reverse CTGAGTACCTGAACCGGCA
forward GGAACCGTTGTTGACCTCAC
reverse GAGGAGCACAGTGCGGAT
forward CTCGGACTGAGAAACGCAAG
reverse ACCTTGTGGCTCTGTCTGTA
forward TTGTCTTTCAGCAAGGACTGG
reverse ATGCGGCATCTTCTAACCTCC
forward GTTCCCTCTGCGTGTTCTCA
reverse CCATCCACCATCAGCCAACT
forward TGTGAGGCGGTTGTAGAAGTT
reverse CGCTTCCATGTATGATCTTTGGTT
forward GAGAGAAGCAGCAGCCTTGA
reverse AGTTTGGGCACTTTCTCCCG
forward ACCTCAGAAGCTGTTGGGATG
reverse CAGCCACGAGATACAGGTCT
forward GAGCTGGAGGGAACCTGATTT
reverse CACTGGCACTACCAAACTGCA
forward CATTCCTGATGCCACCTTCT
reverse TCGTAAGGACAAAACGGGAC
forward CCAAATGCCGGTTCTGTGGA
reverse TCCATTCCATGAAGTCAGCGATA
forward CCTGTGGAGGTGAACACAGT
reverse AGAGGATGGGAAACCATGAG
forward CCGTTACCTGTGTGTGGTGA
reverse AGGTTTCCTCTGGTCCTGGTA
forward GGTGTCTCTTCAACGGAGGAA
reverse TAGTGAGGCATCATCAGTGGC
forward AGCCAGACTGTTCTACCAGA
reverse GGCGTCTTCCAGGCTTTCCA
forward CGCTCATCGAGGGACGCC
reverse TCCTTATTGATGTCTGCAGGTACAC
forward GAGAGCGTTGGGCTTACCTC
reverse ATCGCTAATCACGACGCTGG
forward AGCCCGACTGTTCTACCAGA
reverse AGCGTCTTCCAAACTCTCCA
BCL2
c human
human
 XIAP human
MCL1
c human
human
human
human
P27KIP1
PTEN  
RNF20
b,c
human
human
human
ATR
human
human
BAX human
Oligonucleotide sequence (5'-3')
ABL
a,b
TRIB2
PRMT5
human
humanENOX2
b,c
human
human
human
BIM
BRCA2
CASP3
CASP8
CDC 25 A
ATM
humanBID
c
Trib2 mouse
Hprt
b mouse
human
B2M
b,c
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2.2.2 Total RNA extraction 
An appropriate number of cells (0.2-1x10
6
) were spun and washed in PBS by 
centrifugation at 432 x g for 5 min at 4°C before use. The RNeasy Mini Kit (Qiagen, PN 
74106) was used as per manufacturer‟s instructions. The resulting RNA was quantified and 
examined for purity using a NanoDrop spectrophotometer ND-1000 (Labtech International 
Ltd). RNA was kept on ice at all times and stored diluted in nuclease-free H20 at -80ºC. 
2.2.3 Reverse Transcription PCR 
cDNA was prepared from 1 μg RNA using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, PN 4368814) according to the manufacturer‟s 
instructions. 1 μg of RNA was converted to cDNA in a 20 μL reaction. When low RNA 
yields were obtained, the maximum volume of RNA was added to a 20 μL reaction. 
Briefly, RNA samples were prepared to a concentration of 1 μg per 13.2 μL in nuclease-
free H20 and mixed with 6.8 μL of pre-prepared 2X reverse transcription master mix in a 
PCR tube placed on ice. Components of the master mixture were added to give a final 
concentration/reaction of 1X RT-buffer, 4 mM dNTP mix, 1X RT random primers, 2.5 
U/µL MultiScribe reverse transcriptase and 1 U/µL RNAase inhibitor. The 20 μL reaction 
mixture was run in a Mastercycler
TM
 PCR machine. Thermal cycling conditions were used 
as per the manufacturer‟s instructions: 25ºC for 10 min, 37ºC for 120 min and 85ºC for 5 
sec to denature the reverse transcriptase. The reaction was then cooled to 4°C. Synthesised 
cDNA prepared from 1 μg of RNA was further diluted to a final volume of 40 μL in 
nuclease-free H20 and stored at -20°C.  
2.2.4 Standard Polymerase Chain Reaction (PCR) 
cDNA samples of human cell lines were amplified by PCR reaction for TRIB2 detection. 
Primer sequences are listed in Table 2.4 and were also used for quantitative PCR analysis. 
PCR mix was prepared using FastStart High Fidelity PCR System (Roche, PN 
03553426001) according to the manufacturer‟s instruction. Components of the mixture 
were added to each 0.2 mL PCR tube to give a final concentration per reaction of 1X 
reaction buffer, 200 µM of each dNTP, 0.4 µM of each forward and reverse primer, 2.5 U 
FastStart High Fidelity Enzyme Blend, 1.8 mM MgCl2, 2 µL of cDNA and ddH20 up to a 
final volume of 50 µL. The PCR tubes were heated to 95°C for 2 min and then 35 cycles of 
95°C for 30 sec, 57°C for 45 sec and 72°C for 45 sec were set in a PCR Thermo Cycler. 
After all cycles finished, the tubes were heated to 72°C for 5 min for final extension and 
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then held at 4°C. PCR products were separated by 1.8% agarose gel electrophoresis in 1X 
TBE (5X TBE solution (Table 2.5) diluted in dH20) and visualized by addition of 
SybrSafe™ (Invitrogen, PN S33102). A molecular ladder of 100 bp was run with samples 
to know the exact size of the PCR products. DNA was visualised under UV illumination, 
using the molecular imager® ChemiDoc Chemidoc™ XRS visualisation system. 
Table 2.5 5X TBE 
 
 
2.2.5 Quantitative PCR (qPCR) 
qPCR was performed using Fast SYBR® Green Master Mix (Applied Biosystems, PN 
4385616). In a MicroAmp Optical 384-well reaction plate (Applied Biosystems, PN 
4309849), a total volume of 10 μL/reaction was prepared containing 1X Fast SYBR® 
Green Master Mix (SYBR® Green I dye, AmpliTaq® Fast DNA Polymerase (Ultra Pure), 
Uracil-DNA glycosylase, dNTPs, ROX™ dye Passive Reference, in addition to optimised 
buffer components), 0.25 µM of each primer (forward and reverse at 10 µM) and 1 μL 
cDNA, diluted in nuclease-free H2O. For each sample, each gene was assayed in technical 
triplicates with reference gene(s) used as internal control(s) to normalize input cDNA. 
Genes are indicated in the related Figure legends and primer sequences are listed in Table 
2.4. A negative control containing nuclease-free H2O in place of cDNA was included to 
reject the possibility of contamination. Plate wells were sealed and the plate was briefly 
centrifuged to eliminate any air bubbles and loaded onto a 7900HT Fast Real-Time PCR 
System (Applied Biosystems). The standard thermal cycling conditions were used as per 
the manufacturer‟s instructions: 95°C for 20 sec followed by 40 cycles of 95°C for 1 sec 
and 60°C for 20 sec and a final step of 50°C for 2 min. Data were acquired and analysed 
using SDS and RQ manager software (Applied Biosystems). Obtained baseline and 
threshold settings were reviewed and manually adjusted when needed. After normalization 
to the endogenous control gene(s), levels of gene mRNA expression in each sample were 
determined by the 2-ΔΔCT method of relative quantification and reported as fold change 
(Schmittgen and Livak, 2008). In the particular case of ABL (V-Abl Abelson Murine 
Leukaemia Viral Oncogene Homolog) and TRIB2 mRNA amplification, a melt-curve 
profile was generated after qPCR reaction, confirming absence of non-specific 
Components and final concentration Amount to add per 1 L
445 mM Tris Base 54 g
445 mM Boric Acid 27.5 g
10mM EDTA (0.5 M, pH 8.0) 20 mL
dH20 up to 1 L
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amplification and primer-dimer formation (Figure 2.1). Whenever indicated ABL was used 
as a reference gene based on a multicenter study aimed at selecting controls that are 
applicable for qPCR-based analysis of leukaemia patients. Beillard and colleagues selected 
ABL, B2M and GUS genes for extensive analysis. These genes were selected from 14 
potential candidates based on the absence of pseudogenes and the level and stability of 
expression. Only ABL gene transcript levels did not differ significantly between normal 
and leukaemic samples at diagnosis and was therefore proposed to be used as reference 
gene for qPCR-based diagnosis in leukaemic patients, including quantification of fusion 
gene transcripts or aberrantly expressed genes (Beillard et al., 2003). 
 
Figure 2.1 Melt-curve analysis confirmed specificity of ABL and TRIB2 primers 
Dissociation curve was obtained using the 7900HT Fast Real-Time PCR System. Because 
of their small size, primer-dimers usually melt at lower temperatures than the desired 
product. Additionally, non-specific amplification may result in PCR products that melt at 
temperatures above or below that of the desired product. A single peak matching either 
ABL (left) or TRIB2 (right) amplification was detected, confirming specificity of the 
primers. 
2.2.6 High-throughput qPCR – Fluidigm 
High-throughput qPCR was performed on the 48.48 Dynamic Array™ IFC system 
(Fluidigm, PN BMK-M10-48.48EG) to analyse expression of target genes indicated in the 
related Figure legend. Primer sequences are listed in Table 2.4. Transcriptional analysis 
was conducted on cDNA samples that were purified from shCtrl- and shTRIB2-U937 
sorted cells after 48 and 72 h transduction (2 independent replicates). For specific target 
pre-amplification, a primer mix was prepared by combining 1 μL of each of the 100 µM 
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primers to be included on the chip and diluting with TE buffer (Promega, PN V6231) to 
make a final volume of 200 µL. A total volume of 5 μL/reaction was prepared containing 
3.75 µL of the pre-amplification mixture (1.25 µL primer mix and 2.5 µL Qiagen 
Multiplex PCR Kit (Qiagen, PN 206143)) and 1.25 µL of cDNA. The mixture was run in a 
Mastercycler
TM
 PCR machine with the following conditions: 10 min at 95ºC followed by 
14 cycles of 95 ºC for 15 s and 60 ºC for 4 min. The pre-amplified cDNAs were treated 
with Exonuclease I (New England Biolabs, PN M0293S), 5-fold diluted in 18 L of TE 
buffer and stored at -20ºC. For the fluidigm assay, the 48.48 dynamic array was primed in 
order to close the interface valves and prevent premature mixing of samples and assays. 
The assay mix solutions were prepared by combining 3 μL of 2X Assay loading reagent 
(Fluidigm, PN 85000736), 0.3 µL TE buffer and 2.7 μL of each primer pair (from 100 µM 
stocks of combined forward and reverse primers). The sample solutions were prepared by 
mixing in each tube 3 μL 2X Taqman gene expression master mix (Applied Biosystems, 
PN 4369016), 0.3 μL 20X DNA binding dye sample loading reagent (Fluidigm, PN 100-
0388), 0.3 μL 20X Evagreen DNA binding dye (Biotium, PN 31000) and 2.4 μL of the 
pre-amplified and Exo I-treated sample. 5μl of each “assay” and “sample” tube were 
loaded into their respective inlets on the left and right frames of the chip, respectively. All 
“sample” reactions were carried out in triplicate. Note that a non-template control was 
loaded in sample inlets number 22, 23 and 24. Next, the dynamic array was placed on the 
IFC controller and software interface was used to pressure load the assay components into 
reaction chambers. Assay components were automatically combined on-chip. 
Subsequently, the dynamic array was transferred to a BioMark Real-Time PCR System for 
thermal cycling and fluorescence detection. Amplifications were carried out at 95 ºC for 60 
sec followed by 30 cycles of 96 ºC for 5 sec and 60 ºC for 20 sec on the BioMark System. 
qRT-PCR analysis software was used to visualise and interact with amplification curves 
performed analysis, colour-coded heat maps and Ct data for the run. Data was analysed as 
for qPCR, using ABL, B2M, ENOX2 and RNF20 as housekeeping genes. 
 
2.3 Western blotting 
Briefly, proteins were isolated, fractionated on a gel based on molecular weight and 
transferred to a membrane. Subsequent blotting, against antibodies specific to the proteins 
of interest, allowed expression analysis. 
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2.3.1 Protein lysate preparation 
For preparation of cytoplasmic and nuclear extracts, equal cell numbers were washed two 
times in PBS. Cell pellets were resuspended in 150 µL of ice cold cytosolic extraction 
buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA pH 8.0, 0.1 mM EGTA pH 
7.0) supplemented with freshly added protease inhibitors (1 mM PMSF, 2 µg/mL 
Aprotinin, 2 µg/mL Leupeptin, 1 µg/mL Pepstatin A, 1 mM Na3V04 and 1 mM NaF ). 
Cells were incubated for 45 min on ice with intermittent vortexing for three times. This 
lysis buffer is hypotonic in nature, which allows cells to swell on ice. After 45 min, 4.7 µL 
of 10% NP-40 were added to each cell suspension and vortexed vigorously for 10 sec for 
cell lysis. After centrifugation at 10 000 x g, 4ºC for 1 min, supernatants (cytoplasmic 
extracts) were transferred to pre-chilled eppendorf tubes and stored at -80ºC. Nuclear pellet 
were resuspended in 25 µL of ice-cold nuclear extraction buffer (20 mM HEPES pH 7.9, 
400 mM NaCl, 1 mM EDTA pH 8.0, 1 mM EGTA pH 7.0) containing protease inhibitors 
(as described above for cytosolic extraction buffer). Pellets were incubated on ice for 30 
min with three intermittent vortexings. After centrifugation for 5 min at 10 000 x g at 4ºC, 
supernatants (nuclear extracts) were transferred to pre-chilled eppendorf tubes and stored 
at -80ºC until protein quantification. 
For detection of proteins susceptible to degradation, i.e. C/EBPα, equal cell numbers (0.6-
2.5x10
5
) from each assay were washed with PBS (432 g for 5 min) and the supernatants 
were carefully removed. The cell pellets were immediately resuspended in 20 µL of 2X 
SDS sample/Laemmli lysis buffer (Table 2.6) with freshly added β-mercaptoethanol (30 
µL β-mercaptoethanol to 470 µL 2X SDS), mixed by vortexing and heated at 95ºC for 3 
min. Cell lysates were spun down and stored at -80°C. Prior to use, protein samples were 
heated at 95ºC for 3 min before the loading step for best resolution. 
Table 2.6 2XSDS sample buffer 
 
 
Components and final concentration Amount to add per 50 mL
0.1 M Tris-HCL (1 M, pH6.8) 5 mL
40% (v/v) 10% SDS 20 mL
20% (v/v) Bromophenol Blue 10 mL
20% (v/v) Glycerol 10 mL
dH20 5 mL
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2.3.2 Protein quantification 
Cytoplasmic and nuclear extracts were quantified using Bradford Reagent (Sigma Aldrich, 
PN B6916) as per the manufacturer‟s instructions. Briefly, a stock solution of bovine 
albumin serum (BSA) at 1 µg/µL was used to prepare six protein standards at varying 
concentrations in Bradford reagent fivefold diluted in dH2O. For each standard, 200 µL 
were pipetted in triplicate to a 96-well plate. Test sample lysates were diluted also in 
Bradford reagent (1:1000) and pipetted in triplicate. Absorbance was read at 595 nM on a 
Spectramax M5 plate reader (MDS Analytical Technologies) and analysed with SoftMax 
Pro 5.2 software (MDS Analytical Technologies). Based on the obtained concentrations, 
equal amounts of protein were then added in each assay. 
2.3.3 Gel electrophoresis 
The denaturing separation method SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
was used to analyse protein samples. Protein samples quantified by Bradford assay were 
diluted in the negatively charged detergent 6X SDS sample buffer (Table 2.7) according to 
desired concentrations and boiled at 95ºC for 5 min. Samples were loaded onto an 8 or 
10% acrylamide gel (Table 2.8) alongside 5 µL of pre-stained protein ladder (Biorad, PN 
161-0374) to assess the molecular weight of proteins migrating through the gel. Samples 
were run in running buffer (Table 2.9) for about 2 h at 100 volts (V). Electric current 
allowed protein separation since the negatively charged proteins migrate towards a positive 
electrode at varying speeds according to their molecular weight. 
 
Table 2.7 6X SDS sample buffer 
 
Components and final concentration Amount to add per 50 mL
72 mM Tris-HCL (0.5 M, pH6.8) 7.2 mL
12% (w/v) SDS 6 g
0.06% (w/v) Bromophenol Blue 0.03 g
47% (v/v) Glycerol 23.5 mL
120 mM DTT 0.93 g
dH20 up to 50 mL
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Table 2.8 Resolving and stacking gel  
 
Table 2.9 Running buffer 
 
2.3.4 Membrane transfer 
After protein separation, proteins were transferred from the acrylamide gels onto 
nitrocellulose membranes with a 0.45 µm pore size, (GE Healthcare Life Science, PN 
10600007). Briefly, the nitrocellulose membranes were equilibrated in transfer buffer 
(Table 2.10) prior to assembly of gel/membrane sandwiches using 1.0 mm gel blotting 
paper (Whatman) and sponges in a wet electroblotting system (Biorad). The transfer was 
performed at 100 V for 1 h.  
Table 2.10 Transfer buffer 
 
2.3.5 Immunolabelling 
To very efficiency of the proteins‟ transfer onto the membrane and as a control for even 
protein loading, membranes were stained with 0.1% Ponceau S solution (Sigma, PN 7170). 
Ponceau S de-staining of the membrane occurred with dH2O washes. To prevent antibodies 
from binding to the membrane non-specifically, the blots were blocked in 1X TBS-T (10X 
TBS (Table 2.11) diluted in ddH20 and supplemented with 0.05% Tween 20) containing 
Resolving gel Stacking gel
8%; 15 mL 10%; 15 mL 4 mL
ddH20 6.9 mL 5.9 mL 2.7 mL
30% Acrylamide 4 mL 5 mL 0.67 mL
1.5M Tris (pH8.8) 3.8 mL 3.8 mL -
1.5M Tris (pH6.8) - - 0.5 mL
10% SDS 0.15 mL 0.15 mL 0.04 mL
10% APS 0.15 mL 0.15 mL 0.04 mL
TEMED 9 µL 6 µL 4 µL
a 250 mM Tris Base (30.03 g); 1.9 M Glycine (144 g) in 1L of ddH20
Components and final concentration Amount to add per 1 L
10% (v/v) 10X Westerna 100 mL
1% (v/v) 10% SDS 10 mL 
ddH20 890 mL
a 250 mM Tris Base (30.03 g); 1.9 M Glycine (144 g) in 1L of ddH20
Components and final concentration Amount to add per 1 L
10% (v/v) 10X Westerna 100 mL 
20% (v/v) Methanol 200 mL
ddH20 700 mL
  59 
 
5% BSA (Sigma-Aldrich, PN A3608) or 5% non-fat dried milk for 1 h at RT. Membranes 
were then transferred to a fresh blocking solution with the addition of the appropriate 
primary antibody (Table 2.12) with a gentle rotation at 4ºC O/N. Thereafter, the blots were 
washed 3 times with 1X TBS-T with gentle shaking and incubated with horseradish-
peroxidase (HRP)-labelled secondary antibodies for 1 h at RT with gentle rotation. After 3 
washes with 1X TBS-T, the blots were developed with the ECL solutions (West PICO (PN 
10177533) / West FEMTO (PN 10391544) chemiluminescent substrate), as per 
manufacturer‟s instructions (Thermo Scientific Pierce). Protein signals were captured on 
X-ray films (Thermo Scientific Pierce, PN 10137683) and developed in a dark room using 
the Medical film processor SRX-101A (Konika Minolta). After visualisation of bands 
showing proteins of interest, the blots were blocked and probed with the appropriate 
primary antibody for housekeeping protein to ensure equal protein loading between 
samples. The blots were then probed with the appropriate secondary antibody, washed and 
visualised as detailed above. When proteins of similar sizes were viewed on the same gel, 
nitrocellulose membranes were stripped. For that, the Restore western blot stripping 
reagent (Thermo Scientific Pierce, PN 10057103) was used, following manufacturer´s 
instructions. To quantify protein expression, densitometric analysis of bands was carried 
out with ImageJ Software whenever indicated.  
 
Table 2.11 10X TBS 
 
Components and final concentration Amount to add per 1 L
152mM Tris HCl 24 g
46mM Tris Base 5.6 g 
1.5mM NaCl 88 g
ddH20 up to 1 La
a pH adjusted to 7.6
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Table 2.12 Western blotting antibodies  
 
 
 
 
 
 
 
 
2.4 Crosslinking Co-Immunoprecipitation analysis from 
transfected cells 
4x10
6
 293T human embryonic kidney cells were seeded in 10 cm dishes and after 24 h 
cells were either left untransfected or transiently co-transfected with plasmids expressing 
HA-tagged PRMT5 and Myc-tagged TRIB2. The corresponding empty vectors (pcDNA3 
and PHMA) were used to equalize amounts of transfected DNA where appropriate and X-
tremeGENE HP DNA Transfection reagent (Roche, PN 06 366 244 001) was used 
following manufacturer´s protocol. Briefly, 12 µg of plasmid DNAs (6+6 µg per 1 000 µL 
complex) were diluted in serum-free DMEM medium and 25 µL of transfection reaction 
were added to each mixture followed by 15 min of incubation at RT to allow complex 
formation. Transfection complexes were added to the cells in a dropwise manner and 
dishes were gently swirled to ensure even distribution. At 24 h post-transfection, cells were 
washed, scrapped off the plates in 1 mL of ice-cold PBS and harvested by centrifugation 
(11 000 x g for 45 sec at 4°C). Cell pellets were resuspended in 300 µL of HEPES lysis 
buffer (50 mM HEPES pH7.4, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40 and 5% 
glycerol) supplemented with protease inhibitors (1 mM PMSF, 2 µg/mL Aprotinin, 2 
µg/mL Leupeptin, 1 µg/mL Pepstatin A, 1 mM Na3V04 and 1 mM NaF ) and incubated 
for 30 min on ice. To strengthen protein-protein interactions, lysates were crosslinked with 
Name of Antibody Reactive Species Dilution Manufacurer PN
α-Tubulin Mouse 1: 5000
Sigma-
Aldrich
T5168
β-Actin Mouse 1: 5000
Sigma-
Aldrich
A5316
C/EBPα Rabbit 1: 1000 Cell Signaling 2295
cMyc Mouse 1: 1000 Santa Cruz SC-40
HA Mouse 1: 1000
Sigma-
Aldrich
H9658
HDACI Rabbit 1: 1000 Santa Cruz sc-7872
PRMT5/Skb1Hs Methyltransferase Rabbit 1: 1000 Cell Signaling 2252
TRB-2 Mouse 1: 250 Santa Cruz sc-100878
anti-rabbit-HRP Donkey 1: 2000 GE Healthcare RPN4301
anti-mouse-HRP Sheep 1: 2000 GE Healthcare RPN4201
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1.5 mM DSP (dithiobis (succinimidyl propionate)) prepared according to manufacturer‟s 
instructions (Thermo Scientific, PN 22585). After 1 h on ice, reaction was then quenched 
with 50 mM Tris pH 7.4 for 30 min on ice. Samples were spun at maximum speed for 45 
sec at 4
o
C and cleared supernatants transferred into new tubes for protein quantification by 
Bradford assay (see section 2.3.2). Aliquots containing 50 µg of protein were removed 
from each sample (inputs), heated at 95°C for 5 min with 6X SDS sample buffer (Table 
2.7) and kept at -20°C until loading. Co-immunoprecipitation (Co-IP) was carried out with 
the remaining cell extracts. To eliminate non-specific protein binding, equal amounts of 
each protein lysate (4 mg) were incubated with 20 L of immobilised protein A/G 
Ultralink (DAPI) (Fisher Scientific, PN 53132) beads at 4°C for 30 min in an eppendorf 
rotator. Pre-cleared supernatants were collected upon centrifugation (2 min, full speed at 
4°C) and incubated with 20 L of fresh beads and either α-cMyc (1.5 g/mg of protein) or 
α-HA (3 µL/sample, concentration not stated on the datasheet) antibodies (Table 2.12). To 
capture the immunoprecipitated protein complexes, samples were kept at 4°C under O/N 
rotation. The pelleted beads were washed three times with 1 mL of ice-cold HEPES lysis 
buffer by centrifugation at maximum speed for 30 sec at 4°C. To elute the immune 
complexes from the beads, 25 μL of 2X SDS sample buffer (Table 2.6) were added to each 
sample followed by incubation at 95°C for 5 min. Eluates and inputs were analysed in an 
8% gel by SDS-PAGE and immunoblotting (as described in section 2.3). 
2.5 Animal work 
2.5.1 Ethical issues 
All animal work was performed in accordance with regulations set by the Animals 
Scientific Procedures Act 1986 and UK Home Office regulations. Animals were housed at 
the Beatson Institute for Cancer Research at the University of Glasgow. All experiments 
were carried out under the author´s personal licence (PIL number I4AE3E6BE) and Dr 
Karen Keeshan‟s project licence (PPL number 60/4512). Throughout all animal 
experiments, mice were regularly monitored for symptoms of disease (ruffled coat, 
hunched back, decreased activity and weight loss) using the project license scoring sheet.  
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2.5.2 In vivo models 
2.5.2.1 Tertiary murine Trib2 transplants 
Secondary AML cells from the BM of two independent MigR1-Trib2 transplanted 
C57BL/6 mice –Trib2 AML#A (79% GFP+ cells) and Trib2 AML#B (74% GFP+ cells)- 
were transplanted, respectively, into 4 and 3 sublethally irradiated B6.SJL mice (4.5 Gy, 4h 
prior to transplantation), by tail-vein injection of 0.8x 10
6
 nucleated BM cells per recipient 
(i.e. tertiary transplanted AML cells). Mice were maintained on 2.5% Baytril (Bayer, 
enrofloxacin)-supplemented drinking water until 2 weeks after irradiation. The antibiotic 
regimen consisting of Baytril´s active metabolite (ciprofloxacin) has been shown to 
efficiently decontaminate aerobic Gram-negative and Gram-positive pathogens without 
major effects on haemopoiesis (Velders et al., 2004). Mice were monitored for % of GFP 
positive cells by tail-vein bleed at d28, 40, 53 and 65. Critical organs from tertiary 
recipients were collected and processed as described in 2.5.2.4 at d56 and 74 after 
transplantation, following detection of GFP + cells ≥10% in the PB. This value was used as 
a proxy for marked BM infiltration of leukaemic cells, as assessed by a secondary 
transplant not shown for the sake of redundancy. 
 
2.5.2.2 Xenotransplantation of U937 AML cells 
U937 cells were transduced with shCtrl or shTRIB2 lentivirus and selected 24 h after with 
2 µg/mL puromycin (Sigma-Aldrich, PN P7255, 10 mg/mL stock) for 2 days. Transduced 
cells were harvested and washed, viable cells were counted using trypan blue exclusion 
and % of GFP positive cells was analyzed by FACS analysis on the day of transplant. Non-
irradiated 12 to 18 week-old male non-obese diabetic (NOD)/LtSz-severe combined 
immune-deficiency (SCID) IL-2Rγcnull (NSG) mice were used in the in vivo study. A 
standardized number of 1.2x10
6
 cells with equally high expression of GFP (~67%) was 
injected via tail vein in the xenograft study of shCtrl (n=5) and shTRIB2 (n=8) transplant. 
PB was collected by tail vein bleeding of mice at day 5 and 11. Mice were killed at day 16 
after transplantation and critical organs were collected and processed as described in 
section 2.5.2.4. To assess human cell engraftment, cells were labelled with anti-human 
CD45 antibody conjugated with PE-Cy7 (Table 2.12, Figure 2.2A) and antibody 
expression was quantified alongside with % of GFP positive cells by flow cytometry. As a 
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negative control for FACS analysis of GFP expression, cells collected from 3 male NSG 
mice transplanted with 1.2x10
6
 untransduced U937 cells were also included (Figure 2.2B). 
 
Figure 2.2 FACS gating strategy used to identify xeno-engrafted GFP+ U937 cells 
 (A) Titration of hCD45 PE-Cy7 in both U937 and BM murine cells by using a series of 
dilutions. The 1:250 dilution was selected for further use in the in vivo experiment as it 
resulted in detection of a clear signal for the positive population (left) with no unspecific 
binding (right). (B) Compensation and voltages were set up using single colour controls. 
Viable cells were identified using forward scatter (FSC) and side scatter (SSC) (1). Within 
the viable cells, single (2) and DAPI negative (3) cells were selected. Within the DAPI 
negative cells, % of GFP + cells (4) was determined using, as a negative control, cells 
collected from 3 male NSG mice transplanted with 1.2x10
6
 untransduced U937 cells (5). 
Accuracy of the gate used for detection of human GFP + cells was also evaluated by 
detecting that this population was >90%+ for hCD45 PE-Cy7 (6). Numbers indicate 
percentages of cells within the indicated gates. 
To assess Brtz in vivo efficacy, a similar experimental model to the one described above 
was established with the following changes: U937 cells were transduced only for GFP 
expression (shCtrl lentivirus) and five days after transplantation, mice were randomized 
B
GFP
S
S
C
-W
1 2 3 4 6
5
96.1
96.7
72.0
32.7 99.6
0.58
FSC-A
S
S
C
-A
FSC-A
F
S
C
-H
DAPI
F
S
C
-A
GFP
S
S
C
-W
hCD45 PE-Cy7
C
o
u
n
t
N
o
rm
a
li
z
e
d
 T
o
 M
o
d
e
hCD45 PE-Cy7
U937 cells Murine BM cells
Unstained
1:250
1:100
1:50
Unstained
1:250
A
  64 
 
into two groups of 3 animals each to be treated with Brtz (0.5 mg/kg, intraperitoneal (i.p.) 
administration) or sterile PBS only on days 5, 7 and 11. PB was collected by tail vein 
bleeding of mice at day 5 and 11 before drug treatment. General physical status and 
weights were recorded daily during treatment to assess any signs of impairment of the 
animals caused by Brtz and to ensure that mice received a consistent dose of 0.5 mg/kg 
every treatment. Mice were killed at day 16 post-transplantation. 
2.5.2.3 Xenotransplantation of primary human AML cells 
Adult female NSG mice (6 to 11 week-old) were sublethally irradiated with 2.25 or 2.5 Gy 
of total body irradiation 24 h prior to injection of unsorted MNCs from PB of 6 AML 
patients. Recovery of the cryopreserved leukaemic cells was performed as described in 
section 2.1.3 and cells were incubated for few hours in appropriate culture media (Table 
2.3). Thereafter, cells were cleared of aggregates and debris using a 0.2 µm cell filter and 
washed in PBS/2%FBS. Cells were then resuspended in PBS/2%FBS at a final 
concentration of 1.1-1.6x10
6
 cells per 200 µL per mouse. Each sample was tail-vein 
injected into 3 NSG recipients. Mice were maintained on Baytril-supplemented drinking 
water for the duration of the experiment and were routinely monitored for symptoms of 
disease. Human AML burden was evaluated by flow cytometry of tail-vein blood with 
anti-human CD45 and CD33 (Table 2.13) at week 3, 5, 7 and 8 after transplant. Mice were 
analysed at week 12 post-transplantation for long-term engraftment evaluation. An 
engraftment criterion of >0.1% of hCD45+ hCD33+ in the murine BM cells was used as 
the biologically significant cut-off. 
2.5.2.4 Dissection and processing of blood and critical organs from 
transplanted mice 
Animals were sacrificed using appropriate schedule 1 methods and examined for evidence 
of leukaemia. PB was obtained after killing through cardiac puncture and collected into 
tubes containing EDTA to ensure anti-coagulation. Femur, tibia, hip bones, spleen and 
thymi were dissected and stored in PBS/2% FBS on ice. Brain-sculls were collected when 
indicated and fixed in 10% formalin. Approximately 20 μL of PB were subjected to 
analysis in the Hemavet 950FS system to obtain haematology profiles for each sample. 
Bones from femur, tibia and hips were crushed in PBS/2% FBS using a mortar and pestle 
and made into a single cells suspension through filtering through a sterile 0.2 μm filter. 
Single cell suspensions from spleen and thymi were made in PBS/2% FBS using a sterile 
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plunger and filtered. In all tissues red blood cells (RBC) were lysed in RBC lysis buffer 
(155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA). 
2.6 Preparation of metaphase murine Trib2 AML cells for 
karyotyping 
Total BM derived AML cells collected from two Trib2-leukaemic tertiary recipient mice 
were prepared for metaphase stage arrest. 1 mL of cell suspension (~2x10
6
 cells) from each 
mouse was treated with 10 µL of demecolcine (Sigma-Aldrish, PN 477-30-5) to increase 
the yield of mitotic cells in metaphase. Cell suspensions were retrieved to the incubator for 
45 min. Cells were then transferred to 15 mL falcon tubes and spun down at 200 g for 10 
min. Tubes were flicked to loosen the pellet and 10 mL of pre-warmed 0.075M KCl 
hypotonic solution were added. Cells were vortexed at medium speed and incubated at 
37ºC for 15 min. Cells were then centrifuged at 200 x g for 10 min and supernatant 
discarded. Pellets were disrupted by flicking the tube in remaining drops of the liquid and 5 
mL of freshly prepared methanol:acetic acid (3:1) fixative solution were added dropwise 
while vortexing. Extra 5 mL of fixative solution were added. Cells were centrifuged at 200 
x g for 10 min and supernatant discarded (leaving about 0.5mL). This step was repeated 
one extra time. Cells were resuspended in a small volume of fixative solution (~0.3 mL) 
and transferred to a 1.5 mL tube. To confirm the presence of metaphase cells, 5 µL of cell 
suspension were dropped on a slide. After waiting a few seconds for the slide to dry, DAPI 
(4´, 6´-diamidino-2-phenylindole) was added for fluorescence microscopy analysis. The 
slide was examined under oil immersion at 100X magnification using a UV light source. 
Extra fixative solution (~1 mL) was added to the preparation, the tubes were sealed with 
parafilm and stored at –20ºC until being sent for cytogenetic analysis at Cytocell Ltd 
(Cambridge). 
2.7 Flow cytometry  
2.7.1 Assessment of surface antigen expression 
Cells were harvested and washed in PBS. Cell pellets were then resuspended in 50 µL of 
PBS containing the appropriate fluorochrome- conjugated antibody (Table 2.13 and 
indicated in the related Figure legend). Cells were incubated for 30 min at 4ºC protected 
from light. Cells were washed again in PBS and resuspended in 200 µL of PBS prior to 
FACS analysis. FACS analysis was performed using a BD FACSCanto
TM
 II flow 
cytometer and acquired data was analysed using FlowJo software (Treestar, v10). 
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Table 2.13 FACS antibodies 
 
 
 
 
2.7.2 Cell growth analysis 
To monitor growth of transduced U937 cells, the cells were seeded at 0.15x10
6
/mL after 24 
h transduction (GFP+ cells) or 48 h puromycin selection, as indicated in the related Figure 
legend. Viable cells were counted by trypan blue exclusion at the indicated time points. 
After 48 h counting, cells were split again at 0.15x10
6
/mL. For GFP+ cells, GFP % was 
assessed by FACS analysis at each time point and final results are normalized to the 
corresponding GFP expression. 
2.7.3 Annexin V / DAPI staining 
To analyse cells undergoing apoptosis, cells were harvested, washed once in PBS and 
resuspended in 100 μL of 1X Hanks‟ Balanced Salt solution (HBSS, Sigma-Aldrich) 
containing 1 µL of Annexin V-PE (BD Biosciences, PN 556422) per test. HBSS was used 
to ensure the physiological concentration of calcium required for Annexin V to bind to 
phosphatidylserine, which is translocated to the extracellular membrane of apoptotic cells. 
Cells were incubated for 15 min at RT protected from light. To stop the reaction, 400 μL of 
Name of Antibody Reactive Species Clone Format Manufacturer Dilution
CD33 human WM53 APC Biolegend 1: 250
CD45 human HI30 PE Cy7 Biolegend 1: 250
CD11b mouse M1/70 APC eBioscience 1: 250
CD11b mouse M1/70 PE eBioscience 1: 250
Gr-1 mouse RB6-8C5 APC eBioscience 1: 250
Gr-1 mouse RB6-8C5 PE eBioscience 1: 250
Gr-1 mouse RB6-8C5 PE Cy7 eBioscience 1: 250
B220 mouse RA3-6B2 Biotin eBioscience 0.5 µL per 1x107cells
CD3 mouse 17A2 Biotin eBioscience 0.5 µL per 1x107cells
CD8a mouse 53-6.7 Biotin eBioscience 0.5 µL per 1x107cells
CD11b mouse M1/70 Biotin eBioscience 0.5 µL per 1x107cells
CD4 mouse GK1.5 Biotin eBioscience 0.5 µL per 1x107cells
Gr-1 mouse RB6-8C5 Biotin eBioscience 0.5 µL per 1x107cells
Ter119 mouse Ter-119 Biotin eBioscience 0.5 µL per 1x107cells
c-Kit mouse 2B8 APC Cy7 Biolegend 1: 100
Sca-1 mouse D7 PE Cy7 eBioscience 1: 100
Streptavidin - - V450 BD 1: 100
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1X HBSS were added to each sample and cells were analysed on a BD FACSCanto
TM
 II 
flow cytometer within no more than 30 min post-staining. For combined analysis of 
apoptosis and necrosis, 1 µL of the nucleic acid stain DAPI (Sigma-Aldrich, PN 9542, 
stock at 1 mg/mL) was included in the 100 µL HBSS/Annexin V mixture. For single 
staining with DAPI, the nucleic acid stain was diluted in PBS and added to each sample (1 
µg/mL) just prior to FACS analysis. Control tubes containing unstained cells, Annexin V 
or DAPI single-stained cells were recorded to set FSC/SSC voltages and compensation. 
For data analysis, the FlowJo software (Treestar, v10) was used.  
2.7.4 Cell cycle analysis using Propidium Iodine (PI) staining 
Cells were harvested upon centrifugation at 432 x g for 5 min at RT and washed in PBS. 
Pelleted cells were fixed by adding 1 mL of ice-cold 70% (v/v) ethanol while vortexing, 
and stored at -20°C O/N. Before FACS analysis, cells were spun for ethanol removal 
followed by one washing with PBS and resuspended in DNA staining solution (PI/RNase 
Staining Buffer, BD Pharmingen, PN 550825) for 15 min at RT in the dark. Fluorescence 
labelling of the cellular DNA content was used as a measure of cell cycle progression and 
was acquired by BD FACSCanto
TM
 II flow cytometer. When stated, cell cycle profile was 
also used to estimate apoptosis (% of cells in Sub-G1 phase). Analysis was performed 
using FlowJo software (Treestar, v10).  
2.7.5 GFP+ cells sorting 
For selection of GFP+ cells, cells were harvested, resuspended in approximately 300 µL of 
PBS/2% FBS and passed through a sterile 70 µm cell strainer prior to sorting. Sorting was 
performed by Jennifer Cassels using FACSDiva (BD Biosciences, v6.1.2) flow cytometer, 
as depicted in Figure 2.3. 
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Figure 2.3 Representative plots demonstrating GFP+ cells sorting 
(A) Untransduced, GFP- cells, (B) GFP+ cells prior to sort and (C) post-sort are shown. 
For all, viable (P1) and single (P2) cells were gated using FSC and SSC. % of GFP 
expression was assessed through P3 gate. 
2.7.6 Lineage-Sca1+c-Kit+ (LSK) sorting with lineage depletion 
BM cells from B6.SJL mice were flushed out of femurs and tibiae in PBS containing 2% 
FBS. Prior to sorting of LSK cells in the BM, lineage positive cells were separated as 
follows. RBC-depleted total BM cells were incubated with a panel of biotin-conjugated 
mouse antibodies (CD3, CD4, CD8a, B220, CD11b, Gr-1 and Ter119; Table 2.13) at 4ºC 
for 30 min. After washing with PBS containing 2% FBS, cells were incubated with Anti-
Biotin MicroBeads (Milteny Biotec, PN 130-090-485) at 4ºC for 30 min and Lin- cells 
were purified by magnetic separation. Columns were flushed for collection of Lineage+ 
cells. The Lin- cells were further stained with antibodies against c-Kit, Sca-1 and SA-V450 
(Table 2.13) and sorted by Jennifer Cassels, using FACSDiva (BD Biosciences, v6.1.2) 
flow cytometer. 
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2.8 Statistics 
Statistical analyses and graphing were performed either with the Microsoft Office Excel 
software or the GraphPad Prism Software (v5.03) using the unpaired, two-tailed Student‟s 
t-test. When the Leukemia Gene Atlas (LGA) platform was used as a data analysis tool, the 
Welch‟s t-test was selected. *** for P ≤0.001, ** for P ≤0.01 and * for P ≤0.05 were 
considered statistically significant and were indicated in the related Figure legends and 
graphs. Where n.s. is indicated, the P value is not significant. The results are shown as 
mean ± standard deviation (SD). 
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Chapter 3 
Characterization of TRIB2 tumorigenic role in 
human AML 
When indicated, results presented in this chapter have been published in (Rishi et al., 2014, 
Salome et al., 2015) and the PDFs of the publications are provided in Appendix E and F. 
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3.1 Introduction 
TRIB2 is a pseudokinase that functions as a molecular adaptor mediating degradation and 
changes in signaling cascades as reviewed elsewhere (Lohan and Keeshan, 2013). There is 
accumulating evidence supporting its tumorigenic activity in a variety of malignancies, i.e. 
melanoma (Zanella et al., 2010), lung (Zhang et al., 2012, Grandinetti et al., 2011) and 
liver cancer (Wang et al., 2013a), as well as T-ALL (Sanda et al., 2012) (see Chapter 1, 
section 1.3.3). Significant for the current study, Keeshan et al. observed that murine BM 
cells retrovirally expressing this gene exhibit a growth advantage ex vivo and readily 
establish factor-dependent cell lines. In vivo, Trib2-reconstituted mice rapidly develop 
AML with a mean latency of 179 days and complete penetrance through a mechanism 
involving proteasomal-dependent degradation of C/EBPα p42, which is central to the 
induction of granulocytic development (Keeshan et al., 2006). Moreover, mice 
reconstituted with HSCs co-transduced with Trib2 and HoxA9 have an accelerated onset of 
AML when compared to either gene alone, indicating that these genes may co-operate to 
induce leukaemia (Keeshan et al., 2008). The AML oncogene Meis1 may also promote 
Trib2 expression, which potentially complements the ability of NUP98-HOXD13 to induce 
AML, as shown in another murine BMT model (Argiropoulos et al., 2008). The Trib2 role 
as a myeloid oncogene is thus supported by strong experimental data provided by murine 
models. In human leukaemic cells, its oncogenic potential has been highlighted by gene 
expression profiling studies. Valk et al. analysed 285 patients with de novo AML that was 
characterized by cytogenetic and molecular analyses. They used gene-expression profiling 
to comprehensively classify the disorder and identified sixteen distinct groups of patients 
on the basis of unsupervised cluster analysis (i.e., without taking into account external 
information) and strong similarities in molecular signatures (Valk et al., 2004). The same 
microarray profiling was subsequently examined to investigate TRIB2 mRNA expression 
in human AML patient samples. Based on signals from two different probe sets targeting 
this gene, Keeshan et al. found that TRIB2 transcript levels were enhanced in cluster #4 
when compared to other subsets. While cluster #4 is one of the two distinct expression 
subsets harboring most patients with CEBPA mutations, TRIB2 was primarily elevated in 
tumors that did not carry mutations in the myeloid transcription factor CEBPA. This was 
suggestive of disruption of normal C/EBPα function by other mechanisms, explaining why 
these AMLs shared a CEBPA mutant gene expression signature, while lacking such 
mutations (Keeshan et al., 2006). Cluster #4 leukaemias lacking CEBPA mutations were 
further defined as a specific subgroup of AML. They were associated with CEBPA 
silencing, which was linked to frequent promoter CpG hypermethylation (4/6 patient 
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samples analysed). Comparison of silenced leukaemias to CEBPA mutant cases in cluster 
#4 also revealed that genes significantly overexpressed in the first group were related to T-
cells and T-lymphoid development (e.g., CD7). Moreover, CEBPA silenced leukaemias 
share an immature myeloid/lymphoid phenotype, as determined by simultaneously 
expression of surface markers CD34, CD13, CD7 and terminal 
deoxynucleotidyltransferase (TdT). These TRIB2-expressing AMLs lacking CEBPA 
mutations were further associated with aberrant activation of NOTCH1 by mutations. 
Indeed, TRIB2 was identified as a direct transcriptional target of NOTCH1 (Wouters et al., 
2007). 
Altogether, leukaemic murine models and gene expression analyses of human AML 
cohorts link TRIB2 to tumors with altered C/EBPα function and suggest that elevated 
TRIB2 may have a pathogenic role in a subset of human AML. Therefore, this chapter 
aims to further understand the precise role of TRIB2 in the human leukaemic setting by 
means of functional analysis that are still lacking. 
 
3.2 Aims and Objectives 
The present study hypothesises that TRIB2 will be required for the oncogenic properties of 
human AML cells. To address this, the specific aims of this chapter were: 
i. To investigate how TRIB2 is altered at the genomic level across a panel of human 
tumours; 
ii To establish a murine Trib2-AML model as a source of leukaemic cells for further 
characterization of TRIB2-driven AML  
ii. To perform a phenotypic characterization of the role of TRIB2 in human AML 
cells, both in vitro and in vivo; assessing its putative contribution to AML cells survival 
iii To investigate the clinical relevance of TRIB2 by means of a transcriptional 
analysis in AML patient samples; 
iv To investigate whether increased expression of TRIB2 in AML patient samples 
correlates with the ability of these cells to engraft in the BM of NSG mice. 
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3.3 Results 
3.3.1 TRIB2 oncogenic activity is related to its elevated gene 
expression  
The TRIB2 gene was examined in the catalogue of somatic mutations in cancer (COSMIC, 
v72) database (http://cancer.sanger.ac.uk, (Forbes et al., 2015)), the most comprehensive 
source of curated analysed somatic mutations in human cancer to date. This analysis was 
intended to obtain an overview of whether TRIB2 is altered at the genomic level across a 
panel of tumour samples identified by the tissue of origin. From a total number of 23,983 
unique tumour samples, 86 showed missense (51%), synonymous (46%), nonsense (2%) 
and inframe deletion (1%) mutations in TRIB2 (Figure 3.1A, lower panel). Interestingly, 
although the overall point mutation rate is low, tumours with documented roles for the 
TRIB2 oncogene, such as malignant melanoma and lung cancer, do have detectable TRIB2 
point mutations. In tissues matching AML, which has a very strong association with TRIB2 
oncogenic activity, no mutations were retrieved from COSMIC curated data provided by 
scientific literature and resequencing results from the Cancer Genome Project at the 
Welcome Trust Sanger Institute (1/1942 haematopoietic and lymphoid tissue samples 
identified with a TRIB2 mutation corresponded to a multiple myeloma patient sample) 
(Figure 3.1A, upper panel). Indeed, no mutations have been found in ∼75 AML samples 
analysed by exome sequencing with good coverage across all exons (Ross Levine, personal 
communication to Dr. Karen Keeshan). Interrogation of other genomic alterations affecting 
TRIB2 in the COSMIC database identified subsets of tumour tissues with overexpressed 
TRIB2 (Figure 3.1B). Overall, the frequency rate for these alterations is higher and 
includes lung, skin, liver and haematopoietic and lymphoid tissues samples. Of note, 4/9 
samples overexpressing TRIB2 in the haematopoietic and lymphoid tissues matched AML 
samples. Given that there is strong evidence for a TRIB2 oncogenic function in these 
tumours, these analyses suggest that an elevated TRIB2 expression has potential 
implications on other tumour tissues yet to be explored, e.g. in the endometrium 
(endometrioid carcinoma), central nervous system (astrocytoma grade V), prostate and in 
large intestine samples (both with matches for adenocarcinoma). Other TRIB2 gene 
alterations include copy number variation (CNV), which albeit rare, are found across 
different tumour tissues and are mainly associated with an increased copy number (all 
except for breast, thyroid and kidney, which showed CNV loss) (Figure 3.1C). 
Hypermethylation, associated with chromatin silencing, was found exclusively in prostate 
and large intestine tumour tissues (Figure 3.1D). Together, these analyses suggest that in 
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most cancers TRIB2 oncogenic activity is related to its elevated gene expression rather than 
to different genomic alterations or mutations (data published in (Salome et al., 2015)). 
 
Figure 3.1 Genomic alterations in TRIB2 gene 
(A) Histogram presentation of point mutations in TRIB2 gene in tumour samples using the 
COSMIC database (upper panel). Pie chart referring to the frequency of missense (51%), 
synonymous (46%), nonsense (2%) and deletion inframe (1%) point mutations in the 
identified tumour samples (lower panel). (B) Histogram presentation of gain of TRIB2 
gene expression in the tumour samples indicated. Among them 4/9 haematopoietic and 
lymphoid tissues samples match AML as part of the acute myeloid leukaemia study 
(COSU377) from The Cancer Genome Atlas [TCGA] in which over expression is defined 
after a z-score > 2. (C) Histogram displaying tumour tissues where CNV of the TRIB2 
gene was identified, with the respective frequency in tumour samples. (D) Histogram 
presenting tumour tissues where hypermethylation of the TRIB2 gene locus was identified 
and respective frequency. Data were retrieved by v72 of COSMIC database 
(http://www.sanger.ac.uk) and only tissues displaying TRIB2 alterations are shown. CNV, 
copy number variation; NS*, not specified with histology matching malignant melanoma; 
NS, not specified. The most commonly mutated gene in human cancer, TP53 (Kandoth et 
al., 2013), was also examined as a positive control. The analysis using COSMIC database 
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confirmed that the majority of TP53 mutations are missense substitutions and that 
approximately 50% of samples matching ovary tumour tissue have mutations in this 
tumour suppressor, as reported in the literature (Petitjean et al., 2007, Olivier et al., 2010). 
3.3.2 Primary murine Trib2-BM derived AML cells propagate AML 
in serially transplanted mice 
The above analysis suggests that genomic alterations or mutations in TRIB2 are not 
commonly associated with cancer. Keeshan and colleagues reported that Trib2 itself was a 
bona fide AML oncogene, capable of driving a potent murine AML that was transplantable 
to secondary recipients (Keeshan et al., 2006). It was therefore considered a logical 
approach to take advantage of this model to investigate further the transplantability and 
genomic characteristics of Trib2-driven AML, as it could be also used for expansion and 
propagation of Trib2-AML cells. For that, 0.8 x 10
6 
BM derived AML cells from 
secondary transplanted mice retrovirally expressing Trib2 (MigR1-Trib2) were 
transplanted into sublethally irradiated (4.5 Gy) tertiary B6.SJL recipients. Trib2 was co-
expressed with GFP in a bicistronic construct, thereby enabling disease monitoring by flow 
cytometric analysis of the GFP reporter in the PB. Mice developed GFP+ cells consistent 
with peripheral leukaemia (Figure 3.2A) and were killed at d56 (Trib2 AML#A1, A2, A3 
and B1) and d74 (Trib2 AML#A4, B2 and B3) post-transplant when terminal symptoms 
consisting of %GFP+ ≥10 were detected by tail bleeding. All tertiary recipients (n=7) 
developed AML with similar levels of engraftment when compared to primary transplants 
described in (Keeshan et al., 2006), but with faster disease progression (medium survival 
of 65 vs 179 days after transplant). At necropsy, all mice displayed splenomegaly (n=7; 
range=0.15-0.36 g; Figure 3.2C) and opaque bones (data not shown). By flow cytometric 
analysis of % of GFP positive cells, tertiary leukeamias were associated with extensive BM 
involvement (>80% in all cases), followed by PB, spleen and thymus (Figure 3.2D and 
3.2E, upper panel). Different from the primary transplant, leukocytosis reflecting excess of 
leukaemic cells, was absent throughout the experiment, probably due to increased latency 
of the disease. WBC count of 1.8 to 10.7 x10
6
/100 mm
3
 was within the normal range but 
values can also be found low, normal or high in human AML (Estey and Dohner, 2006). 
Notably, the infiltrating AML cells were detected in the choroid plexus and meninges of 
6/7 brains examined by Dr. Christina Halsey and Dr. Anthony Cousins (University of 
Glasgow), as part of a collaboration with Dr. Karen Keeshan´s group. The 
immunophenotype of leukaemic cells in tertiary recipients paralleled observations 
previously reported for the primary disease (Keeshan et al., 2006), with most cells 
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retaining intermediate expression of Gr-1 and CD11b in the GFP+ population (Figure 
3.2E, lower panel) – a characteristic of immature myeloid precursors and murine myeloid 
leukaemias (de Guzman et al., 2002, Cozzio et al., 2003). In addition to % of GFP positive 
cells, the leukaemic BM cells expressed the expected oncogene, as confirmed by mRNA 
detection of higher Trib2 transcript levels (Figure 3.2B). Together, these data extend the 
previous study reporting Trib2 as a potent murine myeloid oncogene (Keeshan et al., 2006) 
by indicating central nervous system (CNS) involvement and tertiary AML engraftments 
and propagation. Importantly, this model was shown to be useful as a valuable resource of 
leukaemic cells, as described in the section below.  
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Figure 3.2 Robust tertiary engraftment of Trib2-induced AML 
(legend on next page) 
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Figure 3.2 Robust tertiary engraftment of Trib2-induced AML (Figure on previous 
page). (A) Sublethally irradiated mice (4.5 Gy, n=7) received 0.8x10
6
 Trib2-BM cells from 
two secondary leukaemic recipients (named A and B). Mice were monitored for signs of 
illness for 74 days (d) and euthanized when % of GFP+ cells in the PB was above 10. Mice 
were killed at d56 (Trib2 AML#A1, A2, A3 and B1) and d74 (Trib1 AML#A4, B2 and 
B3). Representative histogram depicts increase of % of GFP positive cells in the PB 
detected at various time points (d28, 40 and 53) and at necropsy (d56). (B) Overexpression 
of mouse Trib2 transcripts were verified by qPCR in two independent tertiary AMLs 
(Trib2 AML#A3 and #B1). Values represent gene expression relative to wild type (WT) 
BM and normalized to the reference gene Hprt. (C) Spleen weights were measured. Each 
symbol represents an individual mouse and horizontal bar represents mean value (0.24 g). 
For comparison purposes, spleens from control MigR1 mice were reported to have an 
average weight of 0.09 g (n=10; range=0.06-0.1 g) (Keeshan et al., 2006). (D) Cells from 
BM, PB, spleen and thymus were assessed by flow cytometry for quantification of GFP 
expression used as marker for leukaemic cells. Data are shown by bar graph and (E ) 
representative FACS plots. Lower panel depicts Gr-1-PE and CD11b-APC profile of the 
GFP+ populations. For technical reasons % of GFP positive cells analysis was not 
recorded for thymus and PB of mouse Trib2 AML#A3 and #B2, respectively. 
3.3.3 Murine Trib2-induced AML exhibits normal cytogenetics 
AML is defined by molecular heterogeneity coupled with the current understanding that a 
single mutation appears generally insufficient for overt leukaemia to develop. This is 
supported by the two-hit model of leukaemogenesis, now considered an over-
simplification of the reality, and is true for the Trib2-driven murine model as it is believed 
that at least a second hit must occur to explain the observed 6 month latency for the 
primary AML disease to develop in vivo (Keeshan et al., 2006). The second hits that may 
occur could include chromosomal alterations due to genomic instability in Trib2-
expressing AML cells. Chromosomal alterations are of particular significance in AML, in 
terms of frequency and clinical implications. Thus, a karyotype analysis was performed 
with a view to gaining a better characterization of Trib2 genomic instability in AML. To 
investigate the cytogenetic background of Trib2-leukaemia, total BM-derived AML cells 
collected from two tertiary recipient mice (Trib2 AML#A2 and Trib2 AML#B2; 
GFP+>90%, Figure 3.2D) were prepared for metaphase stage arrest. After microscopic 
visualization of metaphase chromosomes (Figure 3.3A), fixed cell suspensions were sent to 
Cytocell Ltd (Cambridge) to investigate numerical and structural changes in the tumour 
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cells genome. Analysis was performed using a method that combines an 8 square multi-
probe slide and whole chromosome painting probes (labelled in FITC, Texas Red or Aqua 
spectra). The arrangement of chromosome combinations (3 chromosomes per square) is 
specifically designed to facilitate identification of the most common non-random 
chromosome rearrangements found in leukaemia (http://cytocell.com). Chromosome 12 –
where mouse Trib2 gene is localized- was analysed together with chromosomes 11 and 19, 
as depicted in Figure 3.3B. Trib2-AML murine cells were associated with a stable genome, 
with no evidence of copy number variants (normal diploid chromosome number 2n = 40) 
nor translocations (Gothami Fonseka, personal communication).  
 
Figure 3.3 Murine Trib2-AML is genomically stable with no evidence of translocation 
or copy number variants 
(A) Murine Trib2 leukaemic cells treated with a mitotic inhibitor were stained with DAPI 
(blue) for fluorescence microscopy analysis (100X magnification) and condensed and 
highly coiled chromosomes were detected, confirming arrest in metaphase stage. (B) 
Representative picture of three colour chromosome painting (60X magnification) showing 
chromosome 11 (red), 12 (green) and 19 (blue). No numerical or structural changes were 
detected by cytogenetic analysis (picture provided by Gothami Fonseka, Cytocell Ltd). 
3.3.4  TRIB2 mRNA was detected in a subset of human AML cell 
lines 
The data above show that Trib2-induced AML in the murine setting does not, at least in the 
analysed leukaemic clones, correlate with chromosomal alterations as putative secondary 
mutagenic hits. As a starting point for assessing TRIB2 function in the human setting, 
expression of this gene at the mRNA level was tested and evaluated in a cohort of human 
cell lines. Human TRIB2 gene is localized on chromosome 2 band p24.3 and according to 
Ensembl database (http://ensembl.org) has four splice variants. While one is described as a 
non-coding transcript, the other three are associated with known proteins. Of this last 
BA
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group, only one (ENST00000155926, NM_021643) is highly annotated, with a Consensus 
Coding Sequence (CCDS1683) and a UniProt (Q92519) identifiers. Primers were, 
therefore, designed for specific detection of this transcript (sequences listed on Table 2.4; 
Figure 3.4A) and tested in a group of AML (SBRes, MUTZ, OCI-AML5, SB1690CB and 
U937) and non-AML cell lines (CV1810, CV1785, CV1665 and CV1939). cDNA analysis 
by PCR reaction identified the presence of TRIB2 on an agarose gel by band analysis 
matching the expected size (142 bp, Figure 3.4B). For quantitative examination, expression 
was measured by qPCR reaction of cell lines from the AML subgroup. Consistent with the 
band intensity detected on agarose gel, TRIB2 transcript levels were found to be the highest 
in U937 cells when compared to other five AML cell lines (Figure 3.4C), with an average 
Ct value of 23. These results validate the use of the described primers for subsequent 
TRIB2 mRNA detection, suggesting the high expressing-U937 cells as the best suited 
model for further experiments. 
 
Figure 3.4 TRIB2 expression was detected at mRNA level and shown to be highest in 
U937 cells when compared to other AML cell lines 
(A) Human TRIB2 is located on chromosome 2p24.3, covers 25 863 bases of genomic 
sequence and consists of 3 exons depicted by filled boxes. Unfilled boxes represent 
UnTranslated Regions (UTRs) and lines connecting the boxes are introns. Arrows in blue 
indicate primers designed for specific detection of the TRIB2 protein-coding transcript. (B) 
cDNA samples of human cell lines were amplified by PCR reaction for TRIB2 detection  
and expected amplicons (142 bp) were visualized in 1.8% agarose gel. Analysed cell lines 
were the following: SBRes (1), MUTZ (2), OCI-AML5 (3), SB1690CB (4), U937 (5), 
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CV1810 (6), CV1785 (7), CV1665 (8), CV1939 (9) and water negative control (10). M, 
100bp DNA ladder; bp, base pairs. (C) Quantitative PCR (qPCR) analysis identified TRIB2 
mRNA expression to be highest in U937 cells when compared to other AML cell lines. 
Values represent gene expression relative to U937 cells and normalized to the reference 
gene ABL. 
3.3.5 TRIB2 expression is important in the maintenance of the 
oncogenic properties of AML cells  
Based upon observations that overexpression of TRIB2 has a role in cellular 
transformation, the effect of modulating its expression in human AML was examined in 
the U937 cell line, which was adopted as a model for high TRIB2 expressing human AML 
cells. While established from what was described as a diffuse histiocytic lymphoma of a 
37-year-old patient (Sundström and Nilsson, 1976), U937 cells have been used to study 
myeloid differentiation (Ralph et al., 1983) as well as considered a valuable tool for AML 
research (Keeshan et al., 2006, Fang et al., 2011, Banerji et al., 2012). Importantly, TRIB2 
expression was not only detected in these cells but also shown to be the highest when 
compared to other AML cell lines (as detailed above). Therefore, to further examine 
whether TRIB2 is required for leukaemic cellular phenotype, gene knockdown was 
optimized in U937 cells using lentivirally expressed anti-TRIB2 small hairpin RNA 
(shTRIB2) or a control (shCtrl). Effective depletion of TRIB2 expression was verified by 
both mRNA (~80%) (Figure 3.5A) and protein (Figure 3.5B) analysis. Interestingly, 
western blotting also confirmed TRIB2 protein to be preferentially localized in the nucleus. 
While this conclusion has to be treated with caution as it only matches observations from 
one experiment, this is in keeping with the proposed putative nuclear localization sequence 
[K⁄R]2X2[D⁄E]X[D⁄ E] for TRIB family (Hegedus et al., 2006). Sub-cellular localization of 
mouse Trib2 was previously confirmed experimentally by the use of a GFP fusion protein 
and shown to be cytoplasmic (Kiss-Toth et al., 2006). However, overexpessed fusion 
proteins can affect intracellular localization and a better assessment is acquired by looking 
at the endogenous gene product. For subsequent TRIB2 detection, mRNA analysis was the 
preferentially used method, as it was thoroughly validated (Figure 3.4) and showed 
increased consistency over western blotting, likely hampered by TRIB2-specific antibody 
constraints. Gene knockdown inhibited the growth of U937 AML cells measured by cell 
counting with trypan blue exclusion (Figure 3.5C), induced apoptosis assessed by Annexin 
V staining (Figure 3.5D) and analysis of sub-G1 stage (Figure 3.5E), and promoted G1 cell 
cycle arrest with concomitant decrease in S phase (Figure 3.5E). The effect of TRIB2 
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downregulation on apoptosis and cell cycle was evaluated up to 5 days post-transduction 
and found to be more significant after 96 and 72 h transduction, respectively (Figure 3.5D 
and 3.5E), suggesting that U937 cells depleted from TRIB2 arrest in G1 phase before 
undergoing cell death. These results were further confirmed by means of an additional 
shRNA construct (LMP-shTRIB2). Modest knockdown (Appendix A-A) decreased the rate 
of cell growth, as assessed by cell counting by trypan blue exclusion assay, in comparison 
with cells expressing a retroviral control vector (LMP-Ctrl) (Appendix A-B). Altogether, 
these data indicate that TRIB2 expression is required for in vitro survival and proliferation 
of human AML cells (data included in (Rishi et al., 2014)). 
 
Figure 3.5 TRIB2 expression is required for growth and survival of U937 AML cells 
(A) Downregulation of TRIB2 in U937 cells transduced with either shCtrl or shTRIB2 
lentivirus was confirmed at mRNA and (B) protein level. In qPCR analysis values are 
normalized to the reference gene ABL and equal loading in western blot for nuclear and 
cytoplasmic extracts was confirmed by the specific detection of HDAC1 and actin 
expression, respectively. (C) Effect of TRIB2 silencing in shCtrl- or shTRIB2-U937 cells 
was assessed by analysis of cell growth by trypan blue exclusion, (D) cell death by 
Annexin V staining and (E) cell cycle was assayed by PI staining. Data presented are mean 
± SD of duplicate cultures and are representative of 2 independent experiments. *P≤0.05, 
**P≤0.01 by Student´s t-test. 
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3.3.6 Maintenance of TRIB2 expression is required for induction 
of AML in vivo 
To assess the requirement for TRIB2 during leukaemia progression in vivo, an AML 
xenograft model was used (Figure 3.6C). U937 cells were depleted of TRIB2 using the 
previously described lentiviral technology. Transduced cells were enriched by puromycin 
selection and high expression of GFP was confirmed before transplant into NSG 
xenografts (Figure 3.6A). Following efficient TRIB2 knockdown (Figure 3.6B), shCtrl- or 
shTRIB2-U937 cells were xenografted in NSG mice. These are highly immune-deficient 
mice due to a targeted deletion in the IL-2 receptor -common chain that leads to severe 
impairment of B- and T- cell development and function, and completely prevents NK-cells 
development (Shultz et al., 2005). The timeframe (16 days) was chosen based on a 
previous study by Banerji V et al. reporting engraftment and survival of NSG mice 
transplanted with shCtrl-U937 cells to occur within a period of 20 days (Banerji et al., 
2012). Spleen weights at the time of sacrifice (d16) were significantly decreased in the 
cohort of mice transplanted with shTRIB2-AML cells in comparison to control mice (P ≤ 
0.05; Figure 3.6D). Indeed, low levels of TRIB2 knockdown cells were detectable in the 
BM of xenotransplanted mice, while, in stark contrast, mice transplanted with control cells 
revealed a robust engraftment, as assayed by the percentage of engrafting GFP+ cells 
positive for human antibody CD45 expression (Figure 3.6E) and shown by representative 
FACS plots and bar graphs (Figure 3.6D, P≤0.001). Thus, in agreement with the in vitro 
studies, there is a significant growth advantage during leukaemia induction for cells that 
continue to express TRIB2 (data included in (O'Connor et al., 2016)) . 
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Figure 3.6 In vivo TRIB2 expression accelerates progression of AML 
(A) U937 cells were transduced with shCtrl or shTRIB2 lentivirus and selected after 24 h 
with 2 µg/mL puromycin. After 2 days, equally high expression of GFP was detected by 
FACS analysis in both transduced cells. (B) TRIB2 gene knockdown was confirmed at the 
mRNA level in shTRIB2-U937 cells. Values represent gene expression relative to shCtrl 
and normalized to the reference gene ABL (***P≤0.001 by Student´s t-test). (C) Schematic 
representation of the AML xenograft study. NSG mice were transplanted with 1.2x10
6 
U937 cells transduced with shCtrl (n=5) or shTRIB2 (n=8) lentivirus. (D) Spleen weights 
were measured on day 16 after transplant. Each symbol represents an individual mouse and 
horizontal bars represent mean values (*P≤0.05 by Student´s t-test). (E) GFP and hCD45-
PE Cy7 expression in BM were quantified by flow cytometry as a measure of disease 
burden in shCtrl- and shTRIB2-U937 mice and data are shown by representative FACS 
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pseudocolor plots (left panel) and bar graph (right panel) with means ± SD (***P≤0.001 
by Student´s t-test). 
3.3.7 TRIB2 knockdown in U937 human AML cells changes 
expression of a subset of genes 
To further explore the molecular mechanisms underlying TRIB2-induced phenotype in 
U937 AML cell line, expression of selected apoptosis- and cell cycle-relevant genes was 
investigated in these cells after downregulation of TRIB2. U937 cells transduced with 
either shCtrl- or shTRIB2-lentivirus were sorted and mRNA from two independent 
replicates was collected at 48 and 72 h post-transduction. High-throughput qPCR was 
carried out using the 48.48 Dynamic Array™ IFC system (Fluidigm). TRIB2 knockdown 
was confirmed in both analyses (Figure 3.7A and B). When comparing expression of genes 
in response to TRIB2 silencing, samples collected after 48 h transduction (Figure 3.7A) 
showed an increase in expression of the cell cycle regulator genes (ATM, ATR, BRCA2, 
PTEN, P27KIP1 and CDC25A) and also of the pro-apoptotic BIM (BCL2-Like11), CASP3, 
CASP8 and BAX genes. Even if a concomitant downregulation of the anti-apoptotic genes 
(except for XIAP) was not detected, the ratio of pro-apoptotic to anti-apoptotic genes was 
increased suggesting that TRIB2 knockdown results in a pro-apoptotic phenotype. The 
enhanced mRNA expression of the pro-apoptotic genes when TRIB2 was silenced 
correlates with results obtained for the cell death analysis that identified an increase in 
apoptosis after TRIB2 knockdown. Expression of the P27KIP1 cyclin-dependent kinase 
inhibitor and the pro-apoptotic BIM remained transcriptionally up-regulated at 72 h post 
transduction. P27KIP1 encodes a protein that binds to and prevents the activation of cyclin 
E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1 
phase (Toyoshima and Hunter, 1994). BIM is a BH3-only protein from the BCL-2 family 
that is capable of inducing apoptosis (O'Connor et al., 1998). These findings are in line 
with the cell cycle arrest and apoptotic phenotypes observed after 72 and 96 h transduction, 
respectively (Figure 3.5 D and E). Importantly, the transcriptional changes were detected at 
time points (48 and 72 h) that either match or precede the abovementioned phenotypes, 
hence, supporting a cause-and-effect relationship. Results therefore suggest that TRIB2 
modulates apoptosis and cell-cycle sensitivity by influencing the expression of a subset of 
genes known to have implications on these phenotypes. Together the in vitro and in vivo 
experiments support the role of TRIB2 in AML cell survival. 
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Figure 3.7 Differential expression of a subset of genes in U937 cells after modulation 
of TRIB2 expression 
(A) Gene expression analysis to compare TRIB2 knockdown and U937 cells transduced 
with shCtrl was performed with samples collected after 48 and (B) 72 h transduction. 
Genes were normalized against the average of reference genes ABL, B2M, ENOX2 and 
RNF20. Values are relative to shCtrl-U937 and are expressed as log2. *P≤0.05 by 
Student´s t-test. 
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3.3.8 TRIB2 is expressed in a significant number of AML patient 
samples  
The implication of TRIB2 expression in AML cell survival prompted the mRNA analysis 
of TRIB2 across a cohort of twenty-eight AML patient samples. Transcript levels were 
compared to U937 cells and two non-AML cell lines (CV1665 and CV1939) with low 
levels of TRIB2 were included. The clinical characteristics of patients included in this 
study that could be obtained are shown in Table 3.1. High percentage of blasts cells 
(indicated by CD33 antigen, >58%) and enrichment for a more primitive population (% of 
CD34+) were reported for few samples. qPCR analysis detected variable TRIB2 expression 
across the cohort but a significant number of primary AML cells were identified with 
transcript levels comparable to that of the U937 cell line, used as a control reference for 
high expression (Figure 3.8). To avoid seeking an optimal cut point, AML patient samples 
were dichotomized at the mean fold change value (0.4) into 2 expressing level groups: a 
low TRIB2 group with TRIB2 values less than 0.4 (n=14/28; median fold change, 0.15; 
range, 0.02-0.34) and a medium to high TRIB2 group consisting of patients with TRIB2 
values of more than 0.4 (n=14/28; median fold change, 0.76; range, 0.36-1.5).  
 
 
 
Figure 3.8 TRIB2 is detected at significant levels in a cohort of AML patients 
For TRIB2 mRNA analysis U937 AML cell line was used for comparison purposes as a 
control for high TRIB2 expression and two non-AML cell lines (CV1665 and CV1939) 
with low levels of TRIB2 were included. A significant number of AMLs with medium to 
high levels of TRIB2 mRNA (grey bars; 14/28) was detected when using the average of 
fold changes (0.4) as a cut-off value. Values represent gene expression relative to U937 
cells (green bar) and normalized to the reference gene ABL. 
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There were no significant differences between low and medium to high TRIB2-expressing 
patients with respect to age (median age 65 vs 62, respectively), with the exception of 
AML#8 (36-years-old). Moreover, TRIB2 expression levels were randomly distributed 
across gender and the FAB classes. Based on the available information regarding 
cytogenetic/molecular abnormalities and their prognostic relevance described in the 
literature, samples were further classified according to the risk-scoring system (Chapter 1, 
section 1.2.3), as depicted in Table 3.1. All 3/10 reported aberrations that predict for poor 
prognosis (complex karyotype, t (6;11) and monosomy 7) were found in patients with low 
TRIB2 mRNA levels (AML#1, 2 and 13, respectively). Complex karyotype (three or more 
different cytogenetic aberrations) and monosomy of chromosome 7 are consistently 
associated with unfavourable outcome (Löwenberg, 2001) whereas t (6;11) translocation is 
rare in AML but also reported to indicate a poor prognosis (Martineau et al., 1998, Blum et 
al., 2004). Abnormalities associated with favorable outcome, t(8;21) and FLT3-WT, were 
detected in both low (AML#8) and high (AML#23 and 28) TRIB2 expressing subgroups. 
Cytogenetically normal (CN) samples, included in the intermediate risk AML, were also 
detected in both cohorts defined based on TRIB2 status. Taken together, these data 
identified TRIB2 expression in human AML samples at levels, to some extent (14/28), 
comparable to the high expressing U937 AML cell line. Association with the available, 
while incomplete, karyotype/molecular information suggests that AML patients with 
higher TRIB2 expression are more likely to be associated with the favourable or the 
intermediate prognostic subgroups.  
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Table 3.1 Characteristics of the AML patient samples screened for mRNA TRIB2 
expression 
 
FAB, French-American-British; CMML, Chronic Myelomonocytic Leukaemia; MDS, Myelodysplastic 
Syndrome; NOS, not otherwise specified; CN, cytogenetically normal; , samples are positive for these cell 
surface markers but % values are unknown; , AML#27 was excluded from risk-stratification as different 
types of chromosome 9 aberrations described in the literature (trisomy 9 and del(9)) predict for distinctive 
AML outcomes (intermediate and favorable) (Flandrin, 2002, Sole et al., 2005, Zhang et al., 2005). 
 
3.3.9 Higher expression of TRIB2 in primary human AML samples 
is not predictive of preferential engraftment 
TRIB2 was shown here to be important in the maintenance of the oncogenic properties of 
human AML cells (Figure 3.5). In light of these findings, together with the mRNA analysis 
indicating detectable high levels of TRIB2 in a cohort of primary human AML cells, it was 
reasoned that TRIB2 expression could correlate with engraftment capability of AML 
patient samples. Such an experimental approach would allow a deeper characterization of 
TRIB2 role in human AML biology while, simultaneously, assessing its predictive value in 
relation to clinical outcome of patients, as engraftment levels tend to be higher with AML 
samples harboring poor prognostic abnormalities than with those carrying changes 
associated with a favorable outcome (Ailles et al., 1999). To address this, samples from 6 
AML patients classified according to FAB subtype and cytogenetic characteristics when 
available (Table 3.1) were selected for a xeno-engraftment study based on previous 
Patient 
ID
Gender
Age 
(Years)
Clinical 
Status
% CD33 % CD34 
FAB 
classification
cytogenetic and molecular 
information 
Risk-
stratification
TRIB2  mRNA 
AML#1 F 57 - 58.1% - M0 or M1 
Complex (47XX, +4[2]/48, idem, 
+10[3]/48, idem, 
der(2)?t(2,17(q37;q21),+10[8]/46,XX[2] ) 
Poor low
AML#2 - - - - - - t (6;11) Poor low
AML#3 M 79 - - 52.6% - - - low
AML#4 F 70 Relapse - - M6 - - low
AML#5 - - - - - - - - low
AML#6 M 57 - - - CMML/M5 - - low
AML#7 M 73 - - - - - - low
AML#8 F 36 - - 70.6%  M2  t (8;21); negative for FLT3 mutation Favorable low
AML#9 - - - - - - - - low
AML#10 M - Relapse 91.6% -  M5 - - low
AML#11 F 82 - - - - - - low
AML#12 - - - - - - CN Intermediate low
AML#13 - - - - - M2 monosomy 7 Poor low
AML#14 - - - - -  MDS/M4 CN Intermediate low
AML#15 F 64 - 90.6% 14% M6 CN Intermediate medium to high
AML#16 - - - - - - - - medium to high
AML#17 M - -   NOS - - medium to high
AML#18 - - - - - - - - medium to high
AML#19 - - - - - - - - medium to high
AML#20 M 78 Diagnosis   M4 - - medium to high
AML#21 - - - - - - - - medium to high
AML#22 F 48 - - - M3 - - medium to high
AML#23 - - - - - M2  t (8;21) Favorable medium to high
AML#24 M - - - - - - - medium to high
AML#25 F 68 No treatment - - MDS/AML - - medium to high
AML#26 - - - - - - - - medium to high
AML#27
- - - - - -
chromosome 9 aberration  medium to high
AML#28 F 51 - - - - negative for FLT3 mutation Favorable medium to high
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dichotomization into low (AML#1, 4 and 10) and medium to high (AML#15, 17 and 20) 
TRIB2 expression (Figure 3.8A). Choice of patient cells was narrowed by samples/number 
of cells that were available from the bio-bank. For the in vivo experiment, the immuno-
permissive NSG mice were used as recipients. These mice not only have a longer life span 
(>90 weeks) than the NOD/SCID mice due to the unlikelihood of developing thymonas 
(Shultz et al., 2005), but also, and most importantly, represent an improved model over 
earlier immuno-deficient mouse strains. Improvements include both the robustness of 
engraftment and the expansion of unsorted human AML MNCs in primary, secondary and 
tertiary recipients in a manner that seems to model human leukaemic disease progression 
(Sanchez et al., 2009). Published experiments were used as guidelines to design the animal 
study (Figure 3.9A), to define irradiation dosage, sex and age of the animals, number of 
injected cells and time course adopted (Sanchez et al., 2009, Notta et al., 2010, Salvestrini 
et al., 2012, von Bonin et al., 2013, Barth et al., 2014, Pabst et al., 2014). Groups of 3 
female NSG recipients/sample were injected with 1.1 to 1.6x10
6
 unsorted leukaemic PB 
MNCs 24 h after sublethal irradiation (2.25/2.5 Gy). Engraftment was defined by the 
prevalence of hCD33 and hCD45 double positive cells, which are consistent with human 
AML. Mice were monitored by flow cytometric analysis of PB samples taken at week 3, 5, 
7 and 8 after transplantation (data not shown, as values were overall below 0.1). When 
long-term engraftment of human leukaemic cells was evaluated following necropsy at 12 
weeks post-injection, all mice showed >0.1% hCD45+hCD33+ AML cells replacement of 
the BM by FACS analysis (used cut-off value (Sanchez et al., 2009, Notta et al., 2010, 
Sarry et al., 2011)) (Figure 3.9C and D). BM was the primary site of leukaemic cells 
infiltration with 4/17 specimens displaying high levels of engraftment (over 10%), as 
depicted by Figure 9.D. In contrast to previous studies reporting that engraftment levels 
could shift from a heavily infiltrated BM to the spleen, which could be a result of 
progression to marrow fibrosis (Kuter et al., 2007, Sanchez et al., 2009), analysed spleens 
in this study showed limited leukaemic cell expansion (largely < 1%, data not shown). An 
overall correlation between spleen enlargement and efficiency of engraftment was detected 
in NSG mice, exemplified by mice transplanted with AML#10 presenting both high BM 
engraftment (Figure 3.9D) and spleen weight (Figure 3.9B left and right panels) and 
corroborating that NSG mice engrafted with human AML samples display features of the 
human disease. Importantly, this study showed a robust engraftment of unsorted leukaemic 
cells. Engraftment did not correlate with specific FAB subtypes, as samples were randomly 
distributed across classes, and from the cohort selected for NSG transplantation only two 
were annotated with cytogenetic/molecular information. Nevertheless, it is striking that the 
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highest levels of hCD45+hCD33+ AML cells were detected in mice tail injected with the 
complex karyotype AML#1 (Table 3.1), despite differences in the magnitude of 
engraftment (9%,37%,42%). With regard to the differential TRIB2 expression, no 
statistically significant difference (P=0.08) was observed between the two cohorts in their 
ability to engraft the NSG BM with AML cells (Figure 3.9D). It is likely that a bias can be 
introduced by comparing a heterogeneous AML cohort with limited information regarding 
clinical and cytogenetic/molecular features. However, results suggest that a higher 
expression of this oncogene does not correlate with increased engraftment capability in 
NSG mice, and thus not predicting an association with adverse prognosis. 
 
Figure 3.9 Engraftment ability of primary human AML with variable levels of TRIB2 
expression in NSG mice 
(A) Schematic representation of the xenotransplantation. 1.1-1.6x10
6
 human AML cells 
selected for low (AML#1, 4 and 10) and medium to high (AML#15, 17 and 20) TRIB2 
expression were injected through tail vein 24 h after sublethal irradiation of 6-11 week-old 
female NSG mice. Each sample was injected into 3 mice. (B) Spleen weights were 
measured following necropsy at 12 weeks after transplantation, as shown by graph (left 
panel) and representative images (right panel). Pictures are from spleens collected from 
mice transplanted with AML#10 (0.19 g) and AML#17 (0.06 g). (C) Engraftment was 
assessed by flow cytometry detection of hCD45 PE Cy7 +hCD33 APC+ double positive 
BM cells consistent with human AML, as depicted by representative FACS pseudocolor 
plots. (D) No statistically significant differences were detected in marrow engraftment     
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(> 0.1%) based on low vs medium to high TRIB2 expression. Blue line in bar graph 
indicates a high level of engraftment of 10% of murine BM replaced with human AML 
(4/18 mice) detected in both cohorts. For (B) and (D), each symbol denotes a single mouse 
and horizontal bars represent mean values for a given cohort. Mice transplanted with AML 
samples expressing low TRIB2 are highlighted in black whereas grey colour indicates mice 
injected with primary leukaemic cells with medium to high TRIB2 expression; n.s., not 
significant by Student´s t- test. 
3.4 Discussion 
TRIB2 has been reported as a cancer driver in a variety of malignancies. Here, it is shown 
that in the majority of cancers retrieved from COSMIC database, in which AML is 
included, TRIB2 oncogenic activity is related to its elevated gene expression rather than 
associated with different genomic alterations or mutations. This conclusion amplifies 
previous observations reporting a tumorigenic role for TRIB2 in melanoma and lung cells 
found to overexpress this gene (Zanella et al., 2010, Grandinetti et al., 2011). Moreover, 
Trib2 ability to induce murine leukaemia also resulted from its overexpression. In addition, 
increased expression is unlikely to be a result of elevated gene copy number, as CNV was 
rarely found across the different tumours tissues analysed here, underscoring an important 
role for regulators of TRIB2 expression in cancer. Indeed, in a recent paper published 
during the course of the present study, a feedback loop mechanism for the positive 
upregulation of TRIB2 expression in AML was detailed. TRIB2 expression was shown to 
be regulated in AML cells by E2F1, that cooperates with the C/EBPα p30 oncogenic 
isoform to activate the TRIB2 promoter, while in normal GMPs the wild type C/EBPα p42 
is bound to the TRIB2 promoter (Rishi et al., 2014).  
The finding that mouse BM cells overexpressing Trib2 gene could be propagated in vivo 
for three passages, retaining robust levels of engraftment accompanied by shorter latency, 
demonstrates their self-renewal properties and long-term leukaemogenic potential. In 
previous work (Keeshan 2006), serial transplantations to tertiary recipients were not 
performed. Data presented here show that Trib2 effectively and serially engrafts to tertiary 
recipients, maintains the primary AML phenotype and is not associated with secondary 
genomic instability characteristics, such as chromosomal alterations. Moreover, central 
nervous system (CNS) involvement detected in the tertiary recipients underpins 
aggressiveness of Trib2-induced leukaemia, as it can be a serious complication during the 
clinical course of patients with AML (Dohner et al., 2010), and hints at a possible use of 
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this model to investigate mechanisms and treatment of CNS leukaemia. When murine 
Trib2-BM cells were kayotyped for a more comprehensive analysis of this leukaemia, they 
were found in the absence of cytogenetically detectable rearrangements. It is noteworthy 
that other single genes reported to be overexpressed in AML (BAALC (Tanner et al., 2001, 
Baldus et al., 2003), ERG (Marcucci et al., 2005) and MN1 (Heuser et al., 2005)) have 
been associated with adverse human leukaemia prognosis also in the large subset of CN-
AML. This may be indicative that TRIB2 overexpression is rooted in the cytogenetically 
normal group, which could be of particular relevance to help defining a heterogeneous 
subtype for which the WHO classification fails to predict outcome. Indeed, recent studies 
have evaluated the usefulness of global gene-expression profiling to identify prognostic 
subgroups within the CN-AML patients (Baldus et al., 2007). TRIB2 overexpression does 
not seem, however, to be restricted to this cytogenetic subset of AML since it was shown 
to occur in AML patients with abnormal karyotypes (AML#23 and 27, Figure 3.8).  
In contrast to the existing knowledge on Trib2 function in driving murine AML in vivo, the 
study of TRIB2 role in human AML settings is limited to expression analysis to date. With 
that in mind, TRIB2 function in the context of myeloid malignancies was characterized and 
strengthened in a human leukaemia setting. Functional assays clearly showed importance 
of TRIB2 expression for survival of U937 AML cells in liquid culture, which displayed an 
altered cellular phenotype after gene knockdown. TRIB2-specific suppression by means of 
two shRNA constructs led to impaired growth, as a consequence of both an increase in 
apoptosis and a decrease in cell proliferation. Cell culture-based systems are, however, 
limited on their ability to recapitulate primary disease as they cannot replicate cell extrinsic 
interactions with the immune cells or BM niche. Murine xenograft models, albeit limited in 
their ability to address leukaemia-immune cell interactions, are suitable to explore human 
cell specific biology in an in vivo environment (Cook and Pardee, 2013). Moreover, the use 
of well-established, easily grown human cell lines in NSG xeno-engraftment studies has 
the unique advantage of providing a model that recapitulates human disease in a timeframe 
of days or weeks, even if the extent to which they retain features of the original disease in 
vivo is a matter of debate (Kamb, 2005). Therefore, lentiviral knockdown of TRIB2 in 
U937 AML cells was performed and xenotransplantation into NSG mice used as a 
surrogate assay to study the modulating effect of TRIB2 on AML aggressiveness in vivo. 
Consistent with the results obtained in vitro, progression of the AML xenografts was 
significantly impaired (P≤0.001) following TRIB2 knockdown, accompanied by detection 
of a lower spleen weight in this cohort. A significant growth advantage during in vivo 
leukaemogenesis for cells that continue to express TRIB2 was, thus, suggested by the short 
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latency U937-NSG model, supporting the view that this gene is functionally important in 
the maintenance of the malignant phenotype of human AML cells. Based on the 
phenotypic changes observed upon TRIB2 knockdown, it was thus hypothesised that gene 
depletion could elicit downstream transcriptional modifications in genes related with the 
detected apoptotic response and cell cycle arrest. Indeed the overall expression pattern 
observed in cells collected at an earlier time point (48 h after transduction) suggested an 
increase in pro-apoptotic genes discreetly supported by a decrease in anti-apoptotic genes. 
This gene analysis has led to the identification of a smaller subset of genes that could 
explain, to some extent, the observed TRIB2-dependent phenotype. Based on the 
observation that the cell-cycle regulator P27KIP1 and BIM, were consistently upregulated 
upon TRIB2 knockdown, it was questioned whether FOXO3a, an upstream mediator of 
both these genes could be implicated by mediating TRIB2 regulation of both genes. The 
pro-apoptotic BIM is a transcriptional target of FOXO, which is in turn downregulated by 
TRIB2 in melanoma cells after cytoplasmic sequestration. No change in total FOXO3a 
subcellular localization was detected by western blotting after TRIB2 knockdown (data not 
shown). Although not extensively explored here, effects on FOXO3a function rather than 
expression are possible given the known relationship between TRIB2 and FOXO3a in 
melanoma cells (Zanella et al., 2010). 
TRIB2 expression analysis in a cohort of AML patient samples revealed a significant 
number with elevated transcript levels comparable to that of the U937 cells, the human 
AML cell line found to express the highest TRIB2 expression within a group of AML cell 
lines. This result disagrees with a previous study reporting TRIB2 expression to be overall 
low across AML karyotypes or FAB subtypes assessed from publically available 
microarray datasets (Liang et al., 2013). It is conceivable that differences are likely 
attributed to the criteria used to define expression levels. Previous studies reporting TRIB2 
overexpression in malignant melanoma and lung cancer (Zanella et al., 2010, Grandinetti 
et al., 2011) suggest that mRNA analysis of this oncogene would be better assessed by 
comparing tumor tissue of a given patient with its matched normal counterpart. In light of 
the observed TRIB2 mRNA levels, it would be extremely interesting to evaluate C/EBP 
protein status in these samples, given that elevated TRIB2 expression has been linked with 
a subset of human AML characterized by deregulation of this transcription factor (Keeshan 
et al., 2006) and that C/EBPα is a downstream factor of TRIB2 proteolytic activity. TRIB2 
was recently identified as a meaningful biomarker in malignant melanoma, as its 
expression strongly correlates with disease stage and clinical prognosis, predicting, as well, 
clinical response to chemotherapy (Hill et al., 2015). High risk B-cell chronic lymphocytic 
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leukaemia (B-CLL) patients were also associated with differentially expressed TRIB2 
(Johansson et al., 2010). Hence, it would be of interest to know the relapse rate, overall 
survival, disease-free survival and complete remission rate of the analysed leukaemic 
patients to assess if dichotomization based on TRIB2 expression is meaningful as a 
diagnostic marker in the context of AML. 
The presence of FLT3 mutations in AML patient samples correlates with an enhanced 
ability to engraft in NOD/SCID (Rombouts et al., 2000) and NSG (Sanchez et al., 2009) 
mice when compared with FLT3 wild-type-containing human AML. Also, AML harboring 
DNMT3A mutations, which predict for adverse outcome, were shown to engraft with 
exceptional efficiency (Barth et al., 2014), supporting the view that a correlation exists 
between xeno-engraftment potential and disease aggressiveness in humans. With that in 
mind, the NSG model was used to investigate the in vivo leukaemia-initiating capacity of 
human primary AML cells with dichotomized levels of TRIB2 transcripts while assessing 
whether increased expression of this gene could be afforded a prognostic significance. The 
severe impairment of NSG innate immunity and the associated prolonged life span have 
made them the gold standard for long-term studies of primary human AML engraftment. 
Indeed, a global analysis suggests that a robust engraftment can be attained with this 
model, as BM was shown to be replaced by >0.1% hCD45+hCD33+ AML cells. When 
ability to repopulate NSG mice was analysed in terms of TRIB2 expression, higher 
transcript levels in AML patients did not correlate with preferential leukaemic cell 
engraftment. However, caution should be used when concluding differences based on 
TRIB2 expression since a number of other factors could be implicated in differential levels 
of engraftment, namely, elements of BM homing, survival in a foreign niche, expansion in 
the absence of specific human growth factors and supporting stromal cells, as well as 
intrinsic differences among AML samples (as exemplified by poor-risk associated 
AML#1). Further experiments including a larger cohort of well characterized AML 
patients would be needed to clarify TRIB2 significance in a diagnostic setting. 
Taken together, these findings establish a functional role for deregulated TRIB2 expression 
in the pathogenesis of human AML and provided a contextual framework to further 
investigate this oncogene as a therapeutic target, as next described.  
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Chapter 4 
Proteasome inhibition selectively targets AML 
with high TRIB2 expression 
  
When indicated, results presented in this chapter have been published in (O'Connor et al., 
2016) and the PDF of the publication is provided in Appendix G. 
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4.1 Introduction 
AML is primarily a disease of elderly people for whom prognosis remains consistently 
dismal in spite of the past few decades‟ improvement in the overall outlook for younger 
patients. In addition, the mainstays of AML therapy have remained unchanged for the last 
30 years (Tallman et al., 2005, Burnett, 2013, Ferrara and Schiffer, 2013). The 
combination of cytarabine (e.g., cytosine arabinose, Ara-C) with an anthracycline (e.g., 
daunorubicin, idarubicin) is the backbone of induction therapy, which has become the 
standard of care for patients not participating in a clinical trial. These patients receive 
cytarabine as a continuous intravenous infusion for 7 consecutive days, while anthracycline 
is given for 3 consecutive days as an intravenous push. The tolerance of elderly patients to 
this therapy is limited by host-related factors, as well as by the frequent development of 
myelodysplasia, unfavourable karyotypes and overexpression of the multidrug-resistance 
gene MDR-1 at diagnosis (Smith et al., 2004). The main exception to the traditional 
cytotoxic chemotherapy known as “7+3” is the use of all-trans retinoic acid (ATRA), a 
derivative of vitamin A (or retinol) that has held great promise for differentiation-based 
therapy. ATRA, in combination with low-dose chemotherapy, is effective on the rare M3 
acute promyelocytic leukaemia (APL) subtype (5-10% of AML) (Tallmann, 2004). 
Typically, this subtype carries the leukaemia-generating PML-RARα fusion protein, which 
results from t(15;17) translocation (Melnick and Licht, 1999). Pharmacological 
concentrations of the retinoic acid receptor (RAR)-specific ligand ATRA cause a 
conformational change of PML-RARα, which acts as a dominant negative inhibitor of the 
WT RARα. Co-repressors are then released, normal RARα- responsive gene regulation is 
restored and terminal APL cell differentiation into mature granulocytes is induced (Jing 
and Waxman, 2007). Unfortunately, ATRA is not clinically useful for other AML 
subtypes. Most non-APL leukaemia cells respond to ATRA but only at high 
concentrations, which leads to important cytotoxic effects (Gupta et al., 2012). Therefore, 
research strategies that seek to further extend treatment efficacy to non-APL cells are key. 
The use of small-molecule drugs designed to inhibit the proteasome degradation pathway 
has sparked intensive research for the treatment of a variety of cancers, including AML. In 
fact, clinical trials for AML patients have been conducted and are currently on going to 
evaluate Brtz and identify drug combinations showing therapeutic efficacy. Despite the 
lack of single agent activity (Cortes et al., 2004, Horton et al., 2007), Brtz has shown 
promising results when used in combination regimens for AML. Two phase I studies for 
poor-risk groups demonstrated the feasibility and preliminary clinical activity of Brtz in 
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combination with idarubicin (Howard et al., 2013) or with the DNA hypomethylating agent 
decitabine, despite neurotoxicity concerns (Blum et al., 2012). Attar et al. randomized 95 
patients (age 60 to 75 years) with untreated AML to evaluate the safety and efficacy of 
Brtz in combination with daunorubicin and cytarabine and assessed whether Brtz could 
improve the standard induction chemotherapy by increasing the remission rate. Despite the 
neurotoxicity observed in some patients, this phase II/I clinical study reported an 
encouraging remission frequency (Attar et al., 2013). Additionally, the effect of Brtz in 
combination with standard chemotherapy is presently being evaluated on a phase III trial in 
younger patients (0 to 30 years of age) with de novo AML (Children's Oncology Group 
(COG) study AAML1031).  
It is known that the myeloid pathogenicity of TRIB2 relies on its ability to bind the full-
length isoform of C/EBPα (C/EBPα p42) and mediate its proteasomal degradation through 
binding with COP1 E3 ligase while sparing p30 (Keeshan et al., 2006, Keeshan et al., 
2010). Even in a broader tumour context, TRIB2 is found to have an oncogenic role via the 
UPS. In lung cancer, where its expression is elevated and has a role in cellular 
transformation, TRIB2 downregulates C/EBPα via targeting of the transcription factor for 
proteasomal degradation. By means of an immunoprecipitation-mass spectrometry 
approach, it was further found that interaction between TRIB2 at the C terminus and the E3 
ligase TRIM21 is important to this process (Grandinetti et al., 2011). In liver cancer cells, 
TRIB2 binds other E3 ligases including βTrCP, COP1 and Smurf1 (Xu et al., 2014) (see 
Chapter 1, section 1.3.3). The strong link between TRIB2 and the UPS in cancer creates a 
framework for considering proteasome inhibition treatment. 
4.2 Aims and Objectives 
The present study hypothesises that proteasome inhibition would effectively inhibit TRIB2 
function by abrogating C/EBPα p42 protein degradation and that it could be an effective 
pharmacological strategy in TRIB2-expressing AML cells. Therefore, the specific aims of 
this chapter were:  
i. To investigate the chemotherapeutic response of both murine and human TRIB2-
expressing AML cells to proteasome inhibition; 
a. In vitro 
b. In vivo 
ii. To investigate specificity of proteasome inhibition on the TRIB2-C/EBPα axis.  
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4.3 Results 
4.3.1 Murine Trib2 AML cells are sensitive to Brtz treatment in 
vitro 
The antitumor effect of proteasome inhibition in TRIB2 positive leukaemic cells was first 
investigated using the boronic acid derivative Brtz and the murine Trib2-GFP+-AML 
model. This model was considered a logical approach for a first therapeutic evaluation, as 
it was thoroughly characterized and could be used as a source of leukaemic cells. 
Therefore, BM cells harvested from secondary Trib2-AML mice were treated in vitro 
either with Brtz or with DMSO as a vehicle-only control to measure the apoptotic effect. 
The concentration used for the in vitro Brtz treatment was 10 nM, based on the average 
50% inhibitory concentration (IC50) in U937 cells reported in section 4.3.3. After a 24 h 
treatment, cells were analysed by FACS for GFP expression, which was used as a marker 
for both cell viability and detection of leukaemic cells. A significant reduction in Trib2-
expressing cells was detected following Brtz treatment, as evidenced by a decrease in % of 
GFP positive cells depicted in the corresponding FACS plots (Figure 4.1A) and bar graph 
(Figure 4.1B). Subsequently, cells matching one biological replicate were plated for 
colony-forming cell (CFC) assay 24 h after Brtz treatment to determine the growth and 
clonal potential of any remaining cells. After 7 days, there was a significant reduction in 
the number of colonies formed from treated cells when compared to untreated (Figure 
4.1C). Additionally, cell colonies were stained for the myeloid differentiation cell surface 
markers CD11b and Gr-1 and analysed by FACS to evaluate changes in expression of 
these myeloid markers. An increase in the percentage of double-positive cells for both 
antibodies was detected in treated cells (Figure 4.1D), suggesting that Brtz elicits 
differentiation of non-apoptotic AML cells. 
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Figure 4.1Trib2 murine BM cells are sensitive to in vitro Brtz treatment 
(A) BM cells collected from secondary recipient mice with Trib2-induced leukaemia were 
treated in vitro with either Brtz (10 nM) or DMSO. After 24 h, GFP expression was 
quantified. Data are shown by representative FACS pseudocolor plots and (B) 
representative bar graph of 3 independent experiments with mean ± SD of 3 biological 
replicates (3 samples x 3 mice, considered as 3 independent experiment performed in 
triplicate). (C) Brtz or DMSO treated cells from one biological replicate were plated for 
CFC assay. Colonies were scored at day 7 and were normalized to % of GFP positive cells 
(error bar represents the mean ± SD of 2 technical replicates). (D) On day 11 of CFC assay 
the myeloid phenotype was assessed by FACS analysis of CD11b-PE and Gr-1-APC of the 
GFP+ population, as shown by representative contour plots. ***P≤0.001, *P≤0.05 by 
Student´s t-test. 
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4.3.2 Brtz preferentially targets murine Trib2 AML cells rather than 
normal haemopoietic cells 
To investigate whether targeting the UPS, a universal and broadly active cellular 
component, provides the selectivity and specificity required for cancer therapeutics, the 
proteasome inhibitor activity was assessed in normal bulk BM cells from wild type mice. 
Furthermore, it was evaluated whether a consistent result would be detected in normal BM 
stem cell populations. The stem cell populations were purified as outlined in section 2.7.6 
of the methods section. Thus, both total normal BM cells and the most primitive (LSK) and 
more differentiated (lineage+) populations were treated with Brtz (10 nM) and DMSO for 
24 h in vitro as described in section 2.1.8 of Chapter 2. Cell survival was analysed by 
staining with Annexin V and DAPI, and no significant differences were detected when 
comparing treated versus untreated cells in all populations (Figure 4.2A) at a concentration 
shown to have pro-apoptotic effect on Trib2 leukaemic murine BM cells. Consistent with 
these results, the myeloid phenotype (CD11b/Gr-1) of LSK and lineage positive cells did 
not show any change after the 24 h treatment, which rules out Brtz-induced differentiation 
at this time point (Figure 4.2B). Taken together with the data from section 4.3.1, the results 
suggest that Brtz is selectively pro-apoptotic towards leukaemic cells, while sparing 
normal BM cells. 
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Figure 4.2 Normal murine BM cells are not responsive to Brtz in vitro treatment 
Total BM cells, LSK and lineage positive cells from wild-type B6.SJL mice were treated 
with Brtz (10 nM) or DMSO only for 24 h and no significant differences were detected in 
cell viability or myeloid differentiation when treated cells were compared to corresponding 
controls. (A) Cell viability results are presented as a bar graph and results are expressed as 
fold change of Annexin V and DAPI positive cells ± SD of 2 technical replicates relative to 
vehicle-treated cells. (B) FACS analysis of CD11b-APC and Gr1-PE Cy7 is shown by 
representative contour plots of 2 technical replicates (left panel). For the lineage positive 
population, the same results are also shown as fold change of CD11b/Gr-1 double positive 
cells ± SD of 2 technical replicates relative to vehicle-treated cells. 
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4.3.3 Modulation of TRIB2 levels sensitizes AML cells to 
cytotoxicity induced by proteasome inhibition  
The chemotherapeutic response of TRIB2-expressing AML cells was next investigated in 
the human setting, where the role of TRIB2 as a mediator of the Brtz-induced therapeutic 
response was interrogated. To address this, the human U937 cells were used, as they 
express detectable levels of endogenous TRIB2 and C/EBPα, and TRIB2 levels were 
additionally modulated by means of an expression vector. U937 cells were lentivirally 
transduced with Phr control (PhrCtrl) or PhrTRIB2 and treated with either vehicle or Brtz 
(Figure 4.3A) at 10 nM (IC50). The IC50 value of Brtz in U937 cells had been previously 
determined by Fiona Lohan (former PhD student in the Keeshan lab) and is in accordance 
with the average values reported for human AML cells (Horton et al., 2006, Fang et al., 
2012). TRIB2-overexpressing U937 cells (higher transcripts levels confirmed by mRNA 
analysis, Figure 4.3B) showed increased DAPI positivity after treatment with Brtz (68.9% 
versus 45.9% for control Phr, P ≤ 0.05; Figure 4.3C), as well as increased expression of 
cells arrested at sub-G1 cell cycle stage (Figure 4.3D), which reflected an augmented 
cytotoxic response towards proteasome inhibition upon TRIB2 modulation. 
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Figure 4.3 TRIB2 expression sensitizes AML cells to in vitro cytotoxicity induced by 
Brtz (Figure on previous page). (A) Chemical structure of bortezomib (Brtz), 
C19H25BN4O4. (B) TRIB2 overexpression in U937 cells transduced with PhrTRIB2 was 
confirmed at the mRNA level. (C) Sorted GFP+ U937 cells transduced with either PhrCtrl 
or PhrTRIB2 lentivirus were treated with 10 nM Brtz or DMSO only for 16 h. Cytotoxicity 
was assessed by DAPI staining and (D) cell cycle was assayed by PI staining. Results are 
presented for each condition as a percentage of vehicle treated cells and are representative 
of 3 independent experiments. with 2 technical replicates. n.s., not significant; *P≤0.05 by 
Student´s t-test. 
To pursue this observation further, next-generation proteasome inhibitors peptido sulfonyl 
fluoride (SF) (Figure 4.4A) and carfilzomib (Cfz; formerly PR-171) (Figure 4.4A) were 
also used for in vitro experiments with U937 cells. Unlike Brtz, SF and Cfz cause 
irreversible proteasome inhibition with greater selectivity for the proteasomal CT-L 
activity (Brouwer et al., 2012, Demo et al., 2007). SF is an experimental proteasome 
inhibitor, inspired by the backbone sequences of Brtz, epoxomicin and Cbz-Leu3-aldehyde 
(MG132) (Brouwer et al., 2012). The epoxyketone-based inhibitor Cfz has been approved 
by the FDA for the treatment of relapsed/refractory multiple myeloma (Katsnelson, 2012) 
and showed greater efficacy and fewer side effects than Brtz (Vij et al., 2012). Both 
proteasome inhibitors were initially tittered in U937 cells treated with increasing 
concentrations of SF (10 nM-1.5 µM) and Cfz (4-500 nM). Interestingly, SF induced a 
similar % of DAPI+ cells to that obtained with 10 nM Brtz (included as a control) at a 
significant higher concentration (500 nM) (Figure 4.4B). While there are no previous IC50 
values published for this drug, a higher sensitivity of U937 to SF was anticipated based on 
its reported greater selectivity. With regards to Cfz, it was used at 10 nM in U937 cells, 
even if at this concentration the effect on viability was lower than the one obtained with 10 
nM Brtz (Figure 4.4B). This decision was based on published data, which reported an IC50 
<10 nM in multiple cancer cell lines (Demo et al., 2007). When used for in vitro treatment 
of U937 AML cells with high TRIB2 expression (lentiviral PhrTRIB2-GFP) or 
endogenous levels, the next-generation proteasome inhibitors also showed selective killing 
of high TRIB2-expressing AML cells, as assessed by cell viability (Figure 4.4C). Finally, 
an altered cellular phenotype of cell-cycle arrest at Sub-G1/G1 stages confirmed that 
cytotoxicity induced by proteasome inhibition was higher in U937 cells overexpressing 
TRIB2 (Figure 4.4D). Of note, the overexpression model was used in place of 
downregulating TRIB2 given the relevant role of TRIB2 in supporting U937 cell growth 
(see Chapter 3, section 3.3.5). 
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Figure 4.4 Modulation of TRIB2 levels sensitizes AML cells to cell death induced by 
next-generation proteasome inhibitors  
(A) Chemical structure of proteasome inhibitors. Peptido sulfonyl fluoride (SF), 
C32H53FN4O7S and carfilzomib (Cfz), C40H57N5O7. (B) Titration of Cfz and SF in U937 
cells. (C ) Sorted GFP+ U937 cells transduced with either PhrCtrl or PhrTRIB2 lentivirus 
were treated with 500 nM SF, 10 nM Cfz or DMSO only for 16 h. Cytotoxicity was 
assessed by DAPI staining. Representative FACS plots of 3 independent experiments with 
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2 technical replicates each are shown. (C) Cells from the previous experiment were also 
stained with PI for cell cycle distribution. Results are shown by representative bar graph of 
2 independent experiments with 2 technical replicates. n.s., not significant; *P≤0.05 by 
Student´s t-test. 
4.3.4 Brtz is selectively cytotoxic to high TRIB2 cells via the 
TRIB2-C/EBPα axis 
Given the fact that Trib2‟s myeloid oncogenic role results from its ability to induce 
degradation of C/EBPα p42 via UPS engagement (Keeshan et al., 2006, Keeshan et al., 
2010), it was argued that proteasome inhibition would be an effective anti-leukaemic 
therapy in TRIB2-expressing AML cells. Indeed, in vitro cytotoxicity induced by 
proteasome inhibitors was found in these cells (Figure 4.3 and 4.4). In order to correlate 
these observations with the predicted underlying mechanism of action, the effect of Brtz on 
C/EBPα was next examined by western blotting. Sorted GFP+ U937 cells transduced with 
either PhrCtrl or PhrTRIB2 were used for protein analysis after 6 and 8 h treatment 
because these time points precede the measured effects on cell viability. Brtz treatment (10 
nM) rescued the degradation of C/EBPα p42 detected upon overexpression of TRIB2 in 
U937 cells after the 6 and 8 h treatment, as evidenced by densitometry and illustrated in 
Figure 4.5A. To further support the hypothesis that increased sensitivity of high TRIB2 
AML cells to Brtz is related to the inhibition of TRIB2-dependent proteasomal degradation 
of C/EBPα p42, the analysis was extended to cells differentially expressing C/EBPα. Thus, 
cell lines lacking expression of C/EBPα were used to assess the effect of TRIB2 
overexpression upon Brtz treatment. Overexpression of TRIB2 was conducted in K562 and 
Kasumi-1 leukaemic cell lines. K562 cells do not express C/EBPα at protein (Scott et al., 
1992) or mRNA (Radomska et al., 1998) level. Kasumi-1 cells are a t(8;21) AML-M2 cell 
line where C/EBPα has been shown to be undetectable at protein level and very low in 
mRNA analysis (Pabst et al., 2001). On this background, Brtz toxicity assessed by DAPI 
staining was not increased following TRIB2 overexpression (PhrTRIB2) (Figure 4.5B). 
Finally, it was tested whether exogenously enhanced expression of wild type C/EBPα 
could rescue Brtz- induced cell death in U937. Indeed, cells overexpressing MigR1-
C/EBPα had decreased DAPI positivity upon in vitro treatment when compared to MigR1-
U937 control (P ≤ 0.001; Figure 4.5C). Together, these findings support Brtz specificity 
for the TRIB2-C/EBPα axis in high TRIB2 AML cells (data included in (O'Connor et al., 
2016)). 
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Figure 4.5 TRIB2-C/EBPα axis is a key molecular determinant of Brtz-induced 
cytotoxicity in high TRIB2 AML cells 
(A) Sorted GFP+ U937 cells transduced with either PhrCtrl or PhrTRIB2 were treated for 
6 and 8 h with 10 nM Brtz or DMSO only (NDC, no drug control) and cell lysates were 
analysed for C/EBPα expression by western blotting. TRIB2 overexpression was 
confirmed and tubulin was used as loading control. Densitometric analysis was performed 
for quantification of endogenous C/EBPα p42 and p30 proteins. Numbers are depicted 
above and below the lanes, respectively. For each time point, values represent band 
intensity normalized to tubulin and reported as fold change with respect to untreated 
control (Phr, NDC) set to 1. Representative of 2 independent experiments. (B) Sorted 
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GFP+ K562 and Kasumi-1 cells transduced with Phr control or Phr-TRIB2 lentivirus were 
treated with 10 nM Brtz or DMSO only for 16 h and analysed by flow cytometry for cell 
death by DAPI staining. Results are fold change of DAPI positive cells ± SD of 2/3 
technical replicates relative to vehicle-treated cells and are representative of 3 independent 
experiments. (n.s, not significant by Student´s t-test). (C) Sorted GFP+ U937 cells 
transduced with MigR1 control or MigR1-C/EBPα retrovirus were treated +/- 10 nM Brtz 
for 16 h and analysed by flow cytometry for cell death by DAPI staining. Results are 
shown by fold change of DAPI positive cells ± SD of 2/3 technical replicates relative to 
vehicle-treated cells (left panel) and contour plots (right panel) and are representative of 3 
independent experiments (***P≤0.001 by Student´s t-test). 
4.3.5 High TRIB2 AML cells are chemosensitive to proteasome 
inhibition in vivo 
To investigate whether chemosensitivity of high TRIB2 AML cells to Brtz could be 
recapitulated in vivo and, consequently, assess the potential clinical significance of these 
findings, a human AML xenograft model was established. The short latency U937-NSG 
model was used, as it was proven to be a fast and robust AML model, here (Chapter 3) and 
by others (Banerji et al., 2012). Importantly, it was previously shown that AML 
development in this model is tightly correlated with TRIB2 expression (Chapter 3), which 
makes this a suitable in vivo setting to investigate the TRIB2-dependent effect of Brtz. 
GFP+ U937 (shCtrl lentivirus) cells were, therefore, propagated in NSG recipients. Mice 
were treated at d5, 7 and 11 with i.p. injections of PBS or Brtz at the clinically relevant 
dose of 0.5 mg/kg (Liu et al., 2013). Blood samples were taken at d5 and 11 before drug 
administration and the mice were sacrificed at day 16 (Figure 4.6A), following the same 
experimental time course depicted in Chapter 3, section 3.3.6. Brtz significantly impaired 
the engraftment of the TRIB2 expressing U937 cells when compared to vehicle-treated 
animals, as detected by lower BM % of engrafting GFP+ cells, also positive for human 
antibody CD45 expression (Figure 4.6C). The treatment protocol was designed using 
previous studies as guidelines for toxicity assessment (Luo et al., 2011, Schueler et al., 
2013, Ying et al., 2013). Importantly, the Brtz dose and schedule were well tolerated 
throughout the course of the study. There was no significant weight loss from d0 to d16 
(Figure 4.6B , <10%, as defined in (Kamb, 2005),) nor any changes in the overall well-
being of treated mice that would be indicative of drug-associated toxicity. No signs of 
gross pathological abnormalities of the major organs were noted at mice necropsy 
examination. These findings support Brtz pre-clinical efficacy in TRIB2-expressing AML 
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cells, as NSG mice more closely mimic the patient setting (data included in (O'Connor et 
al., 2016)). 
 
 
 
 
 
Figure 4.6 TRIB2 expression sensitizes AML cells to cytotoxicity induced by 
proteasome inhibition in vivo 
(A) Schematic representation of the AML xenograft study. NSG mice (n=6) were 
transplanted with human GFP+ hCD45+ U937 cells. Each group was randomized into 2 
groups for treatment with 0.5 mg/kg Brtz or PBS, i.p., on a regime schedule of 3 injections 
for 16 days. (B) No significant weight loss was detected throughout the 16 days of the 
experiment in both treated (Brtz) and untreated (PBS) cohorts. (C) GFP and hCD45 
expression in BM were quantified by flow cytometry as a measure of disease burden in 
control PBS (n=3) and Brtz (n=3) treated animals and data are shown by representative 
FACS contour plots (left panel) and bar graph (right panel) with means ± SD. *P≤0.05 by 
Student´s t-test. 
 
 
  110 
 
4.3.6 AML patient samples with high TRIB2 expression are 
sensitive to Brtz treatment  
To extend the pre-clinical approach described above, Brtz treatment was further assessed 
in primary human AML samples, which were evaluated in terms of their pharmacological 
response to proteasome inhibition. From the cohort of AML patients stratified according to 
the TRIB2 transcript levels (Chapter 3, Figure 3.8), MNCs were selected for treatment 
based on TRIB2 expression status and availability of cells in the bio-bank. Cells were 
either cultured immediately after patient samples were collected and processed or upon 
thawing of the cryopreserved tubes, available from the bio-bank. While optimized cell 
culture conditions were used, some primary samples (AML#17 and #25) showed very poor 
viability after overnight incubation, hence being excluded from the analysis. When DMSO 
and Brtz-treated low TRIB2 cells were compared, no statistically significant differences 
were found in two samples (AML#1 and #4), while in AML#10 and #11, a potential 
TRIB2-independent response was detected (Figure 4.7A). However, for both samples 
harbouring high expression of TRIB2 (AML#15 and 24) a significant increase in apoptosis 
was demonstrated after 24 h incubation with Brtz (Figure 4.7B and C). Also in support of 
these findings, high-TRIB2 AML#20 treated cells were previously found to have an 
eightfold increase in DAPI positivity when compared to the corresponding DMSO-treated 
cells (data not shown; experiment conducted by Fiona Lohan). These results suggest that 
not all AML patient samples respond to Brtz treatment and agrees with previous studies 
that have demonstrated a pro-apoptotic effect of Brtz on primary AML cells with 
heterogeneous response patterns (Stapnes et al., 2007). While cytotoxicity induced by 
proteasome inhibitors can be modulated by a number of molecular determinants, as 
exemplified by the apoptotic response found in two low TRIB2 cells, this study importantly 
suggests that expression of TRIB2 sensitizes AML cells to Brtz treatment. Together with 
the similar effect found in U937 AML cell, these results show that TRIB2 expressing AML 
cells can be pharmacologically targeted with proteasome inhibition. 
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Figure 4.7 Apoptotic effect of Brtz on primary human AML cells with different 
TRIB2 levels 
(A) AML patient samples with low (AML#1, 4, 10 and 11) and (B) medium to high 
(AML#15 and 24) levels of TRIB2 expression were treated with Bortezomib (10 nM) or 
DMSO in vitro. After 24 h, DAPI was quantified by flow cytometry as a measure of cell 
death. Results are expressed as fold change of DAPI positive cells ± SD of 2/3 technical 
replicates relative to vehicle-treated cells (n.s., not significant; **P≤0.01; ***P≤0.001 by 
Student´s t-test). (C) Representative FACS histograms matching in vitro treatment of 
AML#15 are also shown. 
4.4 Discussion  
The tight correlation between Trib2-mediated proteasomal degradation of C/EBPα p42 and 
its ability to induce leukaemia has been thoroughly investigated and supported by a 
number of studies (Keeshan et al., 2006, Keeshan et al., 2010) which suggest that therapies 
inhibiting degradation of the full-length C/EBPα isoform may be effective in TRIB2-
induced AML. The current study provides proof of concept that AML cells expressing 
TRIB2 oncogene can be pharmacologically targeted with proteasome inhibition due, at 
least in part, to inhibition of the TRIB2 proteolytic function on C/EBPα p42. To this end, a 
number of complementary approaches were taken to evaluate efficiency of the first-in class 
proteasome inhibitor Brtz in a variety of settings, including the Trib2-induced leukaemic 
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mice. Indeed, when murine BM cells collected from secondary recipients were treated in 
vitro with Brtz at concentrations in the low nanomolar range, a significant reduction of 
Trib2 expressing cells was detected, as evidenced by the decrease in GFP % used as a 
surrogate marker for Trib2 expression in this model. Importantly, the current study shows 
that the pro-apoptotic effect of Brtz in suspension cultures also affects the more immature 
clonogenic subset within the hierarchically organized AML cell population, as 
demonstrated by the inhibition of clonogenic growth upon in vitro treatment. The effect of 
Brtz treatment on AML colony formation is in agreement with previous studies (Stapnes et 
al., 2007, Liu et al., 2013). It should be noted that this is a very important effect, since 
these cells are believed to be critical for the genesis and perpetuation of leukaemic disease. 
While recent research on the proteasome as a rational therapeutic target has been 
predominantly focused on malignant tissue, some studies have investigated the effect of 
Brtz on normal cells, due to its clinical relevance for BM toxicity. It has been suggested 
that non-malignant human CD34+ BM cells are susceptible to the apoptotic effect of Brtz, 
even if at slightly higher concentrations from those used for their AML counterparts 
(Stapnes et al., 2007). Moreover, the IC50 of Brtz with CML CD34+38- cells was not 
found to be significantly different from the equivalent non-CML cells (Heaney et al., 
2010). In disagreement with such observations, the Brtz effect on normal murine BM cells 
showed pro-apoptotic selectively towards the malignant cells, as no evidence of 
cytotoxicity was encountered in in vitro assays with different subsets of normal murine 
bulk total BM cells, LSK cells or lineage positive cells. A consistent outcome was, in fact, 
illustrated by both the most primitive and most differentiated populations, at a 
concentration shown to have a pro-apoptotic effect on murine Trib2-AML BM cells. In 
line with these results, myeloid cell surface marker staining did not display any change that 
could suggest Brtz-induced differentiation. The discrepancy between present study and 
published data could be due to species-specific differences and, therefore, caution should 
be exercised when extrapolating obtained results to the human situation and could be 
further clarified by a dose-response treatment using higher concentration values. Long-
term evaluation using colony-formation assay or effect on normal BM mouse engraftment 
would also address this subject. 
Brtz was shown to be cytotoxic to a broad range of the 60 human tumour cell lines 
examined in the National Cancer Institute pre-clinical screen, which clearly highlights the 
potential of proteasome inhibitors as anticancer agents (Adams et al., 1999). However, 
different pathways seem to be important in different malignant cells, and the mechanisms 
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whereby these agents elicit cellular responses are not fully understood (Nencioni et al., 
2007). Having shown an effect of Brtz on the viability of murine Trib2-AML cells, the 
present study moved on to establish that the response to proteasome inhibition was TRIB2-
dependent. The cause-and-effect relationship between TRIB2 expression and treatment 
response was attained by functional studies that measured changes in Brtz-induced 
cytotoxicity after modulation of TRIB2 in U937cell line. This was the preferred model 
since both TRIB2 and C/EBPα are endogenously expressed. Response of the U937 AML 
cells to proteasome inhibition was previously reported by Imajoh-Ohmi et al, who 
examined the effect of another selective inhibitor of the proteasome, lactacystin, on U937´ 
cell proliferation. These authors found that lactacystin induces apoptotic cell death 
(Imajoh-Ohmi et al., 1995), without further investigating the underlying molecular 
mechanism. In the current study, not only was the increased in vitro cytotoxic response 
associated with higher TRIB2 expression, as similar patterns of sensitivity were 
successfully recapitulated with the next-generation inhibitors SF and Cfz. Unlike Brtz, 
these proteasome inhibitors cause irreversible proteasome inhibition and are thus expected 
to have enhanced efficacy, as well as increased clinical applicability.  
Furthermore, the response of high TRIB2 AML cells to proteasome inhibition was deemed 
to be due to blockage of TRIB2 degradative function on C/EBPα p42. This was supported 
by western blotting analysis, which highlighted the molecular interplay between both 
proteins by showing a reduction in C/EBP p42 after TRIB2 overexpression and, more 
importantly, rescue of the transcription factor´s full length isoform degradation after 
proteasome inhibition. These observations mechanistically confirmed the TRIB2-C/EBPα 
p42 dynamic and showed that it is indeed altered by Brtz treatment. Specificity was further 
addressed and supported by a panel of experiments which showed that 1) ectopic 
expression of C/EBPα rescued Brtz- induced death in U937 cells, while 2) TRIB2 
overexpression required the presence of C/EBPα to enhance Brtz-induced cell death, since 
it was not found in a leukaemia background lacking C/EBPα (K562 and Kasumi-1). 
Consistent with these results, it has been shown that a TRIB2 mutant (VPM), unable to 
bind the E3 ligase COP1 responsible for TRIB2-mediated C/EBPα degradation (Keeshan 
et al., 2010), does not enhance Brtz-induced cell death (experiment conducted by Fiona 
Lohan (O'Connor et al., 2016)). Taken together, these findings uncover a novel molecular 
mechanism by which Brtz elicits apoptosis in leukaemia cells via modulation of the 
TRIB2-C/EBPα p42 axis. As previously reported, the accumulation of K48 ubiquitinated 
proteins is thought to mediate Brtz cytotoxicity on a cellular level by triggering ER stress, 
autophagy and apoptosis (Obeng et al., 2006, Fang et al., 2012). Therefore, it is likely that 
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the accumulation of K48 ubiquitinated- C/EBP p42 would be implicated in the cell death 
response found after proteasome inhibition. Indeed, treatment with the proteasome 
inhibitor MG-132 was associated with an accumulation of Ub-conjugated C/EBPα, 
consistent with proteasome inhibition (experiment conducted by Caitriona O´Connor 
(O'Connor et al., 2016)). In addition, C/EBP p42 stabilization by Brtz could promote the 
myeloid maturation programme triggered by this transcription factor. This was suggested 
by an increase in myeloid cell surface markers CD11b and Gr-1 in murine Trib2-leukaemic 
treated cell colonies (Figure 4.1D). Thus Brtz could be additionally implicated in the 
differentiation of cells, which would then senesce. In fact, an analogous role for Brtz was 
previously reported by Ying et al, who showed that Brtz synergizes with ATRA in 
promoting myeloid differentiation of HL60 and NB4 APL cells. These authors reported 
that Brtz elicits this effect by disrupting the ATRA-induced proteasomal degradation of 
RARα, the receptor through which ATRA paradoxically also induces myeloid 
differentiation (Ying et al., 2013).  
The translation of laboratory experiments to the clinical arena is inherently dependent on 
the usefulness of mouse models, which produce a tractable preclinical system for testing 
new therapeutic approaches in a physiological environment. It was therefore important to 
detect Brtz anti-tumour activity in a U937 xenograft model, in which leukaemia burden 
was shown to be strongly dependent on TRIB2 expression (Chapter 3). The observation of 
a significant inhibition of tumour engraftment, together with minimal body weight loss, is 
interpreted by drug developers as indicative of an acceptable therapeutic window in 
humans (Kamb, 2005). Moreover, a cytotoxic response was detected in the high expressing 
TRIB2 AML patient samples. Together, obtained results support pre-clinical evidence that 
AML cells expressing high levels of endogenous TRIB2 can be successfully targeted by 
proteasome inhibition. 
Given the central role of the proteasome in protein homeostasis and cellular physiology it 
is not surprising that discussions on the ultimate targets of proteasome inhibitors are 
ongoing. Results here present compelling evidence for a TRIB2-C/EBPα-dependent effect 
of Brtz in high TRIB2-expressing AML cells. However, inhibition of the proteasome also 
targets other proteins, E3 ligases and their substrates. This, together with the current 
understanding on Brtz´s overall ability to elicit cytotoxicity (see Chapter 1), suggests that 
other molecular determinants could be also implicated in the cellular cytotoxicity found in 
the current study. Such mechanisms could be related to the ones previously described (see 
chapter 1) or dependent on TRIB2 expression. The latter are difficult to predict, as there is 
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currently limited knowledge of TRIB2 degradation substrates in general, and indeed 
knowledge of TRIB2 as a substrate itself of the UPS in cancer.  
To conclude, this study identifies TRIB2 as a novel molecular determinant of cell 
sensitivity to Brtz-induced apoptosis, which is achieved, at least partially, by blockage of 
C/EBPα proteolytic degradation. These findings are relevant in the context of a 
heterogeneous malignancy for which therapy driven by specific molecular subtypes of 
AML is thought to be a logical approach. The ATRA-APL example is a paradigm of such 
a strategy and other models have shown promising effects, including the case of the toxin-
conjugated anti-CD33 antibody Myelotarg on core-binding factor mutated AML (Walter et 
al., 2012) and of FLT3 inhibitors for patients with activating FLT3 mutations (Grunwald 
and Levis, 2013). Moreover, TRIB2 has been implicated in non-haemopoietic human 
cancers so the proposed mechanism of Brtz action may extend to other malignancies where 
TRIB2 has an oncogenic role via UPS involvement. Therefore, this study provides the 
critical basis for further investigations into targeting the UPS as an emerging cancer 
therapy.  
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Chapter 5: 
Potential implication of arginine methylation in 
TRIB2-induced AML via PRMT5 interaction 
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5.1 Introduction 
Despite the widely accepted two-hit model of leukaemogenesis, there is growing evidence 
that the epigenetic landscape is important for the development of AML, as highlighted 
previously (Chapter 1, section 1.2.4). The term epigenetic encompasses all changes in gene 
expression that are not due to alterations in the underlying DNA sequence (Holliday, 
1987). Examples of mechanisms that alter the transcriptional potential of a cell include 
modifications of DNA cytosine residues and post-translational modifications (PTMs) of 
histone proteins via the biochemical processes of acetylation, phosphorylation, 
methylation, and others (Musselman et al., 2012). Arginine methylation is an abundant 
PTM carried out by a family of 11 protein arginine methyltransferases (PRMTs). Based on 
their primary sequence and substrate specificity, PRMTs are designated as PRMT1 to 11. 
Except for PRMT2, 10 and 11, they have been shown to catalyse addition of one or two 
methyl groups to the guanidino nitrogen atoms of arginine (R) residues in both histones 
and non-histone substrates. Depending on whether their catalytic activity towards 
dimethylation is asymmetric or symmetric, PRMTs are classified as either type I or type II 
enzymes, respectively, even if both types catalyze the formation of monomethylated 
arginines as an intermediate (Pal and Sif, 2007). 
PRTM5 (14q11.2) was first identified as JAK-binding protein 1 (JBP1) in a yeast two-
hybrid assay (Pollack et al., 1999) and is the major type II arginine methyltransferase 
(Branscombe et al., 2001). The complete loss of this enzyme is not compatible with mouse 
viability due to the abrogation of pluripotent cells in blastocytes (Tee, 2010). PRMT5 is 
reported to participate in several diverse cellular processes through the methylation of a 
variety of cytoplasmic and nuclear substrates. Symmetrically methylated histones H3 at R8 
and H4/H2A at R3 are well known epigenetic marks of PRMT5 (Pal et al., 2004, Ancelin 
et al., 2006) and are generally associated with gene repression (Fabbrizio et al., 2002). 
Moreover, PRMT5 represses - globin gene expression through symmetric dimethylation 
of H4R3, recruitment of the DNA methyltransferase DNMT3A to the -promoter and 
subsequent additional repressive epigenetic marks, indicating a potential crosstalk between 
repressive histone modification and DNA methylation (Zhao et al., 2009) (Figure 5.1A).  
PRMT5 acts as part of a multimeric complex in concert with a variety of partner proteins 
that regulate its activity, as well as localization and substrate specificity. In mammalian 
cells, PRMT5 is tightly bound by a 50-kDa WD40 repeat-containing protein dubbed 
methylosome protein 50 (MEP50) and together they are assembled as an hetero-octameric 
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structure, as revealed by crystallography (Antonysamy et al., 2012). This interaction has 
been shown to be a crucial node for the regulation of PRMT5 methyltransferase activity 
(Friesen et al., 2002). Indeed, tyrosine phosphorylation of PRMT5 can block MEP50 
binding and can attenuate PRMT5 activity, as it has been shown for the JAK2-V617F 
tyrosine kinase. Found in most patients with myeloproliferative neoplasms, this 
constitutively activated JAK2 mutant interacts with PRMT5 more avidly than does the 
wild-type form. JAK2-V617F phosphorylates PRMT5, greatly impairing its arginine 
methyltransferase activity on histones H2AR3 and H4R3 by blocking its interaction with 
the co-regulator MEP50 (Liu et al., 2011) (Figure 5.1B). In a second example of PRMT5-
MEP50 regulation, it was found that cyclin D1/CDK4 kinase complex phosphorylates 
MEP50 instead and this phosphorylation at threonine 5 increases the intrinsic 
methyltransferase activity of PRMT5, resulting in augmented H4R3/H3R8 methylation and 
PRMT5-dependent transcriptional repression (Aggarwal et al., 2010).  
 
Figure 5.1 Examples of PRMT5 methyltransferase activity 
(A) PRMT5 mediates symmetric dimethylation of histone H4R3 and recruits DNMT3A, 
coupling histone and DNA CpG methylation in -globin gene silencing. Figure modified 
from (Zhao et al., 2009). (B) Phosphorylation of PRMT5 by the oncogenic JAK kinase 
mutant (JAK2-V617F) results in loss of its methyltransferase activity and 
hyperproliferation of haemopoietic stem cells. 
Although MEP50 is the primary co-regulatory factor of PRMT5 activity, other binding 
proteins can function as modulators or adaptors of this complex, influencing substrate 
specificity and the associated cellular processes. These include the human SWI/SNF and 
the MBD2/NuRD chromatin remodelling complexes, which enhance PRMT5-MEP50 
methyltransferase activity towards histone substrates and subsequent transcriptional control 
on target gene expression (Pal et al., 2003, Le Guezennec et al., 2006). Another example is 
  119 
 
the nuclear protein named cooperator of PRMT5 (COPR5) that directs PRMT5-MEP50 
methyltransferase activity towards histone H4R3 rather than histone H3R8 (Lacroix et al., 
2008). The same way that PRMT5 methyltransferase activity can be restricted to specific 
histones, association of PRMT5 with either RIOK1 (RIO-domain-containing protein kinase 
1) or pICln (chloride channel, nucleotide sensitive 1A) directs its catalytic activity towards 
the RNA-binding protein nucleolin (Guderian et al., 2011) or the spliceosomal Sm proteins 
(Pesiridis et al., 2009), respectively. Together with pICln, PRMT5-MEP50 forms a 20S 
complex termed the methylosome that functions in RNA processing by methylating Sm 
proteins and affecting the small nuclear ribonucleoprotein (snRNP) biogenesis (Friesen et 
al., 2001, Friesen et al., 2002, Meister and Fischer, 2002, Chari et al., 2008). The RNA-
binding protein Y14 also interacts with the cytoplasmic PRMT5-containing methylosome, 
facilitating PRMT5 activity towards Sm proteins of the snRPN core (Chuang et al., 2011). 
PRMT5 has been, therefore, implicated in gene regulation processes that include histone 
modification, chromatin remodeling (Dacwag et al., 2007), mRNA splicing (Meister and 
Fischer, 2002, Chuang et al., 2011) and transcriptional elongation via methylation of 
SPT4/SPT5 (Kwak et al., 2003). PRMT5 also functions in DNA replication and repair 
(Guo et al., 2010), maintenance of the Golgi apparatus architecture (Zhou et al., 2010), 
ribosome biogenesis (Ren et al., 2010), cell migration (Guo and Bao, 2010) and cell 
reprogramming (Tee, 2010, Nagamatsu et al., 2011). The role of PRMT5 in tumorigenesis 
has also become evident. While recurrent PRMT5 mutations have not been detected in 
cancer cells, its expression is upregulated in human lymphoid cancers (Pal et al., 2007, 
Wang et al., 2008, Chung et al., 2013) and in many solid tumours, including lung (Wei et 
al., 2012), breast (Powers et al., 2011) and colorectal (Cho et al., 2012) cancer. PRMT5 is 
mechanistically associated with tumorigenesis through silencing of tumour suppressor 
genes, such as ST7 (Pal et al., 2004) and genes encoding Rb family of proteins (Chung et 
al., 2013), or by mediating methylation of non-histone proteins. An example of this is the 
programmed cell death 4 (PDCD4) protein, which shows increased tumorigenicity when 
overexpressed with PRMT5 in an orthotopic model of breast cancer (Powers et al., 2011). 
PRMT5 also regulates a number of other non-histone proteins, namely, the transcription 
factors E2F1 (Cho et al., 2012), NF-kB (Wei et al., 2013) HOXA9 (Bandyopadhyay et al., 
2012) and p53 (Jansson et al., 2008). Moreover, a study has demonstrated that PRMT5 
knockdown results in elevated E-cadherin expression, which is implicated in epithelial-
mesenchymal transition and tumour progression (Hou et al., 2008). In addition, PRMT5 
overexpression promotes anchorage-independent cell growth (Pal et al., 2004), supporting 
the notion that PRMT5 might be an oncoprotein.  
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Important to this study, the epigenetic modifier PRMT5 was recently connected toTRIB2 
by a mass spectrometry analysis (Prof Claire Eyers, University of Liverpool, personal 
communication), indicating that the epigenetic modifier could be involved in the TRIB2-
induced AML. 
 
5.2 Aims and Objectives 
It is hypothesised that TRIB2 has alternate function to C/EBPα p42 degradation that 
provides synergy in the TRIB2-driven myeloid phenotype. Given the increasing 
importance of the epigenetic alterations in leukaemogenesis (Chapter 1), together with the 
reported interaction between TRIB2 and PRMT5, the present study sought to investigate 
this putative partnership to gain a better understanding of the TRIB2-induced AML. 
The specific aims of this chapter were: 
i To identify a phenotypic role for PRMT5 in high TRIB2 AML cells; 
ii To investigate whether PRMT5 cooperates with TRIB2 by means of co-
immunoprecipitation. 
5.3 Results 
5.3.1 PRMT5 is elevated in AML  
Overexpression of PRMT5 has been reported in various transformed cells, including those 
of haematological origin (Pal et al., 2007, Wang et al., 2008, Chung et al., 2013). To 
further address the potential regulatory role of PRMT5 in AML, its expression was 
examined using the Leukemia Gene Atlas (LGA) database (http://www.leukemia-gene-
atlas.org, (Hebestreit et al., 2012)). This is a public platform designed to support research 
and analysis of genomic data published in the leukaemia field. Based on signals from two 
different probe sets, the expression of PRMT5 was found to be significantly (P<0.001) 
increased in AML (n=542), when compared to non-leukaemia and normal BM samples 
(n=73) (Figure 5.2A; shown are the results obtained with probe 1564520_s_at). In silico 
analysis was performed by selecting the Haferlach et al. data set (Haferlach et al., 2010), as 
it allows stratification based on disease status and contains the largest cohort of healthy 
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patients available from the database. PRMT5 mRNA expression was further examined by 
qPCR in the U937 cell line, as well as in primary AML cells previously screened for 
TRIB2 transcript levels. This analysis found amplification of PRMT5 in U937 cell line 
(average Ct value of 22.5), as well as in all examined primary cells (Figure 5.2B). PRMT5 
mRNA expression in AML patient samples was globally comparable to the levels detected 
in U937 cells (medium fold change, 0.86; range, 0.6-1.0). AML samples #9, 18, 26 and 28 
have increasing values of TRIB2 expression (Figure 3.8) while no correlative trend was 
detected for PRMT5 (Figure 5.2B). Even though this study was limited to a small number 
of patients, it does not hint at a putative PRMT5/TRIB2 cooperation at the mRNA level, 
like the one observed for the -globin gene via indirect PRMT5 activity (Zhao et al., 2009), 
suggesting that the alleged interaction would be better assessed at the protein level. 
 
Figure 5.2 PRMT5 is elevated in AML 
(A) Expression of PRMT5 was examined in 542 AML patients and compared with that of 
non-leukaemia/healthy BM (n= 73) by using the LGA platform based on the gene 
expression data set from Haferlach et al. Statistically significant increased expression was 
detected on the AML cohort with adjusted P < 0.001 determined by Welch‟s t-test. (B) 
qPCR analysis identified PRMT5 expression in both U937 cells and AML patient samples. 
Values represent gene expression relative to U937 cells and normalize to the reference 
gene ABL. 
5.3.2 PRMT5 is required for TRIB2-expressing AML cell growth 
and survival 
The association of PRMT5 expression in human AML prompted the investigation of the 
potential cell-transforming activities of PRMT5. As the main aim of this chapter was to 
investigate the association between PRMT5 and TRIB2, the effect of PRMT5 knockdown 
was further examined in U937 cells, which have high levels of TRIB2 transcripts. PRMT5 
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expression was downregulated using two lentiviral shRNAs (shPRMT5 #1 and #2). 
Expression of endogenous PRMT5 was reduced by more than 70% as quantitated by qPCR 
analysis of cells surviving 2 and 5 days of puromycin selection (Figure 5.3A). Effective 
depletion of PRMT5 significantly triggered growth suppression, in comparison with cells 
expressing a control shRNA construct (Figure 5.3B). Downregulation of PRMT5 has 
previously been shown to induce cell death and/or growth arrest in HEL and K562 cells 
but in normal cord blood CD34+ cells it provides a proliferative signal, demonstrating the 
importance of cell context on PRMT5 function (Liu et al., 2011). Data presented here 
support a role for PRMT5 in the maintenance of U937 leukaemic cells and suggest a 
functional redundancy between PRMT5 and TRIB2 since both are required for U937 AML 
cell proliferation and survival, indicating that they may cooperate to maintain survival of 
leukaemic cells.  
 
Figure 5.3 PRMT5 knockdown induce growth inhibition in the TRIB2 expressing 
U937 cells 
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Figure 5.3 PRMT5 knockdown induce growth inhibition in the TRIB2 expressing 
U937 cells (Figure on previous page). (A) PRMT5 was knocked down following lentiviral 
transduction of U937 cells with two different shRNAs. Expression was assessed by qPCR 
after 2 and 5 days of puromycin selection (2 µg/mL) and ABL was used as a reference 
gene. (B) After 2 days of puromycin selection, cell growth of shCtrl-, shPRMT5 #1- and 
shPRMT5 #2 - U937 cells was assayed by trypan blue exclusion over a period of 3 days in 
liquid culture conditions. Data presented are representative of 2 independent experiments 
with 3 technical replicates each. 
 
5.3.3 TRIB2 and PRMT5 interact in physiological conditions  
To examine whether PRMT5 interacts with TRIB2, both proteins tagged with HA and Myc 
epitopes, respectively, were transiently co-expressed in 293T cells. Co-
immunoprecipitation (Co-IP) using c-Myc antibody identified PRMT5 (~72kDa) as a 
TRIB2 interacting protein (Figure 5.4; Appendix B). On this note, it should be mentioned 
that PRMT5 is recognized by the M2-Flag antibody and has thus been purified as a 
„contaminant‟ in many Flag-tagged protein complexes (Nishioka and Reinberg, 2003). 
This technical problem does not, however, compromise the present study since both 
PRMT5 and TRIB2 were expressed as fusions to two other affinity tags. The presence of 
negative controls (untransfected cells and cells transfected singly with each protein) as well 
as the pre-clearing step confirms this positive interaction (see Chapter 2, section 2.4). To 
strengthen specificity of the protein-protein interaction, the reciprocal Co-IP was also 
performed following the same experimental conditions (Appendix C). While PRMT5 was 
successfully immunoprecipitated and transfection was positively confirmed, TRIB2 was 
not detected in the HA-immunoprecipitate. Failure of the control experiment could be 
explained by the following: the α-HA antibody, used to immunoprecipitate PRMT5, can 
potentially interfere with the TRIB2 binding site, proving to be only suitable for 
recognition of the denatured form in the western blotting analysis. The use of a different 
HA antibody could clarify whether this is a technical issue. A different approach would be 
to increase transfection efficiency for PRMT5 expression. While HA-PRMT5 was 
successfully immunoprecipitated, the input lanes showed that this protein was consistently 
expressed at a lower level when compared to TRIB2. Also, when an input blot was probed 
with α-PRMT5 antibody, endogenous and exogenous levels were not significantly different 
(Appendix D). This, together with a possible uneven stoichiometry between the proteins 
interaction, could also explain the obtained result and be further addressed. Alternatively, a 
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different method could be used to validate the data, like the in situ proximity ligation assay 
that allows protein-protein interactions to be visualized and quantified in vivo. 
Nonetheless, the data here presented supports an interaction between PRMT5 and TRIB2 
and, importantly, creates a framework for further investigations on the putative role of 
PRMT5in the molecular pathogenesis of TRIB2-driven leukaemia. 
 
Figure 5.4 PRMT5 interacts with TRIB2 myeloid oncogene 
Exogenous interaction between PRMT5 and TRIB2 was detected in 293T cells transiently 
transfected with vectors expressing HA-PRMT5 alone (lane 2) or with Myc-tagged TRIB2 
protein (lane 4). Immunoprecipitation was performed using an anti-Myc antibody and blots 
were probed with antibodies specific for HA or cMyc. Complete blots of westerns are 
shown in Appendix B. 
5.4 Discussion 
While molecular interaction between TRIB2 and C/EBP p42 has been identified as a key 
driver event in AML via proteolytic degradation and subsequent deregulation of the 
granulopoiesis-related transcription factor, interaction with other partners are yet to be 
fully elucidated. On this note, the widely accepted mutations from the two-hit model, 
which affect proliferation and haemopoietic differentiation, are no longer viewed as 
exclusive causes of AML development. Emerging evidence suggests that a third important 
mechanistic pathway involving epigenetic regulators must also occur and, indeed, a 
putative cooperation between TRIB2 and PRMT5 was suggested by mass spectrometry 
data. The relevance of this epigenetic regulator in tumorigenesis has become evident, since 
increased PRMT5 levels are observed in a range of cancers, including lymphoma (Pal et 
al., 2007). Moreover, PRMT5 has been shown to repress expression of the gene implicated 
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in foetal haemoglobin synthesis (-globin gene), which suggests a role for PRMT5 in 
erythropoiesis and haemopoiesis in general (Zhao et al., 2009).  
Herein, analysis of a public microarray data set found PRMT5 transcripts to be 
significantly higher in AML patients when compared to normal samples. Importantly, this 
study supports a role for PRMT5 in AML cells with high TRIB2 expression, as evidenced 
by the anti-proliferative effect observed upon gene knockdown in U937 cell line. It has 
been reported that PRMT5 preferentially promotes p53-dependent cell cycle arrest at the 
expense of p53-dependent apoptosis (Jansson et al., 2008), which could explain the cell 
death response triggered by downregulation of PRMT5. However, the TP53 gene in U937 
cells has a point mutation that converts G into A (G>A) in the splice donor site at the first 
base of intron 5. This intronic modification appears to inactivate the normal splicing 
junction and alter processing of TP53 mRNA, which is reported to have a 46-bp deletion 
on exon 5 (Sugimoto et al., 1992). Even if detectable at mRNA level by qPCR (Sugimoto 
et al., 1992, Yeung and Lau, 1998), p53 protein synthesis is negligible or null in U937 cell 
line (Danova et al., 1990, Rizzo et al., 1998). Hence, in these AML cells, growth arrest 
detected upon PRMT5 depletion should be triggered by a p53-independent mechanism. 
Hypothesizing that TRIB2 mediates the effect of PRMT5 or vice versa, modulation of one 
should phenocopy modulation of the other, which was indeed detected. Both PRMT5 and 
TRIB2 were found to affect leukaemia cell growth when downregulated singly in the same 
model system, which suggests that PRMT5 and TRIB2 could cooperate to maintain the 
leukaemic cells transforming capabilities. This cooperation was suggested to be better 
assessed at the protein level since no association was detected between TRIB2 and PRMT5 
mRNA levels in a subset of primary AML cells. Also in support of that, analyses retrieved 
from COSMIC database found TRIB2 to be only hypermethylated in prostate and large 
intestine tumour tissues (Figure 3.1D). 
Indeed, the present study identified a molecular partnership between PRMT5 and TRIB2, 
when tagged versions of both proteins were overexpressed in 293T cells and TRIB2 
complexes were purified using an antibody specific for the Myc epitope. Despite the 
previously discussed pitfalls (section 5.3.3), this experiment strongly suggests a true 
physiological PRMT5/TRIB2 interaction, as it validates results previously obtained from a 
mass spectrometry analysis. It would be of significant importance to confirm that 
endogenous TRIB2 and PRMT5 proteins also interact in leukaemia cells. Although the 
exact mechanism(s) that orchestrate this cooperation can only be hypothesized at this stage 
of research, some interactions could be envisaged. TRIB2 could be post-translationally 
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methylated by PRMT5, as it is the case of several non-histone proteins, e.g., p53 (Jansson 
et al., 2008) and PDCD4 (Powers et al., 2011), with functional consequences on its 
activity. Alternatively, and as described for the mutated form of JAK2 (Liu et al., 2011), 
TRIB2 could have a regulatory role on PRMT5 methyltransferase activity by altering its 
phosphorylation status. This would disrupt the PRMT5-MEP50 hetero-octameric structure 
and, ultimately, affect transcription via regulation of specific histones. Such hypothesis 
would seem less likely given the fact that a catalytic activity on any substrate has not yet 
been reported for the pseudo-kinase TRIB2. However, it has been recently shown that 
TRIB2 retains the ability to bind with low affinity to ATP and autophosphorylates in vitro 
(Bailey et al., 2015), hence, providing the rationale to pursue this hypothesis further. 
Future studies on whether TRIB2 affects the enzymatic activity of PRMT5 towards its 
well-known histones epigenetic marks (H2A/H4R3 and H3R8) would provide important 
insights on this matter. If changes in histone methylation were found, the functional 
consequences of this observation would then have to be determined. It is well established 
that post-translational modification of histones represents a fundamental regulatory 
mechanism that has an impact on gene expression (Strahl and Allis, 2000) and PRMT5 is 
generally regarded as a co-repressor. It would therefore be of interest to identify a potential 
subset of genes reciprocally up or downregulated by TRIB2 and PRMT5. Also, since 
PRMT5 functions as part of various high molecular weight protein complexes, the 
identification of the TRIB2/PRMT5 binding partners could provide important insights on 
the potential downstream targets, as they regulate PRMT5 activity, as well as localization 
and substrate specificity. 
Therefore, the experimental finding of a partnership between PRMT5 and TRIB2 opens a 
new level of regulation to consider in AML and empowers further research aimed at 
understanding the underlying mechanism and the functional significance of this interplay. 
Given the multitude of roles that PRMT5 has in several biological processes, such as RNA 
processing, chromatin remodeling and control of gene expression, it is plausible to 
hypothesize that PRMT5 and TRIB2 putative cooperation affects a mechanism other than 
C/EBPα p42 proteolysis. Instead, this interaction would lead to a crosstalk between 
proteasome–dependant degradation of C/EBPα p42 and PRMT5-mediated arginine 
methylation, altering the gene expression profile and collaborating to bring about the 
TRIB2-driven myeloid phenotype.  
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In conclusion, the discovery of an interaction between PRMT5 and TRIB2 reveals a 
potential pathway of regulation in TRIB2-driven leukaemia and sets the stage for further 
experiments that will hopefully have important ramifications in the leukaemia field. 
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Chapter 6: 
Conclusions 
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6.1 Concluding remarks 
AML may best be considered an umbrella term for a heterogeneous group of myeloid 
leukaemias that are all characterized by proliferation of immature, clonal, myeloid 
precursors but differ substantially with regards to the biological cause and clinical features. 
Characterization of the molecular events underlying leukaemic growth furnishes distinctive 
insights into the nature of the disease and provides useful clues to the prognosis of 
individual patients. Indeed, the importance of delineating AML disease entities more 
sharply has gained general appreciation, and cytogenetics as well as specific gene 
mutations has become part of the essential and standard workup of patients with AML.  
While the spectrum of the molecular abnormalities and pathways implicated in AML has 
been extended over the last three decades, more precise distinctions are needed. Trib2 is 
known to be a potent murine oncogene capable of inducing transplantable AML with 
complete penetrance (Keeshan et al., 2006). Here, its tumorigenic role in the context of 
myeloid malignancies is characterized and strengthened in a human leukaemic setting. 
Data clearly show the importance of TRIB2 increased expression for the in vitro and in 
vivo maintenance of the oncogenic properties of AML cells. These findings, together with 
the detection of TRIB2 expression in a number of AML patient samples, add significant 
value to the current understanding of leukaemogenesis. Since treatment of AML has 
evolved side by side with a refinement in the molecular characterization of this 
heterogeneous disease, as exemplified by the ATRA-APL case, two important questions 
from the clinical point of view emerged from the abovementioned findings. These 
questions are related to whether aberrant expression of TRIB2 has prognostic value in the 
context of AML and whether high TRIB2 cells can be therapeutically targeted (as 
discussed in the following paragraph). The xeno-engraftment study with AML patient 
samples harbouring different levels of TRIB2 transcripts predicted an association with less 
aggressive leukaemias. These are, however, preliminary results and a more exact 
estimation of the prognosis can only be validated in large series of patients by multivariate 
analysis encompassing for example the patients´ mutational status of the main recurrent 
abnormalities (i.e., NPM1, FLT3, CEBPA and DNMT3A), as well as information regarding 
age, WBC count or % of CD33 and CD34+ cells, which also have clinical implications 
(Breccia and Lo-Coco, 2011, Gerber et al., 2012).  
The growth-promoting and anti-apoptotic effects of TRIB2 in AML cells, herein described, 
make it a rational target for antineoplastic agents. An approach to preventing TRIB2 
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tumorigenic role is to inhibit the proteasome, hence blocking degradation of the 
granulopoiesis-related C/EBPα p42 via the Ub-proteasome system. The UPS is a selective 
method of proteolysis that constitutes a salient example of how fundamental research can 
have far-reaching implications for human biology and disease. Identified after 20 years of 
research (Hershko, 2005), the Ub-dependent degradation system was found subsequently 
to be aberrantly activated in a variety of malignancies, which resulted in the development 
of drugs aimed at inhibiting the proteasome function. Indeed, two proteasome inhibitors 
(Brtz and Cfz) have entered the clinical arena for the treatment of multiple myeloma and 
mantle cell lymphoma. Current research and on-going clinical trials indicate that the full 
therapeutic potential of proteasome inhibitors is beginning to be appreciated and suggest 
that they will be part of our future armamentarium of drugs against a number of other 
diseases. In fact, there is a body of evidence supporting the use of proteasome inhibitors as 
a strategy for AML therapy, which may improve the currently unsatisfactory outcome of 
the elderly patients. In the present study, it is shown that high TRIB2-expressing AML 
cells are predictive for responsiveness to treatment with proteasome inhibition. These cells 
can be pharmacologically targeted with Brtz, as well as with next-generation proteasome 
inhibitors, due, at least in part, to blockage of the TRIB2 proteolytic function on C/EBPα 
p42. The TRIB2- C/EBPα p42 axis can, therefore, be considered a new mechanism 
whereby Brtz induces cytotoxicity. This is of particular importance as the apoptotic 
cascades induced by proteasome inhibition are not yet fully defined and understanding the 
molecular basis for the selectivity of the proteasome inhibitors will aid in their 
development as anticancer agents. In addition, the therapeutic strategy and the obtained 
results here presented have a potential broader applicability as they support its usefulness 
in other AMLs with deregulated proteasome activity. Moreover, TRIB2 has been also 
shown to have an oncogenic activity associated with proteasomal-degradation of its targets 
in other malignancies (e.g., lung (Grandinetti et al., 2011) and liver (Xu et al., 2014) 
cancer), for which the stated therapeutic strategy could as well be considered a logical 
approach. 
In the light of the main findings described above i.e. characterization of TRIB2 as an 
important myeloid oncogene in human AML that can be selectively targeted by 
proteasome inhibition, it was thereafter aimed to obtain a deeper understanding of the 
processes associated with TRIB2-driven leukaemia, as it is hypothesised that other 
molecular pathways are involved. A major mechanistic theme in AML biology is, in fact, 
the extensive collaboration among genetic changes, fusion oncoproteins, transcription 
factors and chromatin regulators to initiate and sustain an acute leukaemia phenotype 
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characterized by enhanced survival and impaired differentiation. Karyotype analysis of 
murine-Trib2 AML cells suggested that TRIB2-driven AML was associated with the CN-
AML, hence excluding chromosomal alterations as the more likely cooperating events. In 
pursuing this question, the primary enzyme responsible for symmetric dimethylation, 
PRMT5, was identified as a TRIB2 binding partner, supporting previous results obtained 
by mass spectrometry analysis, as well as the increasingly importance given to epigenetic 
regulators in AML. The identification of an interaction between TRIB2 and PRMT5, 
which were also functionally associated by sharing an identical role in AML cell survival, 
reveals a potential pathway of regulation in TRIB2-driven AML that implicates the 
epigenetic modifier PRMT5. These findings have empowered future studies that are 
currently being investigated in the Keeshan lab.  
In conclusion, the current study highlights the important oncogenic role of TRIB2 in 
human AML maintenance and, significantly in such a molecularly heterogeneous 
malignancy, a tailored therapeutic approach is suggested for the treatment of high TRIB2 
AML by demonstration of a chemo-sensitive phenotype towards proteasome inhibitors. 
These data also define a new molecular mechanism of apoptosis induced by these drugs. 
Finally, a framework for further investigations into new TRIB2-AML partners is 
established by the identification of PRMT5 as a cooperating protein. Altogether, these 
findings have repercussions on the understanding of AML and on the portfolio of potential 
therapeutic targets that may improve the outcome of the disease. 
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Appendix A TRIB2 expression is required for growth of U937 AML cells 
(A) Real Time analysis of TRIB2 mRNA levels in U937 cells following transduction with 
LMP-Ctrl or LMP-shTRIB2. (B) Cell growth analysis in U937 cells transduced with LMP-
Ctrl or LMP-shTRIB2 assessed by trypan blue exclusion. Number of viable cells was 
normalized against % of GFP positive cells and is relative to cell count at 0h. Data 
presented are mean ± SD of duplicate cultures and are representative of 2 independent 
experiments. *P≤0.05 by Student´s t-test.   
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Appendix B Original western blots for Figure 5.3 
Samples were analysed in an 8% polyacrylamide gel. Upper panel depicts blot with input 
samples probed with anti-HA, anti-cMyc and anti-Tubulin antibodies, as indicated in the 
Figure. Co-immunoprecipitated proteins are shown in the lower panel. Relevant sizes of 
the molecular ladder are written on the right side of the original films (kDa) and white 
boxes highlight cropped results. For assembly of Figure 5.3, blots were flipped. Samples 
are identified in the anti-HA film as PRMT5+T2; T2; PRMT5 and Empty. T2 symbolizes 
TRIB2.  
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Appendix C Reciprocal Co-IP 
293T cells were transiently transfected with vectors expressing HA-PRMT5 alone (lane 2) 
or with Myc-tagged TRIB2 protein (lane 4). Immunoprecipitation was performed using an 
anti-HA antibody and blots were probed with antibodies specific for HA or cMyc. Western 
blotting failed to detect a band at ~37kDa in sample with overexpression of both PRMT5 
and TRIB2. Result is representative of 3 independent experiments.  
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Appendix D Detection of PRMT5 in Input blot from Co-IP 
Input blot was probed with α-PRMT5 antibody showing that endogenous and exogenous 
levels were not significantly different.  
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Appendix E PDF of “Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML 
cell proliferation” 
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Key Points
• E2F1 regulates Trib2
expression and C/EBPa
modulates E2F1-induced
Trib2 activity at the
granulocyte macrophage
progenitor stage.
• Pharmacological inhibition of
the cell cycle resulting in
a block in E2F1 or Trib2
knockdown abrogates AML
cell proliferation.
The loss of regulation of cell proliferation is a key event in leukemic transformation, and
the oncogene tribbles (Trib)2 is emerging as a pivotal target of transcription factors in
acute leukemias. Deregulation of the transcription factor E2F1, normally repressed by
CCAAT enhancer-binding protein a (C/EBPa)-p42, occurs in acute myeloid leukemia
(AML), resulting in the perturbation of cell cycle and apoptosis, emphasizing its
importance in the molecular pathogenesis of AML. Here we show that E2F family
members directly regulate Trib2 in leukemic cells and identify a feedback regulatory
loop forE2F1,C/EBPa, andTrib2 inAMLcell proliferationand survival. Further analyses
revealed that E2F1-mediated Trib2 expression was repressed by C/EBPa-p42, and in
normal granulocyte/macrophage progenitor cells, we detect C/EBPabound to the Trib2
promoter. Pharmacological inhibition of the cell cycle or Trib2 knockdown resulted in
a block in AML cell proliferation. Our work proposes a novel paradigm whereby E2F1
plays a key role in the regulation of Trib2 expression important forAML cell proliferation
control. Importantly, we identify the contribution of dysregulated C/EBPa and E2F1 to
elevated Trib2 expression and leukemic cell survival, which likely contributes to
the initiation and maintenance of AML and may have significant implications for normal and malignant hematopoiesis. (Blood.
2014;123(15):2389-2400)
Introduction
The tribbles (Trib) family of pseudokinase genes (Trib1, Trib2, and
Trib3) have recently emerged as important regulators of acute
leukemia and hematopoietic development.1 Trib proteins’ diverse
roles include cell proliferation, survival, motility, and metabolism.2
There is a strong correlation between dysregulated Trib2 expression
and acute myeloid and lymphoid leukemia (AML and ALL).
Elevated Trib2 expression associates with a speciﬁc subset of AML
characterized by dysregulated CCAAT enhancer-binding protein a
(C/EBPa) and with T-cell ALL (T-ALL), both linked with NOTCH1
mutations.3-5Mice reconstitutedwith hematopoietic stem cells (HSCs)
retrovirally expressing Trib2 developed AML. The proteasomal-
mediated degradation and inhibition of C/EBPa was required for
the leukemogenic activity of Trib2.4-6 Although Trib2 appears
to integrate a wide variety of signaling pathways, the molecular
understanding of how its expression is controlled in normal and
malignant hematopoiesis is limited.
We identiﬁed Trib2 as a NOTCH1-regulated transcript in T-ALL
cells undergoing growth arrest. As well as NOTCH1,3,5 PITX17 and
TAL18 were also found to up-regulate Trib2 in T-ALL. Both PITX1
and TAL1 are recurrently activated transcription factors in T-ALL
and importantly require the expression of Trib2 for leukemic cell
growth and survival.8 In AML cells, MEIS1 was found to bind to the
Trib2 promoter, andTrib2 could confer growth-enhancing properties
to NUP98-HOXD13/MEIS1-AML cells.9 Additionally, Trib2 ex-
pression is regulated by microRNAs in leukemia cells.10,11 It is clear
therefore that Trib2 expression is controlled in a cell type–, cell
context–, and cell cycle–dependent manner.
The role of Trib2 in cell cycle and cell proliferation is supported by
an established role forDrosophila Tribbles (dTRIB) in the cell cycle.
dTRIB coordinates cell division during gastrulation by promoting
turnover of the cell cycle protein String/CDC25, thereby inhibiting
premature mitosis.12-14 A further study suggested that dTRIB controls
mitosis through inhibition of String and positive regulation of WEE1,
as coexpression of WEE1 and Tribbles showed strong synergistic
interactions that resulted in severe eye and wing developmental
defects.15 Studies of mammalian Trib2 thus far indicate the genetic
interactions of dTRIB and other Drosophila homolog proteins are
conserved in themammalian system. dTRIBpromotes the degradation
of Slbo, theDrosophila homolog of the C/EBP family of transcription
factors, thereby inhibiting Slbo-dependent border cell migration
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during oogenesis,16 and inactivation of C/EBPa by Trib2 has been
shown in the hematopoietic system to block myeloid cell differenti-
ation.4 Likewise, dTRIB has a positive genetic interaction with N
(the Drosophila homolog of NOTCH),17 and this is conserved in
mammals as Trib2 was found to be a direct transcriptional target gene
of NOTCH1.5
The transcription factor C/EBPa is a critical regulator of myeloid
cell proliferation and differentiation. C/EBPa is frequently dysregu-
lated inAMLas a result ofmutation, posttranscriptionalmodiﬁcations,
posttranslational inhibition, epigenetic regulation, and proteasomal
degradation. It is also an important tumor suppressor as it regulates
a variety of cell cycle proteins.18 C/EBPamRNA encodes for 2 major
protein isoforms, C/EBPa-p42 and C/EBPa-p30, produced by alter-
native translational start codons.We have previously shown that Trib2
degrades C/EBPa-p42 and blocks differentiation, with an increase in
the C/EBPa-p30 oncogenic protein. In addition to Trib1- and Trib2-
mediated dysregulation,19 the normal protein expression ratio of
p42:p30 is skewed inAMLas a result of genemutation.20 Importantly,
the p30 isoform lacks a transactivation domain in the N terminus
important for antimitotic activity. This N-terminal domain is crucial
for growth arrest by E2F1-mediated regulation of c-Myc expression,
andC/EBPa-p42 interferes with E2F1 transactivation of the c-Myc
promoter.21-23 E2F1 is a master regulator of cell cycle progression.
C/EBPa inhibition of E2F1 additionally occurs via protein-protein
interaction in non–DNA-binding residues in the C-terminal region
of C/EBPa present in both p30 and p42.22 Mutation of the
C-terminal residues of C/EBPa that interact with E2F1 (BRM2)
leads to a transplantable disorder of the myeloid lineage with
expansion of myeloid progenitors. This revealed a role of C/EBPa-
mediated E2F1 repression in controlling the proliferation of myeloid
progenitors.24 Importantly, however, null mutations inCEBPA do not
occur in AML, andC/EBPa-deﬁcient HSCs do not lead toAML,25,26
demonstrating that C/EBPa is required for AML to develop.
The E2F family of cell cycle regulators are generally classed
as transcriptional activators (E2F1, E2F2, E2F3a, and E2F3b) or
repressors (E2F4, E2F5, E2F6, E2F7, and E2F8), but this simple
classiﬁcation lacks in vivo validation.27 E2F1-3–deﬁcient hemato-
poietic cells have a defect in myeloid cell differentiation, with an
accumulation of granulocyte/macrophage progenitor (GMP) cells
and a decrease in CD11b1myeloid cells in the bone marrow. E2F1-
3s are thus required for cell survival and proliferation at distinct
stages during myeloid differentiation.28 AML with CEBPA mu-
tations has increased E2F3 and decreased miR-34a levels, which
C/EBPa normally regulates in myeloid cells.29 Additional studies
support amolecular network involvingmiR-223,C/EBPa, andE2F1
as major components of the granulocyte differentiation program,
which is deregulated in AML.30
We show here that E2F1, as well as E2F2 and E2F3, is a potent
inducer of Trib2 expression and that E2F1 cooperates with C/EBPa-
p30 to further activate the Trib2 promoter in preleukemic cells,
resulting in elevated Trib2 expression. Conversely, in normal my-
eloid progenitor cells, C/EBPa-p42 is found bound to the Trib2
promoter and inhibits E2F1-mediated activation of Trib2. We dem-
onstrate that inhibition of the E2F1-Trib2 regulatory loop results
in cell cycle arrest and inhibition of leukemic cell proliferation. In
addition, we show that targeted inhibition of this pathway does not
affect the growth and survival of normal hematopoietic cells. Our
work demonstrates that Trib2 expression is regulated by E2F1 in
vivo, and C/EBPa-p30 cooperates with E2F1 to activate Trib2
expression, thus preventing C/EBPa-p42–mediated E2F1 repres-
sion, ultimately contributing to the uncontrolled proliferation and
cell cycle progression seen in AML.
Methods
Trib2-dependent reporter gene assay
3T3 cells were transfected with luciferase constructs alone or in combination
with other expression plasmids and luminescence readings taken (see sup-
plemental Methods on the BloodWeb site for details).
Electromobility shift assay
Nonradiolabeled electromobility shift assays (EMSAs) using the LightShift
Chemiluminescent EMSA Kit (Thermo Scientic) were performed on nuclear
extracts prepared from cells using wild-type (WT) and mutant probes.
Speciﬁcity was assessed by cold competition (see supplemental Methods for
details).
Chromatin immunoprecipitation
Cells were ﬁxed and resuspended in lysis buffer. Isolated nuclei were
resuspended in shearing buffer (Active Motif) and sonicated on ice. Protein/
DNA complexes were immunoprecipitated with the indicated antibody, and
DNA was eluted as per the manufacturer’s instructions (Active Motif) and
column puriﬁed (QIAquick Puriﬁcation Kit; Qiagen). Eluted DNA was
subjected to polymerase chain reaction (PCR) using promoter-speciﬁc
primer sets (see supplemental Methods for details).
Mice
Trib22/2 (B6;129S5-Trib2tm1Lex) mice, backcrossed onto C57B6, were
bred and housed in the University of Glasgow. Cebpa transgenic mice31 were
bred and housed in the University of Copenhagen (see supplemental
Methods for details). All mouse work was performed according to national
and international guidelines and approved by the local United Kingdom and
Danish Animal Ethical Committees.
Dataset analysis
Gene expression values for Trib2 vs E2F1 (GSE14468 and GSE1159) were
plotted, and the line of best ﬁt was calculated using linear regression (see
supplemental Methods for details).
Cell cycle and proliferation analysis
Cells were stained with carboxyﬂuorescein diacetate succinimidyl ester
(CFSE;Molecular Probes) for 10minutes and treated.Drug-treated cellswere
also ﬁxed and stained with Propidium Iodide (PI)/RNase staining buffer
(BD Pharmingen) (see supplemental Methods for details).
Annexin V/496 diamidino-2-phenylindole staining
Total bone marrow cells from WT or Trib2-deﬁcient mice and green
ﬂuorescent protein–sorted U937 cells were suspended in binding buffer
(containing annexinV-phycoerythrin [BDBiosciences] and 496 diamidino-2-
phenylindole [DAPI; Sigma-Aldrich]) and were analyzed by ﬂow cytometry.
Patient AML samples
Blood samples from newly diagnosed AML patients and normal peripheral
blood samples were collected following protocol approved by the Ethics
Review Board and with informed consent. Mononuclear cells were isolated
using Histopaque (Sigma-Aldrich) according to the manufacturer’s instruc-
tions. This study was conducted in accordance with the Declaration of
Helsinki.
See supplemental Methods for all other details.
Results
To investigate how Trib2 expression is regulated, we cloned 2
promoter regions of Trib2 into the pGL3 luciferase reporter: (1)
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500 bp upstream from the transcriptional start site (2500 to11 bp)
and (2) including the entire 59 untranslated region (UTR) and
upstream region (22.6 kb to 11 bp). The promoter activity was
assessed in 293T cells, 3T3 cells, and RAW264.7 cells. Increased
Trib2 promoter activitywas seen in 293T and 3T3 cell lines but not the
RAW cell line with the 2.6-kb promoter construct compared with the
500-bp promoter (Figure 1A). We analyzed the promoter region of
Trib2 using TESS bioinformatic software and found 3 putative
consensusE2Fbinding siteswithin theTrib2promoter. Two siteswere
locatedwithin the 1.3-kb 59UTR (siteB at2943 bp and siteC at2811
bp), and 1 sitewas further upstream (siteA at22.1 kb; Figure 1B).We
assessed the activation of the Trib2 promoter by cotransfection with
E2F1 in 3T3 and K562 myeloid cells. E2F1 expression signiﬁcantly
increased the promoter activity of the 2.6-kb construct in both cell
types (Figure 1C,E). We performed the promoter activity assay using
an E2F1 DNA binding mutant (E132 mutant) and showed that, in the
absence of direct DNA binding, E2F1 is unable to activate the Trib2
promoter in both 3T3 and K562 cells (Figure 1D-E). Together these
data suggest that Trib2 is a target of E2F1.
To identify the role of the predicted E2F1 sites in the Trib2 pro-
moter regions, we constructed a number of deletion and mutagenized
promoter constructs in the luciferase reporter (schematic representation
in Figure 2A-B, upper panels, respectively). We tested the promoter
activity in the presence and absence of exogenous E2F1 expression.
Activation of the 500-bppromoter region canbemodestly increased by
expression of E2F1 (as seen in Figures 1C and 2A), despite the lack of
a consensusE2F1binding site in that region. This indicates a potential
nonconsensus E2F1 binding site or E2F1-mediated activation via
protein-protein interactions. Using deletion constructs containing
only site B (2963-bp construct with site C mutated) or only site C
(2927-bp construct; Figure 2A, upper left) revealed that in the
absence of site A and site B or C, E2F1 is able to further activate the
Trib2 promoter but is unable to restore complete activation as seen
in the full-length promoter construct (Figure 2A, lower). We then
performed site-directed mutagenesis of sites A, B, and C in the
2.6-kb promoter construct. Luciferase activity assay revealed that
mutation of site A or C alone did not abrogate or inhibit E2F1-
induced promoter activity, whereas mutation of B alone or both
Figure 1. E2F1 binds and activates the Trib2 promoter. (A) 293T, 3T3, and RAW264.7 cells were cotransfected with empty pGL3 Basic or 500-bp Trib2 promoter or 2.6-kb
Trib2 promoter constructs and luciferase activity was measured. (B) Schematic presentation of the Trib2 promoter region 2.6 kb upstream from the transcriptional start site and
the location of 3 putative E2F binding sites. (C) 3T3 cells were cotransfected with E2F1 or pcDNA empty expression vector and Trib2 luciferase reporter plasmids (pGL3 control,
500-bp, or 2.6-kb promoter region) and luciferase activity was measured. (D) 3T3 cells were cotransfected with E2F1 or E2F1 E132 DNA binding deficient mutant expression
vectors and Trib2 luciferase reporter constructs (pGL3 control or 2.6-kb promoter) and luciferase activity was measured. Data presented are mean 6 standard deviation (SD) of
duplicate cultures and representative of 3 independent experiments. **P, .005 and ***P, .001 using an unpaired Student t test. (E) K562 cells were cotransfected with E2F1 or
E2F1 E132 DNA binding deficient mutant expression vectors or empty control vector and Trib2 luciferase reporter constructs (pGL3 control or 2.6-kb promoter) and luciferase
activity was measured. Data presented are mean 6 SD and representative of 3 independent experiments. **P , .005 using an unpaired Student t test.
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Figure 2. E2F1 binding is localized to 2 consensus binding sites on the Trib2 promoter. (A) (Upper) Schematic presentation of full-length 2.6-kb and deletion mutant
Trib2 promoter constructs with the indicated E2F1 binding sites. 3T3 cells were (lower left) transfected with Trib2 luciferase reporter plasmids (pGL3 control, 2.6-kb, 500-bp,
927-bp, or 963-bp promoter region) and (lower right) cotransfected with E2F1 or pcDNA empty expression vector, and luciferase activity was measured. (B) (Upper)
Schematic presentation of full-length 2.6 kb with site-directed mutations of the 3 putative E2F1 binding sites. 3T3 cells were (lower left) transfected with Trib2 luciferase
reporter plasmids (pGL3 control, 2.6-kb, MutA, MutB, MutC, or double mutant DM) and (lower right) cotransfected with E2F1 or pcDNA empty expression vector, and
luciferase activity was measured. Data presented are mean 6 SD of duplicate cultures and representative of 3 independent experiments. *P , .05, **P , .005, and
***P , .001. (C) Nuclear extracts prepared from K562 cells transfected with pcDNA3 empty or E2F1 were assayed for E2F1 binding for sites A, B, and C by EMSA. Arrow
indicates E2F1 binding. FP, free probe; comp, cold competition; MT, mutant type. (D) 3T3 cells were cotransfected with E2F1 WT or E2F1 E132 DNA binding deficient mutant
or empty expression vector and Trib2 luciferase reporter constructs (pGL3 control, 2.6-kb, 500-bp, or DM promoter region), and luciferase activity was measured. Data
presented are mean 6 SD of duplicate cultures and representative of 2 independent experiments. **P , .005 and ***P , .001 using an unpaired Student t test. (E) K562 cells
were cotransfected with E2F1 WT or E2F1 E132 DNA binding deficient mutant or empty expression vector and Trib2 luciferase reporter constructs (pGL3 control, 2.6-kb,
500-bp, or DM promoter region), and luciferase activity was measured. Data presented are mean 6 SD and representative of 2 independent experiments. ***P , .001 using
an unpaired Student t test.
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sites B and C together reduced Trib2 promoter activity (Figure 2B,
lower). EMSA analysis showed that, on transfection of K562 cells
with E2F1, there was an increase in binding to the WT probes for
the E2F1-speciﬁc sites A, B, and C and a lack of E2F1-inducible
binding to 3 distinct mutant probes for sites A, B andC (Figure 2C).
Mutation of B and C together signiﬁcantly reduced Trib2 promoter
activity in both 3T3 (Figure 2D) and K562 cells (Figure 2E) but not
to as great an extent as the 500-bp promoter (lacks sites A, B,
and C). Together, these data reveal that E2F1 binds at sites A, B,
and C in the Trib2 promoter in ﬁbroblasts and myeloid cells.
We next tested whether this was speciﬁc to E2F family members.
Luciferase assays in 3T3 cells using the full-length 2.6-kb Trib2
promoter construct revealed that E2F1, E2F2, E2F3, and E2F4
activated the Trib2 promoter, whereas E2F5 was unable to induce
Trib2 promoter activity (Figure 3A). To test the ability of these E2F
family members to bind to Trib2 promoter in a myeloid leukemia
cell, we performed chromatin immunoprecipitation (ChIP) analysis
using antibodies for endogenous E2F1, E2F2, E2F3, E2F4, and
E2F5 in K562 cells (express high levels of Trib2 protein; Figure 7E).
In comparison with the IgG-negative control, there was enrichment
Figure 3. Other E2F family members can bind and activate Trib2 promoter. (A) 3T3 cells were cotransfected with E2F1, E2F2, E2F3, E2F4, E2F5, or pcDNA empty
expression vector and Trib2 luciferase reporter plasmids (pGL3 basic control or 2.6-kb promoter region), and luciferase activity was measured. Data presented are mean 6 SD
of duplicate cultures and representative of 3 independent experiments. *P , .05 and ***P , .001. (B) K562 cells were chromatin immunoprecipitated using anti-E2F1, anti-E2F2,
anti-E2F3, anti-E2F4, anti-E2F5, antiacetylated histone 4 (Ac-His4), or normal IgG control antibodies. PCR was performed using primers directed against the E2F binding region
containing sites B and C and using primers against a 25-kb region as a negative control. Graphs represent fold enrichment of DNA compared with the IgG control and are
representative of 3 independent experiments, and error bars denote 6 SD of each sample. *P , .05, **P , .005, and ***P , .001.
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of E2F1, E2F2, and E2F3 on the Trib2 promoter region containing
sites B and C, but not at a 25-kb Trib2 promoter region used as a
negative control (Figure 3B). The Trib2 promoter region was shown
to be transcriptionally active as demonstrated by the presence of
acetylated histone 4. There was no signiﬁcant enrichment of E2F4
or E2F5 on the Trib2 promoter. These data show that E2F1, E2F2,
E2F3, and E2F4 are capable of activating the Trib2 promoter; in
leukemia cells, only E2F1, 2, and 3 actually bind the Trib2 promoter.
These data demonstrate that E2F proteins directly regulate Trib2
expression.
To further analyze the role of E2F1 in Trib2 regulation, we
assessed E2F1-induced Trib2 mRNA expression in cells transfected
with E2F1. 293T, E2F12/2 mouse embryonic ﬁbroblasts (MEFs),
andK562 cells were transfectedwith control pcDNAvector, E2F1, or
intracellular activated Notch1 ([ICNX] as a positive control5), and
Trib2 mRNA expression was measured. There was a signiﬁcant
increase in Trib2 mRNA following overexpression of E2F1
(Figure 4A). Indeed there was signiﬁcant reduction in Trib2 mRNA
expression in E2F12/2MEFs compared withWTMEFs (Figure 4B).
E2F12/2 MEFs express little to no Trib2 protein expression
(Figure 4C), and on transfection with E2F1 (and ICNX as positive
control), we saw an increase in Trib2 protein expression (Figure 4D,
left, lane 2). Similarly, transfection of K562 cells with E2F1 leads
toan increase inTrib2protein expression (Figure4D, right).Conversely,
small interfering RNA (siRNA) directed against E2F1 in 293T, HeLa,
and K562 cells resulted in decreased Trib2 mRNA expression levels
compared with siRNA scramble controls (Figure 4E-G), and
analysis of a previously published transcriptional proﬁle ofE2F1-32/2
CD11b1myeloid cells28 revealed a 4.6-fold reduction in Trib2.
We also identiﬁed putative C/EBPa binding sites in the Trib2
promoter using the TESS bioinformatics analysis tool. Indeed E2F1
binding sites B and C surround a region of the Trib2 promoter that
contains a high conﬁdenceC/EBPbinding site (2900 bp) (Figure 5A).
C/EBPa-mediated inhibition of E2F1 is pivotal for granulopoiesis. As
our previous work has shown that Trib2 degraded C/EBPa-p42
leaving increased expression of the oncogenic C/EBPa-p30 form
in AML, we tested whether there was an E2F1-C/EBPa feedback
loop regulating Trib2 expression. EMSA revealed that both
C/EBPa-p42 and -p30 bind to this region at 2900 bp using a
C/EBPa binding site–speciﬁc probe (Figure 5B). Trib2 promoter
assays showed a dose-dependent decrease in activity following
cotransfection of increasing doses of C/EBPa-p42 compared with
E2F1 alone (Figure 5C, left). Signiﬁcantly, cotransfection of E2F1
and C/EBPa-p30 resulted in a dose-dependent increase in E2F1-
induced Trib2 promoter activity (Figure 5C, right). These data
show that the E2F1 regulation of Trib2 can be modulated by the
presence of C/EBPa-p42 and C/EBPa-p30. Importantly, Trib2
mRNA expression decreased in myeloid K562 cells on C/EBPa-
p42 expression, and reciprocally, Trib2 expression increased on
C/EBPa-p30 expression (Figure 5D). This was not due to an
increase in E2F protein expression by C/EBPa-p30 (supplemental
Figure 1). This regulation was seen in K562 nuclear extracts at the
DNA binding sites, as EMSA analysis showed that C/EBPa-p42
and -p30 modulated the binding of E2F1 to the Trib2 promoter at
site B only (Figure 5E). The slower-migrating protein complex
induced by C/EBPa-p30 contained both E2F1 and C/EBPa-p30 as
seen by the disappearance of this complex in a supershift assay,
indicating that these proteins are components of this complex
(Figure 5F). Additionally, the E2F1-induced Trib2 promoter activity
in K562 cells was modulated by C/EBPa-p42 and -p30 expres-
sion (Figure 5G). To investigate the physiological binding of C/EBPa
to the Trib2 promoter in the myeloid lineage, we performed ChIP
analysis for C/EBPa in normal murine GMPs at 2900 bp. We
detected C/EBPa bound to the Trib2 promoter in the region
spanning the identiﬁed E2F1 binding sites B and C (Figure 5H)
revealing that in normal GMPs, C/EBPa is recruited onto the Trib2
promoter. This is consistent with the ability of C/EBPa-p42 to inhibit
E2F1 in normalmyelopoiesis. Interestingly, real-time quantitative PCR
analysis of normal WT GMPs compared with GMPs isolated from
preleukemic mutant C/EBPa knockin mice that retain p30 expression
but have lost p42 expression (Lp30, 2/p30) reveals a signiﬁcant
increase inTrib2 expression in themutantGMPs (Figure 5I).Therefore,
in the presence of C/EBPa-p30 in the preleukemic GMP population,
Trib2 mRNA expression is increased. Together, these data reveal that
C/EBPa localizes to the Trib2 promoter in GMP progenitor cells, and
the balance of C/EBPa-p42 and C/EBPa-p30 modulates the ability
of E2F1 to activate Trib2 expression in normal and preleukemic
myeloid cells.
To target the E2F1 pathway and determine the effect on Trib2 and
the leukemic cell, we used known cyclin-dependent kinase inhibitors
(CDKis), ﬂavopiridol (a pan CDK inhibitor),32 pentoxifylline (PTX,
a nonspeciﬁc phosphodiesterase inhibitor), and dibutyryl cAMP
(a cAMP analog).33 We treated U937 cells (AML cells that express
high levels of Trib2 protein; Figure 7E) with escalating doses of
ﬂavopiridol and PTX and assessed cell death (Figure 6A). Both
ﬂavopiridol (IC50 of 94 nM) and PTX (IC50 of 4 mM)were cytotoxic
to U937, whereas up to 4 mM dibutyryl cAMPwas not cytotoxic. At
a lower-dose (2 mM PTX, 4 mM dibutyryl cAMP, and 62.5 nM
ﬂavopiridol) treatment at 24 hours, U937 cells underwent G1 cell
cycle arrest without increased apoptosis (sub-G1 DNA content) as
assessed by propidium iodide staining (Figure 6B) and had reduced
proliferation as assessed by CFSE staining at 96 hours (Figure 6C).
Using low drug doses that inhibit cell proliferation but have minimal
cytotoxicity and apotosis, we assessed the effect on cell cycle pro-
teins E2F1 and Trib2. Western blot analysis determined that PTX,
dibutyryl cAMP, and ﬂavopiridol led to a reduction in Cdk6, Cdk2,
phospho-RB (phosphorylated-retinoblastoma), E2F1, and Trib2
with 24-hour treatment (Figure 6D). Importantly, global protein
expression of RB is not decreased, and C/EBPa levels remain
unchanged, if not slightly increased at the lower concentrations
when cell cycle arrest occurred. These results show that the inhibition
of CDKs results in cell cycle arrest and reduced proliferation, inhibition
of E2F1, and a decrease in Trib2. To determine the effect in normal
cells, we treated WT and Trib2 knockout (KO; Trib22/2) total bone
marrow (BM) cells and HSCs (Lineage2Sca-11c-Kit1) with PTX,
dibutyryl cAMP, andﬂavopiridol. Therewas very little cytotoxic effect
on WT BM cells and HSCs as assessed by Annexin V/DAPI staining
(Figure 6E-F), and no differencewas observed in cell death in Trib22/2
BM and HSC cells compared with WT cells (Figure 6E-F). No cy-
totoxic effect was seen in colony-forming assays of untreated and
treated HSCs from WT and Trib22/2 animals (Figure 6G). These
data show that there is limited cell toxicity of targeting this
pathway using these drugs in normal cells or cells that lack Trib2
expression.
To prove that inhibition of Trib2 expression plays a role in leu-
kemic cell proliferation, we used lentiviral technology to knockdown
Trib2 expression in AML cells (Figure 7A; supplemental Figure 2).
Trib2 knockdown inhibited the growth of AML cells (Figure 7B),
induced apopotosis and decreased cell viability (Figure 7C), and
induced G1 cell cycle arrest (Figure 7D), indicating that Trib2
expression is required for the survival and proliferation of AML
cells. Therefore, to assess the prevalence of high Trib2 expression in
AML, we analyzed primary AML patient samples by mRNA and
western blot analysis and compared the levels to normal peripheral
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blood samples (N1-6), normal lymphoblast cell lines (CV1665 and
CV1939), and myeloid leukemic cell lines (K562, U937, ML-1,
Kasumi, and SB1690CB). We detected high Trib2 expression in
AML patient samples compared with normal controls (Figure 7E).
High E2F1 expression correlated with high Trib2 protein expression
(Figure 7E). AML patient datasets were investigated for a correlative
Figure 4. E2F1 regulates Trib2 mRNA and protein expression levels. (A) (Left) E2F12/2 (KO) MEFs, (center) 293T, or (right) K562 cells transfected with E2F1, pcDNA
control, or ICNX as indicated were measured for Trib2 mRNA expression by real-time PCR analyses. Data are presented relative to control pcDNA transfected cells 6 SD of
duplicate cultures. *P , .05, **P , .005, and ***P , .001. (B) WT and E2F12/2 (KO) SV40 MEFs were measured for (left) E2F1 and (right) Trib2 mRNA expression by real-
time PCR analyses. (C) Western blot analyses of E2F1 and Trib2 protein levels in WT and E2F12/2 (KO) MEFs. Actin shown as protein loading control. (D) (Left) E2F12/2
(KO) MEFs or (right) K562 cells were transfected with pcDNA3 empty vector, E2F1, ICNX, or Trib2 as indicated, and western blot analyses were performed for Trib2, E2F1,
and actin as a loading control. (E) 293T, (F) HeLa, and (G) K562 cells were transfected with scrambled control siRNA and siE2F1 (1 or 2 different E2F1 siRNAs as indicated),
and real-time PCR analysis was performed for E2F1 and Trib2. Data are presented relative to control transfected cells and representative of 2 independent experiments. Error
bars denote 6 SD of each sample measured in triplicate. *P , .05, **P , .005, and ***P , .001.
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relationship between elevated Trib2 expression andE2F1 expression.
Using 2 previously published AML patient microarray datasets,34,35
we found a signiﬁcant positive correlation between E2F1 and the high
Trib2-expressing patient samples (Figure 7F). As positive controls,
we determined that there was a signiﬁcant positive correlation
between Trib2 and NOTCH1 and a signiﬁcant negative correlation
Figure 5. C/EBPa p42 and p30 oppositely modulate Trib2 expression via binding of the promoter. (A) Putative binding sites of C/EBP family of transcription factors in
the Trib2 promoter. Several binding sequences are shared among members a, b, and d of the C/EBPa family. E2F putative binding sites are also indicated (long dash line),
and the region is targeted for ChIP-PCR analysis. (B) Nuclear extracts prepared from K562-C/EBPa-p42-ER or K562-C/EBPa-p30-ER cells induced with b-estradiol for
24 hours were assayed for C/EBPa binding by EMSA. Arrows indicate C/EBPa binding. FP, free probe; comp, cold competition. (C) 3T3 cells were cotransfected with empty
control, E2F1 alone, or in combination with increasing amount of (left) C/EBPa-p42 or (right) C/EBPa-p30 and Trib2 luciferase reporter constructs (pGL3 control or 2.6-kb
promoter), and luciferase activity was measured. Data presented are mean6 SD of duplicate cultures and representative of 2 independent experiments. *P , .05 and **P, .005.
(D) K562-C/EBPa-p42-ER and K562-C/EBPa-p30-ER cells induced with b-estradiol or vehicle control for 24 hours were measured for Trib2 mRNA expression by real-time PCR
analyses. Data are presented relative to vehicle control and representative of 2 independent experiments. Error bars denote6SD of each sample measured in triplicate. **P, .005
and ***P , .001. (E) Nuclear extracts prepared from (upper) K562-C/EBPa-p42-ER and (lower) K562-C/EBPa-p30-ER cells transfected with E2F1 and induced with b-estradiol or
vehicle control for 24 hours were assayed for E2F1 binding for WT sites B and C by EMSA. FP, free probe. (F) Supershift EMSA assay was performed in nuclear extracts prepared
from K562-C/EBPa-p30-ER cells transfected with E2F1 and induced with b-estradiol or vehicle control for 24 hours using antibody specific for E2F1 or C/EBPa. Oligonucleotide for
WT site B was used as a probe. FP, free probe. (G) K562 cells were cotransfected with empty control, E2F1 alone, or E2F1 in combination with C/EBPa-p42 or C/EBPa-p30 and
Trib2 luciferase reporter constructs (pGL3 control or 2.6-kb promoter region), and luciferase activity was measured. Data presented are mean 6 SD and representative of 2
independent experiments. ***P , .001 using an unpaired Student t test. (H) Normal murine GMP cells were chromatin immunoprecipitated using anti-C/EBPa or normal IgG
control antibodies. PCR was performed using primers against the region indicated in A. Error bars denote 6SD of each sample measured in triplicate. ***P , .001. (I) Real-time
PCR analysis of Trib2 mRNA levels in WT (1/1) GMP and 2/p30 GMP cells. **P , .005.
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Figure 6. CDK inhibition decreases Trib2 resulting in a block in AML cell proliferation. (A) PTX and flavopiridol dose response of U937 cells assessed by
3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide; 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay at 24 hours. Data are expressed as
percentage over untreated control. Values are expressed as mean 6 SD (N 5 2, performed in triplicate). (B) Cell cycle analysis of PTX, dibutyryl cAMP, and flavopiridol
dose response in U937 cells at 24 hours. (C) Cell proliferation of PTX and flavopiridol dose response of U937 cells assessed by CFSE staining 96 hours after treatment.
(D) Western blot analysis of protein lysates from U937 cells treated for 24 hours with different concentrations of (left) PTX, (center) dibutyryl cAMP, and (right)
flavopiridol. Shown are Cdk6, Cdk2, pRB (phosphor-RB), E2F1, Trib2, and C/EBPa-p42. Actin, total RB, and histone deacetylase 1 (HDAC1) are shown as protein
loading controls. (E) WT and Trib22/2 (KO) total bone marrow cells were treated with different concentrations of (left) PTX, (center) dibutyryl cAMP, and (right)
flavopiridol and assessed for apoptosis by AnnexinV/DAPI staining. (F) WT and Trib22/2 (KO) HSCs were treated with different concentrations of (left) PTX and (right)
flavopiridol and assessed for apoptosis by AnnexinV/DAPI staining. (G) WT and Trib22/2 (KO) HSCs were treated with 2 mM PTX or 62.5 nM of flavopiridol (FLV) for
24 hours and plated in a CFC assay. Data presented are mean 6 SD of duplicate cultures.
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between Trib2 and C/EBPa (data not shown). Therefore, these data
strongly support the role of E2F1-regulated Trib2 expression inAML
and its function in the dysregulation of myeloid cell proliferation.
Our data support theﬁnding that the perturbation ofC/EBPa byTrib2
functions in a positive feedback loop to enhance E2F1-mediated
Trib2 expression in AML.
Figure 7. AML cells express high levels of Trib2 protein and correlate with E2F family members mRNA expression. (A) Real-time analysis of Trib2 mRNA levels in
U937 cells following transduction with pLKO.1 control (Ctrl) or pLKO.1 Trib2. (B) Cell growth analysis in U937 cells transduced with pLKO.1 ctrl or pLKO.1 Trib2 assessed by
trypan blue exclusion. (C) Cell death analysis in U937 transduced with pLKO.1 ctrl or pLKO.1 Trib2 assessed by (left) Annexin V and (right) DAPI staining. (D) Cell cycle
analysis in sorted U937 cells transduced with pLKO.1 ctrl or pLKO.1 Trib2. Data presented are mean 6 SD of duplicate cultures and representative of 2 independent
experiments. (E) Western blot analysis of Trib2 protein expression in (top left) myeloid leukemia lines (K562, U937, ML-1, and Kasumi-1), (middle left) normal cell lines
(CV1665 and CV1939), and (bottom left) normal peripheral blood (PB and N1-5). (Top right) Real-time analysis of Trib2 mRNA levels in AML patient samples. (Bottom right)
Western blot analysis of Trib2 and E2F1 protein expression in normal PB (N6), AML patient samples (denoted by their subtypes), ALL patient samples, and U937 cells. Actin
is shown as a protein loading control. (F) Correlation analysis of Trib2 vs E2F1 in the top 95th and 96th percentiles of patient samples from the dataset GSE115934(N 5 14)
and GSE1446835 (N 5 21). P , .05 and correlation coefficient (Pearson r, close to 11) show significant positive correlations.
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Discussion
Trib2 expression may be differentially regulated depending on the
cell type (myeloid or lymphoid, immature or mature), cell context
(normal or malignant), and the cell cycle (quiescent or self-renewing
or proliferating). Herewe described the regulation of Trib2 in normal
myeloid and leukemic cells via an E2F1 and C/EBPa feedback
mechanism. We demonstrated a correlation between the expression
levels of E2F1 and Trib2 in AML cells and showed that E2F1 is
recruited to the Trib2 promoter, activating Trib2 expression. E2F1-
regulated Trib2 activation was negatively and positively modulated
via C/EBPa-p42 and C/EBPa-p30 expression, respectively. We
demonstrated the recruitment of C/EBPa-p42 to the Trib2 promoter
in normal myeloid cells and the elevation of Trib2 expression in
C/EBPa-p30 expressing preleukemic myeloid cells. Our results
reveal a positive feedback loop for E2F1, Trib2, and C/EBPa-p30
in AML. Our data suggest that the regulation of Trib2 expression
in AML cells is pivotal for AML cell proliferation and survival.
The identiﬁcation of E2F direct gene targets via consensus and
nonconsensus binding sites has been globally assessed using ChIP
technologies.36 Indeed the recruitment of E2F1 to promoters does not
always require DNA binding, as other transcription factors have
been shown to recruit E2F1, such as nuclear factor-kB, Myc, and
C/EBPa.27 C/EBPa-p30 has been shown to recruit E2F1 to the
promoter of PIN1, and increased PIN1 expression was proposed to
contribute to the differentiation block in AML.37 We showed and
validated the presence of E2F1 binding sites in the Trib2 promoter.
Using site-directed and deletional mutagenesis and EMSA analysis,
we conclude that E2F1 binds directly to the Trib2 promoter and is
modulated by C/EBPa speciﬁcally at site B at2943 bp. We demon-
strate the recruitment of C/EBPa to this region in normal GMP cells.
Using a ChIP assay, we were unable to distinguish between C/EBPa-
p42 and C/EBPa-p30 binding to the Trib2 promoter in normal or
preleukemic cells. It has been suggested that C/EBPa-p30 has in-
dependent functions of C/EBPa-p42 and that it can target and
modulate a unique set of genes in addition to its role as a dominant
negative of C/EBPa-p42.38,39 Given that we have shown that
C/EBPa-p30 preleukemicGMP cells have elevated Trib2 expression
above that present in normal GMPs, these data support the positive
feedback loop that we propose between E2F1, C/EBPa, and Trib2.
The central mechanisms identiﬁed for the negative regulation of
cell proliferation by C/EBPa are repression of E2F,22 interference
with Cdk2 and Cdk4 function,40 and p21 stabilization (a Cdk
inhibitor).41 Flavopiridol is a small molecule cyclin-dependent
kinase inhibitor that induces cell cycle arrest, apoptosis, and clinical
responses in AML patients. Following the inhibition of Cdks, phos-
phorylationofRB is inhibited, andE2F is released anddrives cell cycle
arrest and apoptosis. Studies have shown that ﬂavopiridol induces
apoptosis in leukemic blasts from patients with poor-risk AML or
ALL42 and represses E2F1 expression in leukemic blasts frompatients
with refractory AML.43 PTX has been shown to induce cell cycle
arrest and apoptosis of AML and ALL cells44,45 and has been used in
combination therapy for patients with myelodysplastic syndromes and
AML.46,47 Elevated cAMP, as a result of PTX and dibutyryl cAMP
treatment, has been shown to target CDK and E2F1 in leukemic cells,
leading to cell cycle arrest,33 apoptosis,48 and leukemic cell
differentiation.49 Notwithstanding, these drugs also target other
pathways, for instance, nuclear factor-kB and antiapoptotic
proteins.44 Therefore, the inhibition of CDK has been shown to
induce a number of effects in different subtypes of AML, which all
prove to be detrimental to the leukemic cell (differentiation, cell
cycle arrest, and apoptosis). The inhibition of CDK activity in high
Trib2-expressing AML cells resulted in the arrest of cells in G1
phase of the cell cycle and a subsequent decrease in cell in S phase.
Using concentrations of drug that induced minimal apoptosis and
a block in proliferation, there was a decrease in E2F1 expression
and a subsequent decrease in Trib2 expression, and these effects
ultimately led to apoptotic cell death (sub-G1 increase) of the
AML cell. The fact that we did not observe any proliferative
defect following treatment in nonleukemic WT and Trib2-
deﬁcient BM cells corroborates the role of Trib2 in the control
of leukemic cell proliferation.
Here we identify a positive regulatory loop controlled by E2F1
that contributes to the aberrant expression of Trib2 inAMLcells. Our
ﬁndings provide a novel link between oncogenic Trib2 function and
AML cell proliferation. Whether E2F-mediated regulation of Trib2
occurs also in ALL remains to be investigated and of great interest.
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Supplementary methods, figures and legends 
 
Methods 
Cell culture, transfection and siRNA knockdown 
RAW 264.7 macrophage cells, NIH3T3 cells, 293T, HeLa, and wild type and E2F1-/- 
MEFs cells were cultured in DMEM supplemented with 10% FBS. K562 and U937 
cells were cultured in RPMI with 10% FBS. K562-C/EBPalpha-p42-ER and K562-
C/EBPalpha-p30-ER cell lines were cultured in RPMI (no phenol red) with 10% FBS 
Charcoal stripped. β-estradiol at a concentration of 5µM was used to induce 
translocation of the fusion proteins into the nucleus. WT and Trib2-/- bone marrow 
cells were cultured in DMEM supplemented with 15% FBS, 6ng/ml IL-3, 5ng/ml IL-
6, 100ng/ml SCF. Transient transfection of expression plasmids was carried out using 
Turbofect (Fermentas) or Attractene (Qiagen) transfection reagent according to the 
manufacturer’s instructions. Nucleofection of K562, K562-C/EBPalpha-p42-ER and 
K562-C/EBPalpha-p30-ER cell lines were carried out using the Amaxa kit for 
nucleofection and the Nucleofector™ II device (Amaxa) according to manufacturer’s 
instruction. For siRNA transfection, cells were incubated with control siNEG 
(Scrambled siRNA, AllStar, Qiagen 1027281) or siRNA directed against E2F1 
(Validated E2F1 Flexitube siRNA Qiagen, SI02664410, Hs_E2F1_6 FlexiTube 
siRNA) (Qiagen), Hs_E2F1_9 FlexiTube siRNA) (Qiagen). 
Trib2-dependent reporter gene assay  
3T3 cells were transfected with luciferase constructs alone (firefly luciferase 
constructs in pGL3-Basic and the internal control Renilla luciferase plasmid pRL-TK) 
or in combination with other expression plasmids using Turbofect transfection reagent 
(Fermentas). 24 hours post-transfection Trib2 firefly luminescence readings were 
normalised for renilla values and reported relative to a calibrator sample. The two-
tailed unpaired t-test was used to assess the significance of data. 
Chromatin Immunoprecipitation  
For K562 cell line, cells were fixed in 1% formaldehyde for 10min with agitation. 
Fixation was ceased by adding 1ml of 1.25M glycine and incubating for 5 min with 
agitation. Cells were pelleted and resuspended in 1ml of lysis buffer (Active Motif) 
for 30 mins and dounce homogenised to isolate nuclei. Nuclei were pelleted and 
resuspended in 350µl shearing buffer (Active Motif) and sonicated on ice (K562 cells, 
5 pulses, 50% duty cycle and 30% output). Sheared chromatin samples were 
centrifuge at 15,000 rpm for 10 min at 4º C. Protein/DNA complexes were 
immunoprecipitated with indicated antibody, DNA was eluted as per manufacturer’s 
instructions (Active Motif) and column purified (QIAquick Purification Kit, Qiagen). 
Eluted DNA was subjected to PCR using promoter-specific primer sets (flanking 
putative E2F1-binding sites in the Trib2 promoter: Forward 5’-
GGGGAGACGGGGTGATTGCA-3’, Reverse 5’-CGGGCTGGGCGCAGGTA-3’, 
negative control -5kb Trib2 Promoter: Forward 5’- 
GAGGCTCCGTGGAAAACTCACTTG-3’, Reverse 5’-
TTCCCAACTCTCAAGCGC TCTGC-3’). The two-tailed unpaired t-test was used to 
assess the significance of data. 
For GMP cells, 500.000 were FACS sorted, fixed and quenched as above for 2 min. 
Cells were resuspended in lysis buffer (100mM NaCl, 66mM tris-HCl, 5mM EDTA, 
0.3% SDS, 1.5% triton X-100) and incubated for 20 min at RT with vortexing every 5 
min. Cell lysates were sonicated (30 cycles, 15 s burst, 30 s break) using a bioruptor 
(Diagenode), and centrifuged for 10 min. Protein/DNA complexes were 
immunoprecipitated with antibodies for IgG (sc-2027, Santa Cruz) or 
C/EBPalpha(14-AA, Santa Cruz) and the complexes were treated with RNase A for 
30 min at 37°C followed by addition of SDS (0.5%) and proteinase K (0.5 mg/ml) 
and an additional incubation for 16 hours at 37°C. Finally, chromatin complexes were 
de-cross-linked by incubation at 65°C for 6 h, phenol-chloroform extracted and 
precipitated using NaOAc and EtOH supplemented with glycogen. Eluted DNA was 
subjected to qPCR using primers targeting the C/EBPalpha site in the Trib2 promoter: 
Forward 5’-AGCTGAGTAGGGAGTGCGCGGAGTA-3’ and Reverse 5’-
TCATCGGAGGAGGATCTGGGACGT-3’. 
Electromobility shift assay (EMSA) 
For making nuclear extracts, cells were allowed to swell in buffer A (10 mM HEPES 
pH 7.9, 10 mM KCl, 0.1 mM EDTA pH 8.0, 0.1 mM EGTA pH 7.0 and protease 
inhibitors) for 45 min on ice followed by addition of NP-40, sedimenting the nuclei 
by centrifugation for 1 mint at 10,000 rpm and incubating the nuclear pellet in buffer 
B  (20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA pH 8.0, 1 mM EGTA pH 
7.0 and protease inhibitors) for 30 min on ice and collecting nuclear extract by 
centrifugation for 5 min at 10,000 rpm at  4°C. EMSAs were performed using 
LightShift Chemiluminescent EMSA Kit (Thermo Scientiﬁc). Briefly, 10 µg of 
nuclear extract were incubated with 3’-biotin labeled oligonucleotide in a binding 
reaction mixture containing 10mM Tris (pH 7.5), 50 mM KCl, 1 mM DTT, 2.5% 
glycerol, 5 mM MgCl2, 2 ug BSA, 1 ug poly (dI-dC) for 20 min at 37°C. The DNA-
protein complexes were resolved on 4.5% nondenaturing polyacrylamide gel in 0.5X 
Tris borate EDTA at 100 V at 4°C, transferred onto nylon membrane, UV crosslinked 
followed by the streptavidin detection of biotinylated oligonucleotides. For the cold 
competition, nuclear extracts in the presence of binding buffer were incubated with 
100 fold excess of unlabelled oligonucleotide for 15 min at 37°C. After incubation, 
labeled oligo was added and proceeded for regular binding reaction.   
For supershift assay, nuclear extracts were preincubated with 2µg antibody specific 
for E2F1 (sc-193X, Santa Cruz) or C/EBPalpha (sc-61X, Santa Cruz) for 30 min at 
room temperature and thereafter were proceeded for binding with oligonucleotide as 
described above. The oligonucleotides used for the EMSAs were as follows: 
E2F1(site A, wild type) 5’ – ATGTGTTCTTGGCCTAAATACT -3’, E2F1 (siteB, 
wild type) 5’-CAGGACCCCCGGAAAGCTCCTG- 3’, E2F1 (site C, wild type) 5’- 
GGCTTTGTCGCGGTACCTGT -3’, C/EBPalpha (between site E2F1 site B and C, 
wild type) 5’- TCACCGCCCGCACTTCTTGCTTCATCGGAG -3’. The underlined 
indicates the putative binding site within murine Trib2 promoter. For mutant, the 
sequences of putative binding sites were considerably changed as follows and 
underlined: E2F1 (site A, mutant type) 5’- ATGTGTTTAAAAGGCAAATACT -3’, 
E2F1 (site B, mutant type) 5’-CAGGACCTGGAATTGGCTCCTG-3’, E2F1 (site C, 
mutant type) 5’- GGCTTTGCGCTACTACCTGT -3’, C/EBPalpha (between site 
E2F1 site B and C, mutant type) 5’- 
TCACCGTGGATTCTTTAAATAATGTCGGAG -3’. 
Immunoblotting  
Whole cell lysates were prepared using modified radioimmune precipitation assay 
buffer (50mM Tris, pH 8.0, containing 0.5% NP-40, 0.25% sodium deoxycholate, 
150mM NaCl, 1mM EDTA, with protease and phosphatase inhibitors). Cytoplasmic 
lysates were prepared in ice cold lysis buffer (10 mM HEPES pH 7.9, 10 mM KCl, 
0.1 mM EDTA pH 8.0, 0.1 mM EGTA pH 7.0, 1 mM DTT, with protease and 
phosphatase inhibitors). Nuclear lysates were prepared using ice-cold nuclear 
extraction buffer (20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA pH 8.0, 1 mM 
EGTA pH 7.0, 1 mM DTT, with protease and phosphatase inhibitors). Samples were 
resolved on SDS-PAGE gels, transferred to nitrocellulose membrane and analysed by 
immunoblotting with antibodies against Trib2 (sc-100878, Santa Cruz), E2F1 (sc-193, 
Santa Cruz), C/EBPalpha (sc-61, Santa Cruz), Actin (A5441, Sigma Aldrich), Cdk6 
(sc-177-G, Santa Cruz), Cdk2 (2546, cell signaling), phospho-RB (sc-16670-R, Santa 
Cruz), RB (9309, cell signaling), HDAC1 (sc-7872, Santa Cruz). Patient protein 
samples were prepared by direct lysis of the mononuclear cells in 2X SDS sample 
buffer.  
Quantitative Real-Time RT-PCR (qPCR) 
RNA was extracted from cells using the RNeasy Mini Kit (Qiagen) and reverse 
transcribed with SuperScriptIII reverse transcriptase (Invitrogen). qPCR was 
performed using KAPA SYBR® FAST Universal 2X qPCR Master Mix (Anachem) 
on a MJ Research Opticon 2 (3200 model). 18S and B-actin was used as internal 
controls, and relative mRNA expression levels were calculated using the 2 -ΔΔCT 
method. Primers for human Trib2: Forward 5’- AGCCAGACTGTTCTACCAGA -3’, 
Reverse 5’- GGCGTCTTCCAGGCTTTCCA -3’, murine Trib2: Forward 5’- 
AGCCCGACTGTTCTACCAGA -3’, Reverse 5’- AGCGTCTTCCAAACTCTCCA -
3’. mRNA expression levels between samples were compared by two-tailed student t-
test.  
shTrib2 lentiviral and retroviral transduction and qPCR 
U937 cells were transduced either with lentiviral constructs (pLKO.1-puro-CMV-
TurboGFP or pLKO.1-puro-CMV-TurboGFP-shTrib2, Sigma-Aldrich) or retroviral 
constructs (LMP control or LMP-shTrib2, (sequence 
TCCTAATCTCTTCAATCAATAAA) and sorted for GFP expression. Trib2 
knockdown was analyzed at mRNA levels by qPCR. Total RNA was extracted using 
RNeasy Mini Kit (QIAGEN) and reverse transcribed with the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). qPCR was performed using Fast 
SYBR® Green Master Mix (Applied Biosystems) on a 7900HT Fast Real-Time PCR 
System (Applied Biosystems). ABL was used as internal control, and relative mRNA 
levels were calculated using the 2 -ΔΔCT method. Primers for human Trib2 (forward, 
5’- AGCCCGACTGTTCTACCAGA-3’; reverse, 5’- 
GGCGTCTTCCAGGCTTTCCA-3’) and ABL (forward, 5’-
TGGAGATAACACTCTAAGCATAACTAAAGGT-3’; reverse, 5’- 
GATGTAGTTGCTTGGGACCCA-3’).  
Mice 
Trib2-/- (B6;129S5-Trib2tm1Lex ) mice were purchased from Lexicon 
pharmaceuticals, and backcrossed onto C57B6 to F6. The Trib2-/- mice were bred and 
housed in the University of Glasgow. Cebpa transgenic mice 35 were bred and housed 
in the University of Copenhagen. Young adult (10-12 weeks old) Cebpa fl/p30;Mx1Cre 
(n=2) , Cebpa+/+;Mx1Cre (n=3) mice were injected every other day for a total of 3 
times with 0.3 mg polyinosinic-polycytidylic acid (pIpC) (Amersham Biosciences). 
Mice were sacrificed and bone marrow (BM) cells were isolated 3 weeks after first 
injection. All mice used were female. All mouse work was performed according to 
national and international guidelines and approved by the local UK and Danish 
Animal Ethical Committees. 
Preparation of GMP cell isolation 
The total isolated BM cells were c-Kit enriched using CD117 microbeads and MACS 
LS separations columns (Miltenyi Biotec) prior to staining with CD41-FITC, CD135-
PE, Gr-1-PECy5, B220-PECy5, CD3-PECy5, Ter199-PerCp5.5, CD16/CD32-Alexa 
Flour 700, c-Kit APC-Alexa 750, CD127-Biotin, Sca1-PB (All eBioscience), Mac1-
PECy5 (BD Biosciences), CD105-PECy7 and CD150-APC (BioLegend), 
Streptavidin-QD655, and 7-AAD (Invitrogen) as viability marker. GMPs (defined as 
previously described 36) were sorted on a FACSAria Cytometer (BD Biosciences, San 
Jose, CA, USA) using FACSDiva software. 
Bioinformatic dataset analysis 
Gene-expression values for Trib2 versus E2F1 were plotted and the line of best fit 
calculated using linear regression. Patient samples that showed Trib2 expression in 
the top 96% percentile of the Valk and Wouters dataset (GSE14468 and GSE1159) 
were used. Standard P value (significance below 0.05) and Pearson’s R values were 
calculated. A positive and negative R value indicates a positive and negative 
correlation respectively, and the closer the r-value is to 1 (or -1 in the case of a 
negative correlation) the stronger the correlation.  
Cytotoxic assay 
Cells (104/100 µl) were seeded in 96-well plates and treated with different 
concentrations of pentoxifylline (0–8 mM) or flavopiridol (0-250 nM) for 24 h. At the 
end of the treatment, 10 µl of MTT (3 mg/ml in PBS) was added to each well and 
cells were further incubated for 3 h. Formazan crystals formed were dissolved in 
100 µl of solubilizing solution (10% sodium dodecyl sulphate- 0.01N HCl). The 
absorbance of solubilized formazan was read at 570 nm using ELISA reader 
(Molecular devices). 
CFSE proliferation assay 
U937 cells were harvested, washed in PBS-2%FBS and stained with 1µM 
carboxyﬂuorescein diacetate succinimidyl ester (CFSE) (Molecular Probes) for 10 
min at 370C. The staining was quenched with ice cold PBS containing 20% FBS. 
Residual CFSE was removed by washing with PBS-2%FBS. CFSE-labeled cells were 
then seeded in 24-well plate, treated with different concentrations of Pentoxifylline, 
Dibutyryl cAMP or flavopiridol and grown for 96 hours in cell culture medium. The 
CFSE ﬂuorescence intensity was measured by ﬂow cytometry using a BD FACS 
CantoTM II. 
Cell cycle analysis 
Cells treated with different concentrations of PTX, Dibutyryl cAMP, flavopiridol or 
transduced with pLKO.1-puro-CMV-TurboGFP or pLKO.1-puro-CMV-TurboGFP-
shTrib2 were harvested, washed in ice-cold PBS, fixed in 70% ethanol. Cells were 
stained with PI/ RNase staining buffer (BD Pharmingen) for 15 min at room 
temperature and analyzed at BD FACS CantoTM II. The populations of cells in various 
phases of cell cycle were quantified using the FlowJo program. 
Annexin V/DAPI staining 
Total bone marrow cells, HSCs (Lin- c-kit+ Sca1+) isolated from wild type or Trib2-
deficient mice and GFP sorted U937 cells were suspended in binding buffer 
(containing annexin V-PE (BD Biosciences) and DAPI (Sigma). Thereafter, the 
samples were incubated in the dark for 15 min at room temperature and then analyzed 
at BD FACS CantoTM II. 
CFC (Colony forming cell) assay 
Total bone marrow cells, HSCs (Lin- c-kit+ Sca1+) were sorted from total wild type or 
Trib2 –deficient mice bone marrow and treated with 2mM PTX or 62.5nM of 
flavopiridol for 24 h.  Cells were then seeded in duplicate in methylcellulose media 
(Methocult M3434; Stem Cell Technologies). Colonies with >50 cells were scored 
and assessed at D6. 
Statistical Analysis 
All statistics were performed using GRAPHPAD PRISM5.  
Supplementary Figures and Legends 
 
Figure S1. Western blot analysis for E2F1 and C/EBPalpha in nuclear extracts 
prepared from (A) 3T3 cells transfected with pcDNA empty, C/EBPalpha-p42 or 
C/EBPalpha-p30 and (B) K562-C/EBPalpha-p42-ER or K562-C/EBPalpha-p30-ER 
cells induced with β-estradiol or vehicle control for 24 hours. HDAC1 is shown as 
protein loading control. 
  
 
Figure S2. A) Real Time analysis of Trib2 mRNA levels in U937 cells following 
transduction with LMP-control (Ctrl) or LMP-shTrib2. B) Cell growth analysis in 
U937 cells transduced with LMP-Ctrl or LMP-shTrib2 assessed by trypan blue 
exclusion and normalized to GFP values. 
 
157 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix F PDF of “TRIB2 and the ubiquitin proteasome system in cancer” 
Tribbles pseudokinases on the crossroads of metabolism, cancer, immunity and development 1089
TRIB2 and the ubiquitin proteasome system in
cancer
Mara Salome`*, Joana Campos* and Karen Keeshan*1
*Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, G12 0ZD, Scotland
Abstract
Tribbles family of pseudokinase proteins are known to mediate the degradation of target proteins in
Drosophila and mammalian systems. The main protein proteolysis pathway in eukaryotic cells is the
ubiquitin proteasome system (UPS). The tribbles homolog 2 (TRIB2) mammalian family member has been
well characterized for its role in murine and human leukaemia, lung and liver cancer. One of the most
characterized substrates for TRIB2-mediated degradation is the myeloid transcription factor CCAAT enhancer
binding protein α (C/EBPα). However, across a number of cancers, the molecular interactions that take place
between TRIB2 and factors involved in the UPS are varied and have differential downstream effects. This
review summarizes our current knowledge of these interactions and how this information is important for
our understanding of TRIB2 in cancer.
TRIB2 gene dysregulation in cancer
Tribbles homolog 2 (TRIB2) is a pseudokinase that functions
as a molecular adaptor mediating degradation and changes
to signalling cascades [1]. TRIB2 is also shown to be a
potent oncogene in a variety of malignancies, including
myeloid [2] and lymphoid [3] leukaemia, melanoma [4], lung
cancer [5], and liver cancer [6]. The oncogenic activity of
TRIB2 is linked to its dysregulated expression, rather than
its dysregulation via mutation in the majority of cancers. We
analysed TRIB2 gene in the catalogue of somatic mutations
in cancer (COSMIC) database (http://cancer.sanger.ac.uk,
[7]), the most comprehensive source of curated analysed
somatic mutations in human cancer to date. This analysis
has allowed us determine whether TRIB2 is altered at
the genomic level across a panel of tumour samples
identified by the tissue of origin. From a total number
of 23,983 unique tumour samples, 86 were found with
missense (51%), synonymous (46%), nonsense (2%) and
inframe deletion (1%) mutations in TRIB2 (Figure 1A).
Interestingly, although the overall point mutation rate is low,
tumours with documented roles for TRIB2 oncogene such
as malignant melanoma and lung cancer do have detectable
TRIB2 point mutations. In tissues matching acute myeloid
leukaemia (AML), which has a very strong association with
TRIB2 oncogenic activity, no mutations were retrieved from
COSMIC curated data provided by scientific literature and
resequencing results from the Cancer Genome Project at
the Wellcome Trust Sanger Institute (1/1942 haematopoietic
Key words: cancer, leukaemia, TRIB2, ubiquitin proteasome.
Abbreviations: AML, acute myeloid leukaemia; ATF4, activating transcription factor 4; CNV,
copy number variation; COP1, constitutive photomorphogenesis 1; COSMIC, catalogue of somatic
mutations in cancer; DUBs, deubiquitinases; PI, proteasome inhibitors; SCF, SKP1–CUL1 (Cullin)–F-
box; SMURF1, Smad ubiquitination regulatory factor 1; TRIB2, tribbles homolog 2; UPS, ubiquitin
proteasome system; YAP, Yes-associated protein.
1To whom correspondence should be addressed (email Karen.keeshan@glasgow.ac.uk).
and lymphoid tissue samples identified with a TRIB2
mutation corresponded to a multiple myeloma patient
sample). Indeed no mutations have been found in ∼75 AML
samples analysed by exome sequencing with good coverage
across all exons (Ross Levine, personal communication).
Interrogation of other genomic alterations affecting TRIB2
in the COSMIC database identified subsets of tumour
tissues with TRIB2 overexpressed (Figure 1B). Overall the
frequency rate for these alterations is higher and includes
lung, skin, liver and haematopoietic and lymphoid tissues
samples. Of note, 4/9 samples overexpressing TRIB2 in
the haematopoietic and lymphoid tissues matched AML
samples. Given that there is strong evidence for TRIB2
oncogenic function in these tumours, these analyses suggest
that elevated TRIB2 expression has potential implications
in other tumour tissue contexts yet to be explored e.g.
endometrium (endometrioid carcinoma), central nervous
system (astrocytoma grade V), prostate and large intestine
samples (bothmatching adenocarcinoma).OtherTRIB2 gene
alterations include copy number variation (CNV), which
albeit rare, are found across different tumours tissues and
mainly associated with increased copy number (all except
for breast, thyroid and kidney which showed CNV loss)
(Figure 1C). Hypermethylation, associated with chromatin
silencing,was found exclusively in prostate and large intestine
tumour tissues (Figure 1D). Together these analyses suggest
that TRIB2 oncogenic activity is related to its elevated gene
expression rather than associated with different genomic
alterations or mutations.
It is important to understand how TRIB2 gene expression
is regulated given its elevated expression in cancer. TRIB2
gene expression has been shown to be regulated by a number
of genes in normal and malignant haematopoietic cells,
including NOTCH1 [8], MEIS1 [9], E2F1 and C/EBPα
[10], GATA2 and FOG1 [11], PITX1 [12] and TAL1/E
Biochem. Soc. Trans. (2015) 43, 1089–1094; doi:10.1042/BST20150103 C©2015 Authors; published by Portland Press Limited
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Figure 1 Genomic alterations in TRIB2 gene
(A) Histogram presentation of point mutations in TRIB2 gene in tumour samples using the COSMIC database (top). Pie
chart referring to the frequency of missense (51%), synonymous (46%), nonsense (2%) and deletion inframe (1%) point
mutations in the identiﬁed tumour samples (bottom). (B) Histogram presentation of gain of TRIB2 gene expression in the
tumour samples indicated. Among them 4/9 haematopoietic and lymphoid tissues samples match AML as part of the acute
myeloid leukaemia study (COSU377) from The Cancer Genome Atlas [TCGA] in which over expression is deﬁned after a
z-score > 2. (C) Histogram displaying tumour tissues where CNV of the TRIB2 gene was identiﬁed, with the respective
frequency in tumour samples. (D) Histogram presenting tumour tissues where hypermethylation of the TRIB2 gene locus
was identiﬁed and respective frequency. Data were retrieved by v72 of COSMIC database (http://www.sanger.ac.uk) and
only tissues displaying TRIB2 alterations are shown. NS*, not speciﬁed with histology matching malignant melanoma; NS,
not speciﬁed.
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protein complex [3]. A number of microRNAs also regulate
the expression levels of TRIB2, including but not limited
to miR-511, miR-1297 [13], miR-99 [14,15], miR-155 [16],
and let-7 [17]. An example of how TRIB2 expression is
regulated in AML has been shown where E2F1 cooperates
with the C/EBPα p30 oncogenic isoform to activate the
TRIB2 promoter in AML cells. Indeed, wild type C/EBPα
p42 is bound to the TRIB2 promoter in normal granulocyte
macrophage progenitor (GMP) cells. This study detailed
the feedback loop between TRIB2, C/EBPα p42 and
p30, and E2F1 that contributes to AML cell growth and
survival [10]. The centralmechanismofTRIB2-inducedAML
identified in this study is based on specific TRIB2-C/EBPα
interactions, with C/EBPα being a key substrate of TRIB2
induced proteasomal degradation. The proteasomal mediated
degradation of TRIB substrates and interaction with proteins
of the ubiquitin proteasome system (UPS) are central toTRIB
function in a number of cancers and will be discussed further.
TRIB2: the ruler of E3 ubiquitin ligase
activities
The degradation of damaged or no longer necessary proteins
is mainly regulated by the UPS. The targets of this pathway
are marked by the addition of a ubiquitin tag. Ubiquitin is
a short peptide covalently bound to a lysine (Lys) residue
C©2015 Authors; published by Portland Press Limited
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on the target. This complex protein modification requires
the activity of at least three enzymes: an E1 ubiquitin
activating enzyme, an E2 ubiquitin conjugating enzyme
and an E3 ubiquitin ligase. The E3 ligase family comprise
over 1000 enzymes with different substrate specificities.
Moreover homologous ubiquitin like proteins (UBL) and
deubiquitinases (DUBs),whichhydrolyse ubiquitinmoieties,
represent additional layers of regulation for the proteolysis
of specific targets [18]. In addition to the 26S proteasome
complex, an immunoproteasome complex is present in cells
of haematopoietic origin and potentially relates to the higher
sensitivity of proteasome inhibition in leukaemic cells [19].
The first connections between TRIB and protein de-
gradation functions were identified in drosophila, where
drosophila tribbles was shown to promote degradation of
its targets; string (homologous of the mammalian CDC25
phosphatase, positive regulator of cell cycle progression) and
slow border cells (Slbo) (promoter of cell migration and
homologous of the human C/EBPα) [20]. The members
of the C/EBP family of transcription factors are involved
in regulation of differentiation in many tissues and control
proliferation through interaction with cell cycle proteins.
In the haematopoietic system C/EBPα acts as a tumour
suppressor that promotes cell cycle arrest and induces
granulocytic differentiation through inhibition of E2F
activity [21,22]. Both mammalian TRIB1 and TRIB2 have
been shown to retain the degradative functions towards the
C/EBPα protein and promote C/EBPα p42 degradation
and this function underlies their oncogenic potential in
leukaemia [2,23,24]. Moreover, TRIB2-dependent C/EBPα
p42 degradation is mediated by the proteasome and
constitutive photomorphogenesis 1 (COP1). COP1 is an
E3 ubiquitin ligase recruited by TRIB2 for the interaction
with C/EBPα, suggesting TRIB2 functions as a scaffold
protein to colocalize the enzyme with its target [25]. The
COP1 binding site in the C-terminus is conserved among the
TRIB family of proteins and indeed COP1 is the E3 ligase
responsible for TRIB1-mediated degradation of C/EBPα
[23] and TRIB3-mediated degradation of acetyl-coenzyme
A carboxylase (ACC) in fasting condition [26]. TRIB2 also
regulates C/EBPα protein levels in liver cells, and mediates
C/EBPα degradation in lung cancer models [5,6]. In the
latter case, the E3 ligase TRIM21 was identified to function
in TRIB2-mediated C/EBPα degradation. With regard to
specific TRIB2 substrates, another member of the C/EBP
family, C/EBPβ, has been shown to be degraded by TRIB2
in adipogenesis. In this study, TRIB2 functions as a negative
regulator of adipogenesis associated with Akt inhibition [27].
Another example of TRIB-dependent degradation of target
proteins in cancer is represented by activating transcription
factor 4 (ATF4) which occurs during hypoxia in human
tumour cells overexpressing TRIB3 [28]. Interestingly, the
murine ortholog of TRIB3 Neuronal cell death-inducible
putative kinase (NIPK) has also been associated with down-
regulation of ATF4 transcriptional activity, but in absence of
proteolytic degradation [29]. The protein interaction ofATF4
with TRIB2 or TRIB1 as not been reported.
Cell context, especially with regard to protein–protein
interactions is highly relevant in deciphering the function of
many signalling molecules, including TRIB proteins. TRIB2
has been implicated as a positive or negative mediator of
proteasomal degradation. For example, TRIB2 interacts with
the substrate binding subunit of the ubiquitin complex
SKP1–CUL1 (Cullin)–F-box (SCF) βTrCP in liver cancer
cells [6]. This complex is responsible for Yes-associated
protein (YAP) degradation, but TRIB2 binding on βTrCP
subunit leads to YAP stabilization and transactivation of
YAP target genes. The C-terminal domain of TRIB2 was
shown to be responsible for the interaction with βTrCP
in these liver cancer cells. Noteworthy in the same study,
TRIB2 also targets C/EBPα for degradation, but this was
not via βTrCP E3 ligase. As described above, COP1 or
TRIM21 are known to mediate TRIB2 dependent C/EBPα
degradation in AML and lung cancer, whereas the E3
ligase has not been clarified in liver cells. TRIB2 and
the E3 ligase Smad ubiquitination regulatory factor 1
(SMURF1) also interact in liver cancer cells. SMURF1
is the enzyme responsible for TRIB2 ubiquitination and
proteasomal dependent degradation and SMURF1 inhibition
triggers TRIB2-dependent carcinogenesis in the liver [30].
Nonetheless, TRIB2 is also a partner of SMURF1 in the
inhibition of theWnt signalling effector β-catenin and TCF4.
Indeed, deletion of the SMURF1 binding sites on the TRIB2
protein abolished its ability to down-regulate β-catenin and
transcription factor 4 (TCF4) [31]. COP1 or βTrCPwere also
described as additional modulators in this same pathway [32].
Together these data reveal the complexity of TRIB2 and UPS
interactions in liver cancer cells, and highlight the importance
of cell context in TRIB family protein function.
UPS aberration in leukaemia
Dysregulation of E3 ligase enzymatic activity has been
reported in differentmalignancies. Transformingmutant vari-
ants of the E3 ubiquitin ligase Casitas B-lineage lymphoma
proto-oncogene (cClb) have been found in human myeloid
malignancies and all these mutations were associated with
loss of E3 ubiquitin ligase activity in addition to a malignant
gain of function [33]. Mutations in the E3 ligase FBW7
have been associated with oncogenic signalling mechanisms
in different cancers including NOTCH1 activation in T-
ALL [34]. Moreover, the recent profiling of the somatic
mutation landscape of epigenetic regulators in paediatric
cancer identified the deubiquitinase USP7 as one of the most
frequent mutations in T-ALL [35]. This DUB is associated
with chromatin remodelling and it is referred as an ‘eraser’
among epigenetic modifiers. Its physiological function is to
stabilize the histone H2B (as well as other targets), removing
ubiquitin subunits from the substrates. In 8%of T-ALL cases
sequence variation translates to loss of function of the protein
and the consequent epigenetic alteration is associated with
the leukaemic disease [35]. This case supports the important
role of ubiquitination signalling beyond terminal protein
degradation in leukaemic transformation. The proteolytic
C©2015 Authors; published by Portland Press Limited
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pathways of UPS and autophagy in AML cell lines are
directly involved in the response to chemotherapeutic drugs
cytarabine and doxorubicin. Studies show that the response
to chemotherapy is highly dependent on the basal level of
activation of the UPS in leukaemic cells [36]. It is possible
to measure the proteasome expression and activities in the
plasma of AML, ALL and MDS patient samples and higher
levels of UPS protein and activities are detectable in patients
plasma samples [37]. Importantly, the levels of proteasome
activities can be used to risk stratify for the prognosis of
different blood tumours. Since it is likely that the activities de-
tected in the AML patients’ plasma is reflecting the activities
in the leukaemic cells, screening of the proteasome activities
in the plasma samples from patients could be advantageous
not only as a biomarker, but also to identify the most suitable
therapeutic combination taking advantage of the new drugs
available in clinical trials targeting the UPS system.
Targeting UPS in blood tumours
Proteasome inhibitors
Leukaemic cells express high levels of proteasomes [38]
and this is probably one of the reasons why therapeutic
proteasome inhibition has shown better results in blood
cancers than in solid tumours [39]. Multiple toxicity
mechanisms of proteasome inhibition have been validated in
preclinical studies. These comprise NFkB inhibition through
stabilization of its regulator IkBα; cell cycle arrest due to
deregulation of cyclins and other cell cycle regulator proteins;
induction of a proapoptotic state through stabilization of
p53 and Bax and down-regulation of Bcl-2; ROS production;
transmembrane mitochondrial potential gradient dissipation;
aggresome formation; endoplasmic reticulum (ER) and
unfolded protein response (UPR) [40].
Eight classes of proteasome inhibitors (PI) have been
recognized across natural compounds and synthetic mo-
lecules (peptide aldehydes, peptide vinyl sulfones, syrbactins,
peptide boronates, peptide α′β ′-epoxyketones, peptide
ketoaldehydes, β-lactones, and oxatiazol-2-ones). Only
representativemembers of some classes have reached the stage
of clinical trials investigations in cancer. Many have failed due
to lack of specificity and or toxicity in preclinical studies.
The main PIs of interest in the treatment of haematological
malignancies include three peptide boronates, two peptide
epoxyketones and one marine natural product, β-lactone.
The boronate compound Bortezomib (BTZ) is a reversible
inhibitor of the proteasome and the immunoproteasome
and the first PI ever entered in clinical trials [41]. BTZ
is currently approved for use as single agent or in
combination therapies in multiple myeloma or mantle cell
lymphoma patients. Moreover a number of clinical trials
have been assessing its efficacy in aggressive disease like
acute leukaemias (CALGB (Alliance) Study 10502, COG
AAML 1031) [42]. To overcome toxicity and resistance
challenges with BTZ, a great effort has been spent in the
design and characterization of next generation inhibitors.
Among them Carfilzomib has been approved by the FDA
for the treatment of relapsed/refractory multiple myeloma
[43], andOprozomib, Ixazomib,Marizomib andDelanzomib
have already reached clinical trials investigation. The activity
of immunoproteasome specific inhibitors is also currently
being assessed in preclinical investigation in models of
immunological disorders [41].
Other UPS targets
The recent interest in targeting the UPS system has brought
attention to the identification of druggable targets upstream
of the proteasome, which by their nature are predicted to
lead to more specific inhibition and fewer side effects. In
this category there are E1 activating enzyme inhibitors, E2
conjugating enzyme inhibitors, E3ubiquitin ligases inhibitors
andDUB enzyme inhibitors [44]. Indeed the inhibition of the
UBL modifier Nedd8 is currently in clinical trials for AML
and MDS [45]. More than one E3 ligases have been chosen as
potential targets in the drug discovery process for treatment
of haematological malignancies and many small molecules
have been studied. Examples among the most targeted E3
ligases are MDM2, involved in p53 regulation [46], and SCF
multi-subunit E3 ligases [47].
Concluding remarks and future perspective
Given that C/EBPα stability is tightly regulated at molecular
level and that TRIB2 mediated dysregulation of this pathway
is linked to AML, liver and lung carcinogenesis, targeting
the related network of E3 ligases could open new exciting
therapeuticwindows, resulting in amore specific andpossibly
more effective treatment of these malignancies. There is
an urgent need for alternative therapeutic strategies in the
treatment of blood diseases. Increasing interest has been
raised around themodulation of proteolytic pathways such as
autophagy and UPS, which often play critical roles in cancer
cells. TRIB2, as a signalling pathway modulator and binding
partner of different E3 ubiquitin ligase enzymes has gained
attention over the past decade as a major regulator in solid
tumours and different leukaemia subtypes. TRIB2 has been
proposed as a valid biomarker for diagnosis and progression
of melanoma, correlating higher TRIB2 expression levels
with advanced stages of the disease [48]. Given the strong
preclinical data regarding TRIB2 in AML, the screening
of TRIB2 protein expression in leukaemia patients would
be extremely useful to complement the current information
available on TRIB2 carcinogenesis and mutational profile.
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ORIGINAL ARTICLE
The presence of C/EBPα and its degradation are both required
for TRIB2-mediated leukaemia
C O’Connor1, F Lohan1, J Campos1, E Ohlsson2,3,4, M Salomè1, C Forde5, R Artschwager6, RM Liskamp6, MR Cahill7, PA Kiely8,
B Porse2,3,4 and K Keeshan1
C/EBPα (p42 and p30 isoforms) is commonly dysregulated in cancer via the action of oncogenes, and speciﬁcally in acute myeloid
leukaemia (AML) by mutation. Elevated TRIB2 leads to the degradation of C/EBPα p42, leaving p30 intact in AML. Whether this
relationship is a cooperative event in AML transformation is not known and the molecular mechanism involved remains elusive.
Using mouse genetics, our data reveal that in the complete absence of C/EBPα, TRIB2 was unable to induce AML. Only in the
presence of C/EBPα p42 and p30, were TRIB2 and p30 able to cooperate to decrease the latency of disease. We demonstrate that
the molecular mechanism involved in the degradation of C/EBPα p42 requires site-speciﬁc direct interaction between TRIB2 and C/
EBPα p42 for the K48-speciﬁc ubiquitin-dependent proteasomal degradation of C/EBPα p42. This interaction and ubiquitination is
dependent on a critical C terminal lysine residue on C/EBPα. We show effective targeting of this pathway pharmacologically using
proteasome inhibitors in TRIB2-positive AML cells. Together, our data show that excess p30 cooperated with TRIB2 only in the
presence of p42 to accelerate AML, and the direct interaction and degradation of C/EBPα p42 is required for TRIB2-mediated AML.
Oncogene advance online publication, 21 March 2016; doi:10.1038/onc.2016.66
INTRODUCTION
The C/EBPα (CCAAT/enhancer binding protein α) transcription
factor is commonly mutated in acute myeloid leukaemia (AML)
and dysregulated in a number of cancers (that is, liver, prostate,
lung, squamous cell carcinoma). Mutations in CEBPA occur
exclusively in haematological diseases and result in perturbed C/
EBPα protein expression and function. C/EBPα promoter methyla-
tion perturbs C/EBPα expression in AML,1 chronic myeloid
leukaemia2 and head and neck squamous cell carcinoma.3 In
AML, oncogene-mediated dysregulation of C/EBPα mRNA expres-
sion and/or protein activity occurs in cytogenetically abnormal
subtypes of AML, including AMLs with t(8;21)[AML1-ETO], inv(16)
[CBFb-MYH11], t(15;17)[PML-RARA] and t(3;21)(AML-1-MDS-1-Evi-1
fusion protein) translocations, and in cytogenetically normal AMLs
with FLT3-ITD mutation, or with elevated TRIB2 expression.4 C/
EBPα protein is also dysregulated by a number of posttranslational
modiﬁcations including phosphorylation, sumoylation and
ubiquitination.5
CEBPA is an intronless gene with N terminal transcriptional
activation domains and a C terminal basic region leucine zipper
(LZ) domain. CEBPA mutations, which occur across the entire
coding region, are present in 5% and 10% of childhood and adult
AML, respectively.6 Somatic and inherited mutations in CEBPA co-
occur, are often biallelic and are found with higher frequency in
cytogenetically normal AML.7,8 CEBPA is a favourable prognosis
factor in AML, speciﬁcally for cases that present with double
mutations in CEBPA, typically an N terminal and a C terminal basic
region LZ gene mutation. C/EBPα protein exists as two isoforms, a
full length C/EBPα p42 isoform classiﬁed as a tumour suppressor
and an N terminally truncated p30 isoform classiﬁed as an
oncogene. N terminal mutations typically are frame-shift muta-
tions that lead to a premature stop in translation of p42, while
retaining p30 expression. In contrast, C terminal mutations
typically are in-frame insertions/deletions in the LZ domain that
disrupt DNA binding or dimerization. C/EBPα functions by forming
stable homodimers and heterodimers with itself and other C/EBP
family members, which act to stabilize their protein expression.9
TRIB2 is a potent oncogene capable of inducing fully penetrant
AML in murine models, and can cooperate with other AML
oncogenes to disrupt signalling pathways and transcription
factors in AML disease.10–13 TRIB2 expression was shown to be
elevated in a cohort of AML patients with a mixed myeloid/
lymphoid phenotype and a dysregulated CEBPA gene expression
signature. In fact, TRIB2 leads to the degradation of C/EBPα p42 via
E3 ligase COP1 binding whilst sparing p30 from degradation,
resulting in disturbed granulopoiesis. This modulation of C/EBPα
was found to be critical for the induction of AML in vivo.10,13 E2F1
cooperates with C/EBPα p30 to activate the Trib2 promoter in
preleukaemic cells resulting in elevated TRIB2 expression. This was
shown to be an important mechanism regulating TRIB2 expression
and survival of AML cells.12
In normal cells, C/EBPα is a key transcription factor in the
transition from the pre-granulocyte macrophage to the
granulocyte-macrophage progenitor stage of differentiation, and
in the transcriptional and epigenetic control of haematopoietic
stem cell (HSC) self-renewal.14–16 In granulocyte-macrophage
progenitor cells, C/EBPα p42 is found bound to the Trib2 promoter
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and inhibits E2F1-mediated activation of Trib2. At the HSC stage,
C/EBPα acts to prime HSCs for differentiation along the myeloid
lineage via DNA binding to regulatory regions of genes induced
during differentiation.16 Although conditional Cebpa knockout
mice do not develop disease, the loss of Cebpa in adult HSCs leads
to an increased number of functional and proliferative HSCs15,17
and loss of HSC pool maintenance in serial transplantations.16
Cebpa expression is required for AML disease initiation by the
oncogene MLL-ENL but not for disease maintenance.18 In contrast,
Cebpa is required for the maintenance of Hoxa9/Meis1 AML
disease.19 Loss of Cebpa did not abrogate BCR/ABL-induced
leukaemia but it did alter the resultant disease phenotype.20 Thus,
it appears that a certain threshold of C/EBPα expression is
important for the development of myeloid leukaemic disease. This
is supported by the observation that leukaemia-derived CEBPA
mutations are virtually never null mutations.21,22 The combination
of N and C terminal mutations have distinct features that result in
leukaemia development.23,24 Murine knockin studies investigating
p30 oncogenicity in the absence of C/EBPα p42 showed that p30
induced fully penetrant transplantable AML.25 p30 is sufﬁcient for
haematopoietic commitment to the myeloid lineage, it enables
transition from the common myeloid progenitor to the
granulocyte-macrophage progenitor stage. However, it does not
retain the ability to control proliferation and myeloid progenitors
have greatly increased self-renewal capacities.25
Although TRIB2 disrupts the ratio of C/EBPα p42:p30 and
functions to degrade C/EBPα, it is unclear whether the loss of
C/EBPα p42 or the expression of C/EBPα p30 is critical for TRIB2-
mediated AML disease. Here, we show using mouse genetics that
the presence of C/EBPα is paradoxically required for TRIB2-
induced AML, and only in the presence of C/EBPα p42, is there
a cooperative effect seen with TRIB2 and C/EBPα p30. We dissect
the molecular details of the degradative relationship between
TRIB2 and C/EBPα p42, and show that the direct interaction
between TRIB2 and C/EBPα p42 is required for TRIB2-mediated
ubiquitin-dependent proteasomal degradation of C/EBPα p42. We
identify lysine 313 of C/EBPα as a site of TRIB2-mediated
ubiquitination. We show that we can target TRIB2 AML cells with
proteasome inhibition. Together, these data show that C/EBPα
presence is required for the initiation of TRIB2-induced AML and
subsequent C/EBPα p42/p30 disruption is critical for TRIB2 AML
disease.
RESULTS
C/EBPα p42 accelerates AML in the presence of TRIB2 and excess
p30
To establish whether C/EBPα is essential for TRIB2-induced AML,
we performed a bone marrow (BM) transplant using a previously
described conditional Cebpaﬂ/ﬂ; Mx1Cre mouse model and used
polyinosinic-polycytidylic acid (pIpC) to facilitate ablation of
Cebpa #x003B1; in the haematopoietic compartment. Two weeks
post deletion, c-Kit+ haematopoietic stem and progenitor cells
from the BM of pIpC-treated control Cebpaﬂ/ﬂ and CebpaΔ/Δ
animals were transduced with either empty MigR1 or MigR1-TRIB2
retrovirus. Transduced cells were transplanted into irradiated
recipients, and monitored for disease progression. As expected, all
mice reconstituted with Cebpaﬂ/ﬂ cells expressing TRIB2 developed
lethal AML with a median latency of 33 weeks, accompanied
by accumulation of GFP+ cells (mean fraction of Cebpaﬂ/ﬂ GFP-
expressing cells 93% +/− 5.2%) in the BM and splenomegaly (data
not shown). In striking contrast, TRIB2-transduced CebpaΔ/Δ
haematopoietic stem and progenitor cells did not give rise to
AML (Figure 1a and Supplementary Figure 1B). Notably, 14 months
after transplantation, CD45.2+GFP+ cells were detected suggesting
that the TRIB2-expressing CebpaΔ/Δ cells are able to properly
home to the BM but do not give rise to leukaemia. Therefore,
although TRIB2 functions to degrade C/EBPα p42 leading to
AML,10 the complete absence of C/EBPα abrogates TRIB2
oncogenicity. Thus, it appears that a certain threshold of C/EBPα
(p42 or p30) expression is necessary for the initiation of
TRIB2 AML.
Having established the necessity of C/EBPα expression for TRIB2
AML, we next sought to elucidate whether p42 degradation or p30
accumulation is the key driver of this pathway, and whether p30
can cooperate with TRIB2 to accelerate disease onset.
To investigate this, we designed a transplant model which utilized
donor cells from an established Cebpa conditional knockout
model that only expressed p30 isoform (referred to here as
CebpaΔ/p30), or were heterozygous for this allele still expressing
p42 on one allele (referred to as Cebpaﬂ/p30 cells) (see methods
and Figure 1b). CD45.2+ donor cells from pIpC-treated 8–14-week-
old Cebpaﬂ/+, Cebpaﬂ/p30 and Cebpaﬂ/p30; Mx1Cre mice were
harvested 2 weeks post deletion, transduced with MigR1 or
MigR1-TRIB2 retrovirus and transplanted into CD45.1+ recipients.
CD45.2 and GFP expression were monitored at 7 weeks post
transplant in peripheral blood (Supplementary Figures 1C and D)
and every 2 weeks thereafter, showing recipient reconstitution
with donor cells. The cohort of mice transplanted with TRIB2-
transduced Cebpaﬂ/+ cells developed AML disease as previously
published10 with a median latency of 49 weeks. However, mice
transplanted with TRIB2-transduced Cebpaﬂ/p30 cells developed a
much more aggressive AML with an accelerated latency of
29 weeks (Figure 1c) as evidenced by accumulation of GFP+ cells
in the BM, elevated white blood cell counts and splenomegaly
(Supplementary Figures 1E-J). Mice transplanted with MigR1
transduced CebpaΔ/p30 cells developed AML with a median
latency of 40 weeks, as expected and previously published for
CebpaL/L mice25(‘L’ refers to p30), and no signiﬁcant acceleration of
the disease was seen in mice transplanted with TRIB2 transduced
CebpaΔ/p30 cells (median latency of 35 weeks) (Figure 1d).
Comparing TRIB2 AML in Cebpaﬂ/p30 and CebpaΔ/p30 cohorts, p42
accelerated AML in the presence of TRIB2 and excess p30
(Figure 1e). Control cohorts of mice transplanted with Cebpaﬂ/p30
and Cebpaﬂ/+ cells transduced with MigR1 as expected did not
develop any disease. Flow cytometry analysis showed that mice in
both of these groups had normal haematopoietic compartments
(Supplementary Figures 1E-I). Flow cytometry analysis revealed
that the leukaemic proﬁle of GFP+ Cebpaﬂ/+-TRIB2, Cebpaﬂ/p30-
TRIB2, CebpaΔ/p30-TRIB2 and CebpaΔ/p30-MigR1 AML cells was
predominantly c-Kit+ (Figure 1f). Protein analysis of the leukaemic
BM cells between the GFP+ Cebpaﬂ/+-TRIB2, Cebpaﬂ/p30-TRIB2,
CebpaΔ/p30-TRIB2 and CebpaΔ/p30-MigR1 AML cells groups veriﬁed
expected p42 and p30 expression levels in mice (leukaemic ratio
p42:p30 in Cebpaﬂ/+-TRIB2 cohort, p42 and increased p30 in
Cebpaﬂ/p30-TRIB2 and Cebpaﬂ/p30-MigR1 cohort, comparable p30 in
the absence of p42 in CebpaΔ/p30-MigR1 and CebpaΔ/p30-TRIB2
cohorts (Figure 1g)). Taken together, these data show that despite
TRIB2 functioning to degrade p42, C/EBPα is essential for the
initiation of TRIB2-mediated AML and only in the presence of C/
EBPα p42 is there a cooperative effect seen with p30.
Identiﬁcation of speciﬁc amino acids involved in the TRIB2 and
C/EBPα interaction
Having shown the requirement for C/EBPα p42 in the initiation of
TRIB2-induced AML, we next focused on the interaction between
C/EBPα and TRIB2. We ﬁrst determined using subcellular
fractionation and confocal microscopy that the co-localization of
TRIB2-C/EBPα was nuclear (Supplementary Figures 2A and B).
Using GST pull-down experiments, we show that the C terminal LZ
domain of C/EBPα is required for the interaction with TRIB2 as a
GZ mutant expressing an unrelated LZ could no longer bind TRIB2.
However, TRIB2 can still bind a C/EBPα LZ mutant (L12V) that can
no longer dimerize, indicating TRIB2 binding to C/EBPα is
Deciphering the C/EBPα and TRIB2 relationship
C O’Connor et al
2
Oncogene (2016), 1 – 10 © 2016 Macmillan Publishers Limited
Figure 1. C/EBPα p42 accelerates AML in the presence of TRIB2 and excess p30. (a) Kaplan–Meier survival curve of mice reconstituted with
either Cebpaﬂ/ﬂ or CebpaΔ/Δ BM cells transduced with TRIB2-expressing retrovirus. The median survival of mice reconstituted with Cebpaﬂ/ﬂ-
TRIB2 cells was 33 weeks (n = 12), none of the mice reconstituted with CebpaΔ/Δ-TRIB2 cells developed leukaemia within 60 weeks (n= 10).
***Po0.0001 by Log-rank test. (b) Schematic representation of Cebpa alleles. (c) Kaplan–Meier survival curve of mice reconstituted with either
Cebpaﬂ/+ or Cebpaﬂ/p30 BM cells transduced with MigR1- or TRIB2-expressing retrovirus. None of the mice reconstituted with Cebpaﬂ/+-MigR1
(n= 9) or Cebpaﬂ/p30-MigR1 (n= 6) developed leukaemia within 60 weeks. The median survival of mice reconstituted with Cebpaﬂ/+-TRIB2 cells
was 49 weeks (n = 4), while the median survival of mice reconstituted with Cebpaﬂ/p30-TRIB2 was 29 weeks (n = 8). ***Po0.0001 by Log-rank
test. (d) Kaplan–Meier survival curve of mice reconstituted with CebpaΔ/p30 BM cells transduced with MigR1- or TRIB2-expressing retrovirus.
The median survival of mice reconstituted with CebpaΔ/p30-MigR1 cells was 40 weeks (n= 6), while the median survival of mice reconstituted
with CebpaΔ/p30-TRIB2 cells was 35 weeks (n= 8). P = 0.8111 by Log-Rank test. (e) Kaplan–Meier survival curve comparing mice reconstituted
with Cebpaﬂ/p30-TRIB2 or CebpaΔ/p30-TRIB2 BM cells. *P⩽ 0.05 by Log-rank test. (f) Average percentage of c-Kit expression in CD45.2+ BM of
each group +/− s.d. (g) Protein analysis of C/EBPαp42 and p30 expression in BM of mice. n.s.=non-speciﬁc band.
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independent of amino acids involved in C/EBPα dimerization
(Supplementary Figures 2C, D and E). To more precisely identify
speciﬁc regions of interaction with TRIB2, we SPOT-synthesized
a peptide array containing a series of 18-amino acid overlapping
peptides identical to the C terminus LZ domain of C/EBPα.
GST-TRIB2 bound to eight peptides within the C terminus LZ of C/
EBPα (Figure 2a). To identify the speciﬁc amino acids required for
the interaction, we used a Speciﬁc Alanine Scanning Substitution
Array, where consecutive amino acids of the parent peptides were
substituted to an alanine. This identiﬁed residues R333, R339 and
R343 of C/EBPα as potential mediators of interaction with TRIB2
(Figure 2b). Using site-directed mutagenesis, we show that
mutation of R339A abolished the interaction with GST-TRIB2 in
a pull-down assay (Figure 2c). This was conﬁrmed by
co-immunoprecipitation in mammalian cells (Supplementary
Figure 2F) indicating that R339 of C/EBPα is required for
interaction with TRIB2.
Reciprocally, we used TRIB2 peptide arrays that covered the
entire TRIB2 protein to identify speciﬁc amino acids in TRIB2
responsible for the interaction with C/EBPα. Recombinant C/EBPα
protein bound to peptides that spanned from amino acids 25–318
indicating extensive interaction of C/EBPα with TRIB2 (Figure 3a).
Speciﬁc Alanine Scanning Substitution Array of amino acids in
peptide 2 (DHVFRAVLHSHGEELVCK) identiﬁed R77, which is
homologous to R107 in TRIB1 that exists as a gain-of-function
TRIB1 mutation in AML.26 Speciﬁc Alanine Scanning Substitution
Array of amino acids in peptide 4 (PEILNTSGSYSGKAADVW)
identiﬁed a putative GSK3 phosphorylation site (which has
the consensus GSK3 phosphorylation site motif S/TXXXS/T).
Speciﬁc Alanine Scanning Substitution Array of peptide 5
(HPWFSTDFSVSNSGFGAK) identiﬁed K322 (Figure 3b). Three
mutants R77A, S227A/S229A/S231A/K233A (4-AA) and K322A
were generated (Figure 3c). Co-immunoprecipitation showed that
mutation of the sequence S227A/S229A/S231A/K233A (4-AA)
abolished the interaction with C/EBPα completely, and K322A
and R77A although reduced could still bind C/EBPα (Figure 3d and
Supplementary Figure 2G).
Ubiquitin-mediated mechanism of TRIB2-induced p42
degradation
We next assessed the ability of TRIB2 to induce ubiquitin-speciﬁc
degradation of C/EBPα. A ubiquitination assay was performed in
293 T cells transfected with C/EBPα, TRIB2 and Ubiquitin (Ub).
Increased C/EBPα ubiquitination was observed in TRIB2-expressing
cells compared with controls and this was exclusively K48-
mediated ubiquitination (proteasome degradation K48-speciﬁc
polychains as opposed to non-degradative ubiquitination
mediated by K63 polychains) as detected by K48- and K63-
speciﬁc antibodies (Figure 4a). This was conﬁrmed using ubiquitin
mutants, which do not express the K48 ubiquitin polychain
(UB/K48R-HA) and the K63 ubiquitin polychain (UB/K63R-HA) in
a ubiquitination assay (Figure 4b, compare lanes 7, 8 and 9).
We show using the R339A C/EBPα-binding mutant that the direct
binding between TRIB2 and C/EBPα was required for TRIB2-
mediated ubiquitination of C/EBPα compared with the control
mutant R343A that retains the TRIB2 interaction (Figure 4c).
Reciprocally, using the TRIB2-binding mutant S227A/S229A/
S231A/K233A (4-AA) revealed a loss in C/EBPα ubiquitination as
compared with the mutants R77A and K322A that retain higher
C/EBPα-binding afﬁnity or WT TRIB2 (Figure 4d). Together these
data show that the direct binding interaction between TRIB2 and
C/EBPα was required for TRIB2-mediated ubiquitination of C/EBPα.
To investigate the site on C/EBPα susceptible to TRIB2-mediated
ubiquitination, Ubpred online software analysis of C/EBPα was
performed, and it identiﬁed a number of lysine residues as
Figure 2. Identiﬁcation of R339 as crucial C/EBPα amino acid in TRIB2 binding. (a) Peptide arrays encompassing C terminus of C/EBPα were
generated as described in Materials and methods. Eight binding peptides unique to C/EBPα were identiﬁed. The table displays the amino acid
identity of these peptides. This array is representative of two independent SPOT-synthesized arrays. Dark spots are indicative of peptide
binding. (b) Speciﬁc Alanine Scanning Substitution Arrays on a region spanning the C terminus of C/EBPα were probed with GST-TRIB2. The
binding of GST-TRIB2 to each alanine-substituted peptide was quantiﬁed by densitometry and presented as a percentage of the control
unmutated WT sequence, with an underlay identifying the amino acid, which was substituted with an alanine. More than 50% reduction in
binding intensity indicative of involvement in the interaction. (c) Western blot analysis of 293 T cell lysates expressing WT C/EBPα and C/EBPα
mutants (left panel). GST pull-down, performed in the presence of MG-132, using GST-TRIB2 followed by western blot analysis for GST (top and
bottom panels) and C/EBPα (middle panel).
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potential ubiquitination sites with low to high conﬁdence scores.
K313 was predicted with medium conﬁdence as a potential
ubiquitination site (Figures 5a and b) which has been identiﬁed as
a recurrent C/EBPα mutation (K313dup) that results in an extra
lysine adjacent to K313. This duplication occurs in 10% of C/EBPα-
mutated AMLs and identiﬁed to have a shorter protein half-life
than wild-type C/EBPα as determined by cycloheximide assay.27
Mutation of K313 to K313R resulted in the loss of TRIB2-induced
C/EBPα ubiquitination as compared with WT C/EBPα (Figure 5c).
As a control, we show that this mutation retains functional C/EBPα
transcriptional activity as both WT and mutant C/EBPα stimulated
the G-CSFR luciferase reporter construct, a known C/EBPα target
gene (Figure 5d). These data show that K313 serves as the site of
ubiquitin conjugation on C/EBPα in the presence of TRIB2 and
mutation of K313 abrogates TRIB2-mediated ubiquitin-dependent
proteasomal degradation of C/EBPα. This site is also present in p30
yet we do not observe TRIB2-mediated p30 ubiquitination
(Figure 5e), suggesting that perhaps the N terminus of C/EBPα
p42 functions in the degradative complex.
Proteasome inhibition selectively targets AML with high TRIB2
expression
Our data suggest that inhibition of the proteasome would
effectively inhibit the function of TRIB2 by abrogating C/EBPα
protein degradation and would be an effective pharmacological
targeting strategy in TRIB2-positive AMLs. To test this, U937 cells
(express detectable levels of endogenous TRIB2 and C/EBPα)
transduced with retroviral MigR1-GFP control and MigR1-TRIB2-
GFP were treated with 10 nM bortezomib (a reversible inhibitor
of the proteasome chymotryptic activity resulting in the
accumulation of K48 ubiquitin-linked proteins). An increase in
cytotoxicity in the TRIB2-overexpressing cells compared with
MigR1 control transduced cells was observed and cells expressing
TRIB2-VPM that cannot degrade C/EBPα behaved similarly to
control cells (Figure 6a, panels 1 and 2). Overexpression of MigR1-
C/EBPα was able to rescue bortezomib-induced cell death in U937
cells (Figure 6a, panels 3). In C/EBPα-negative leukaemia cells,
K562 and Kasumi 1 bortezomib toxicity was not increased
following TRIB2 overexpression supporting the speciﬁcity of
bortezomib on the TRIB2-C/EBPα axis (Figure 6a, panels 4 and
5). Second generation irreversible proteasome inhibitors28,29 also
showed selective killing of high TRIB2 (lentiviral Phr-GFP)-
expressing AML cells as assessed by cell viability (Figure 6b).
Bortezomib treatment rescued the degradation of C/EBPα p42
seen with TRIB2 overexpression in U937 cells (Figure 6c). In fact,
p30 expression remains upon TRIB2 overexpression, conﬁrming
our ubiquitination data in Figure 5. We next established a human
AML orthotopic xenograft model in which U937 cells were
propagated in NSG xenografts and mice were either treated with
bortezomib in vivo (Figure 6d and described in methods), or TRIB2
was knocked down using shRNA lentivirus (Figure 6e12). In vivo
bortezomib treatment signiﬁcantly impaired the engraftment of
U937 cells as determined by lower % of engrafting GFP+ cells
positive for human antibody CD45 expression (Figure 6f). In
addition, engraftment of U937 cells expressing shTRIB2 lentivirus
in NSG xenografts showed that in comparison with control (shctrl),
knockdown of TRIB2 impaired the progression of U937 orthotopic
xenografts (Figure 6g). Together our data show that TRIB2-
expressing AML cells can be pharmacologically targeted with
Figure 3. Identiﬁcation of the C/EBPα-binding site on TRIB2. (a) Peptide arrays encompassing TRIB2 were generated as described in Materials
and methods. Five binding peptides spanning amino acids 25–318 of C/EBPα protein were identiﬁed. The table displays the amino acid
identity of these. This array is representative of two independent SPOT-synthesized arrays. Dark spots are indicative of peptide binding.
(b) Speciﬁc Alanine Scanning Substitution Arrays on regions spanning TRIB2 were probed with C/EBPα protein. The binding of C/EBPα protein
to each alanine-substituted peptide was quantiﬁed by densitometry and presented as relative intensity of the control unmutated
WT sequence, with an underlay identifying the amino acid which was substituted with an alanine. More than 50% reduction in binding
intensity indicative of involvement in the interaction. (c) 293 T lysates expressing WT TRIB2 and mutants R77A, 4-AA (S227A/S229A/S231A/
K233A) immunoblotted with anti-TRIB2 and actin serving as a loading control. (d) TRIB2-binding mutants 4-AA (S227A/S229A/S231A/K233A),
R77A and K322A and WT C/EBPα were expressed in 293 T cells and C/EBPα was immunoprecipitated and lysates were immunoblotted for
TRIB2 and C/EBPα (top panels). Western blot of total input lysates shows levels of protein expression (bottom panels). Densitometric analysis
was performed and the ratio of IP:Input, normalized to actin are presented (underneath bottom panels).
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proteasome inhibition due, in part, to inhibition of the TRIB2
proteolytic function on C/EBPα.
DISCUSSION
Although C/EBPα dysfunction is a common occurrence in different
cancers, details on the mechanisms involved in bringing about the
loss of C/EBPα protein expression in Cebpa wild-type and mutated
AML are yet to be fully elucidated. In this study, we identify the
molecular mechanism involved in the dysregulation of C/EBPα
expression via TRIB2 in AML. We and others10,13,30 have previously
demonstrated that TRIB2 overexpression induces AML and that it
degrades C/EBPα p42. Here, we provide novel insights on this
process and show that the presence of C/EBPα p42 is required not
only to initiate TRIB2 AML, but also for TRIB2 to cooperate
with C/EBPα (p42 loss and increased p30) in driving AML disease.
Our data support the emerging notion that C/EBPα functions in
the initial transformation, as supported by the data showing that
C/EBPα regulated a transcriptional programme essential for
initiation yet dispensable for the maintenance of MLL-ENL
disease.18 Our data clearly show loss of C/EBPα p42 via TRIB2-
induced ubiquitin-mediated degradation and excess p30 expres-
sion cooperates to accelerate AML.
Using BM transduction and transplantation approaches,
we show that C/EBPα p42 isoform expression from one Cebpa
allele is necessary and sufﬁcient for TRIB2 to cooperate with p30
isoform in AML. The addition of TRIB2 does not further accelerate
AML induced by excess p30 itself, but does accelerate AML when
p42 is present. This suggests that p30 is necessary for TRIB2-
mediated AML induction. The possibility remains that TRIB2 may
convert p42 to p30 to form additional p30 protein but we do not
have any evidence for this here. Under normal physiological
conditions, the protein levels of C/EBPα p42 are greater than p30
protein levels, and when this balance changes toward more p30
levels, it is considered ‘leukaemic’, as observed in leukaemic cell
lines and AML patients.22 We showed that K313 in the C terminus
of C/EBPα p42 was critical for TRIB2-mediated ubiquitination and
proteasomal degradation. This lysine residue is a common
mutation in AML patients (~10% of all C/EBPα mutations) which
results in the duplication of the single lysine to KK leading to
Figure 4. TRIB2 induces binding-dependent K48-speciﬁc ubiquitin-dependent proteasomal degradation of C/EBPα. (a) 293 T cells were
transfected with ubiquitin-HA, TRIB2, C/EBPα and PHMA empty vector control. Ubiquitination assay was performed. Immunoblotting for HA
detects ubiquitination (top IP panel), K63 species of polyubiquitination (second IP panel), K48 species of polyubiquination (third IP panel) and
C/EBPα detects IP protein (bottom IP panel). Immunoblotting for TRIB2 and C/EBPα detects input levels and actin serves as a loading control
(input panels). (b) Ubiquitination assay as outlined in (a) including ubiquitin mutants that do not express the K48 (K48R) ubiquitin polychain
and the K63 (K63R) ubiquitin polychain. (c) Ubiquitination assay as outlined in (a) including C/EBPα mutants; R339A and R343A. (d)
Ubiquitination assay as outlined in (a) including TRIB2 binding mutants R77A, 4-AA (S227A/S229A/S231/K233A) and K322A. Indicated
experiments (b–d) were treated with 10 μM MG-132 for 5 h before ubiquitination assay was performed.
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reduced protein stability.27 Using mouse genetics, it was shown
that this duplication of K313 to K313KK (K313dup) resulted in an
increased proliferation of long-term HSCs leading to an expansion
of premaligant HSCs not seen with the N terminal mutations.23
Our data show that the absence of this lysine by mutation to an
arginine (K313R) abrogates the susceptibility of C/EBPα to
degradation whilst retaining its DNA-binding and transcriptional
activation function. This suggests that TRIB2 degrades C/EBPα p42
via ubiquitination of K313 and duplication of this residue as occurs
in AML patients samples would lead to an increase in C/EBPα p42
degradation in the presence of TRIB2. Patients with K313dup had
TCR rearrangements and CD7 expression,27 lymphoid features
associated with unfavourable outcome and which we have
previously linked with TRIB2 and C/EBPα perturbation.31 Previous
investigation of the combination of a C terminal mutation (K313
duplication) with C/EBPα p30 expression revealed cooperation
and provides a possible explanation for the high prevalence of
one N terminal mutation and one C terminal mutation in ~ 90% of
biallelic C/EBPα-mutant AMLs.23 We propose that the K313dup
mutation in patients contributes to leukaemic transformation by
increasing the susceptibility of C/EBPα to ubiquitination resulting
in increased degradation of C/EBPα p42. A thorough investigation
of TRIB2 function in K313 mutant patient cells would further
validate this.
C/EBPα p42 R339 and K313 amino acids are both present in
p30 yet TRIB2 does not degrade p30. One explanation may be
that the protein complexes containing TRIB2 and C/EBPα p42 or
TRIB2 and p30 are different. Our previous work showed that
TRIB2 binds with COP1 E3 ligase and this interaction is necessary
for C/EBPα p42 degradation.13 Although our peptide mapping
clearly shows speciﬁc sites in both TRIB2 and C/EBPα responsible
for the direct interaction, in the absence of crystal structure
information, we cannot predict further based on our data the
reason why p30 is not targeted by TRIB2 for degradation. Our
Figure 5. TRIB2 ubiquitinates C/EBPα on K313. (a) Ubpred analysis of C/EBPα Ensembl gene ID (ENSRNOG00000010918) showing the
probability of each lysine acting as ubiquitination sites. (b) Schematic diagram displaying the localization of K313 in C/EBPα. (c) Ubiquitination
assay performed with C/EBPα-K313R and TRIB2 in 293 T cells. (d) 293 T cells were co-transfected with the G-CSFR promoter ﬁreﬂy luciferase
constructs containing either the C/EBPα WT (WT G-CSFR) or mutant binding sites (Mut GCSFR), and either an empty PHMA vector or vector
containing C/EBPα or K313R, along with a pRL-TK Renilla luciferase internal control plasmid. Luciferase activity was measured 24 h post
transfection. Bar chart represents reporter luciferase activity for each sample normalized for renilla values, and graphed relative to the control
sample. Results analysed using two-tailed unpaired t test and representative of three independent experiments. (e) Ubiquitination assay
performed with C/EBPα p30 and TRIB2 in 293 T cells.
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data do not discount a role for p30 in TRIB2-mediated AML; p30
presence may, for example, activate a unique set of genes,
inhibit other C/EBPs or bind to a unique set of proteins distinct
from C/EBPα p42 as previously reported.32,33 Indeed, U937 cells
express endogenous C/EBPα but are less sensitive to bortezomib-
induced killing compared with TRIB2-overexpressing cells. This
suggests that TRIB2 must be affecting something in addition to
C/EBPα p42 degradation to provide synergy in AML. Our data
Figure 6. Modulation of TRIB2 levels sensitizes AML cells to cell death induced by proteasome inhibition. (a) Sorted GFP+ cells transduced with
MigR1 control, MigR1-TRIB2, MigR1-VPM or MigR1-C/EBPα retrovirus were treated +/− 10 nM bortezomib for 16–24 h and analysed by ﬂow
cytometry for cell death by 4',6-diamidino-2-phenylindole (DAPI). Graph of fold change in cell death as determined by DAPI-positive cells. Data
displayed are average of three technical replicates, and are representative of two independent experiments. (n.s. denotes not signiﬁcant,
*Po0.05, **Po0.005 by Student's unpaired t test). (b) Sorted GFP+ U937 cells transduced with either Phr or Phr-TRIB2 were treated with
10 nM bortezomib, 500 nM sulfonyl ﬂuoride (SF), 10 nM carﬁlzomib (Cfz) or dimethyl sulfoxide (DMSO) only for 16 h. Cytotoxicity was assessed
by DAPI staining. Representative ﬂuorescence-activated cell sorting (FACS) plots of three independent experiments with two technical
replicates each are shown. (c) Sorted GFP+ U937 cells transduced with either Phr or Phr-TRIB2 were treated for 6 and 8 h with 10 nM
bortezomib or DMSO only (NDC, no drug control) and cell lysates were analysed for C/EBPα expression by western blotting. TRIB2
overexpression was conﬁrmed and tubulin was used as the loading control. Representative of two independent experiments. (d) Schematic
representation of the AML xenograft study. NOD-SCID IL2Rγnull mice (NSG) were transplanted with GFP+hCD45+ U937 cells (n= 6). Each group
was randomized into two groups for treatment with 0.5 mg/kg bortezomib or phosphate-buffered saline (PBS), intraperitoneally, on a regime
schedule of three injections for 16 days. (e) TRIB2 gene knockdown was conﬁrmed at the mRNA level in shTRIB2-U937 cells selected with 2 μg/
ml puromycin for 48 h. Values represent gene expression relative to shctrl-U937 cells and normalized to the reference gene ABL (***Po0.001
by Student's t test). (f) GFP and hCD45 expression in BM were quantiﬁed by ﬂow cytometry as a measure of disease burden in control PBS
(n= 3)- and bortezomib (n= 3)-treated animals and data are shown by representative FACS contour plots (lower panel) and bar graphs (upper
panel) with means± s.d. (*Po0.05 by Student's t test). (g) GFP and hCD45 expression in BM were quantiﬁed by ﬂow cytometry as a measure of
disease burden in shctrl (n= 5) and shTRIB2-U937 (n = 8) mice and data are shown by representative FACS contour plots (lower panel) and bar
graphs (upper panel) with means± s.d. (***Po0.001 by Student's t test).
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support further investigations into the proteomic proﬁling of AML,
with a focus on the involvement of C/EBPα ubiquitination and the
need for an in-depth understanding of the C/EBPα ubiquitin
regulatory pathway in normal versus leukaemic (CEBPA WT and
mutant) settings.
Whilst TRIB2 itself is an oncogene capable of driving AML, the
molecular interaction identiﬁed here between TRIB2 and C/EBPα
leading to dysregulated C/EBPα may have implications in other
models of AML and indeed other cancers. It is clear that the loss of
C/EBPα function is a common occurrence in a number of different
cancer types. What is not clear at this point is the extent of the
involvement of TRIB2 function across different haematological
malignancies and other cancers. To date, cooperation between
TRIB proteins and other oncogenes in AML has been demon-
strated, most often with Hoxa9 and Meis1, suggesting that TRIB2
protein function downstream of commonly occurring oncogenic
events may impact on C/EBPα.34,35 TRIB2 is found elevated in lung
cancer and associated with the E3 ligase TRIM21.30 In liver cancer
cells, TRIB2 associated with other E3 ligases including β-TrCP,
COP1 and Smurf1.36 Thus, there is a strong link between TRIB2 and
the ubiquitin-proteasome system in cancer.
As shown here, high TRIB2-expressing cells are sensitive
to bortezomib-induced cellular toxicity. However, inhibition of
the proteasome also targets other proteins, E3 ligases and their
substrates. We currently have limited knowledge of TRIB2
degradation substrates in general, and indeed knowledge of
TRIB2 as a substrate itself of the ubiquitin-proteasome system in
cancer. This study highlights the important molecular interplay
between TRIB2 and C/EBPα in driving AML, and provides
a framework for further investigations into targeting the
ubiquitin-proteasome system as an emerging cancer therapy.
MATERIALS AND METHODS
Murine BM transduction and transplantation
Cebpaﬂ/ﬂ; Mx1cre were crossed to Cebpa+/p30 (25p30 referred to as ‘L’ allele
previously) to yield Cebpaﬂ/+; Mx1Cre, Cebpaﬂ/p30; Mx1cre, Cebpaﬂ/+ and
Cebpaﬂ/p30. Genotyping and evaluation of Cebpa excision methods
provided in Supplementary Information. Eight- to 14-week-old Cebpaﬂ/ﬂ,
Cebpaﬂ/ﬂ; Mx1Cre, Cebpaﬂ/+, Cebpaﬂ/p30 and Cebpaﬂ/p30; Mx1Cre mice were
pIpC-treated (three injections every second day with 300 ug pIpC) to excise
the Cebpa allele. Resultant genotypes are Cebpaﬂ/ﬂ (expressing solely p42
alleles which can give rise to p30), CebpaΔ/Δ (null for p42 and p30), Cebpaﬂ/+
(expressing solely p42 alleles which can give rise to p30), Cebpaﬂ/p30
(expressing one p42 and one solely p30 allele) and Cebpaﬂ/p30; Mx1Cre
(referred to as CebpaΔ/p30, solely expressing one p30 allele) (Figure 1b). Two
weeks post deletion, CD45.2+ BM cells were collected and either c-Kit-puriﬁed
by magnetic-activated cell sorting (Figure 1a), or total BM (Figures 1c and d)
was transduced with 40% titre-matched retrovirus in the presence of IL3, IL6
and SCF. Freshly transduced unsorted cells (1×106 Figure 1a, 3×106
Figure 1c) were injected by tail vein into lethally irradiated CD45.1+ recipients
generating Cebpaﬂ/ﬂ-TRIB2 (n=12), CebpaΔ/Δ-TRIB2 (n=10), Cebpaﬂ/+-MigR1
(n=9), Cebpaﬂ/+-TRIB2 (n=4), Cebpaﬂ/p30-MigR1 (n=6), Cebpaﬂ/p30-TRIB2
(n=8), CebpaΔ/p30-MigR1 (n=6), CebpaΔ/p30-TRIB2 (n=8). Mice were mon-
itored for 14 months and killed when they developed physical signs of disease
(behavioural changes, laboured breathing, hunched posture) or high white
blood cell counts. For NOD-SCID IL2Rγnull (NSG) mice Xenograft transplanta-
tion, 1×106 U937 cells transduced with shTRIB2-GFP (n=5) or shCtrl-GFP
(N=8) were transplanted into non-irradiated NSG mice via tail vein injection.
To assess bortezomib in vivo efﬁcacy, GFP ctrl transduced U937 cells were
injected, and 5 days post injection, mice were randomized and treated with
either bortezomib (0.5 mg/kg, n=3) or phosphate-buffered saline (intraper-
itoneal administration, n=3) at days 5, 7 and 11 post transplant, which was
well tolerated. Mice were killed on day 16. Animals were maintained at the
University of Copenhagen and the University of Glasgow, housed in
accordance with their respective institutional guidelines. All work was carried
out under the approval of the Danish Ethical Committee and the Home Ofﬁce
of the United Kingdom.
Flow cytometry
Cell suspensions were stained on ice in ﬂuorescence-activated cell sorting
buffer (phosphate-buffered saline pH 7.0, 10 mM Hepes, 0.02% sodium
azide, 0.2% bovine serum albumin). Analytical ﬂow cytometry was
performed on a FACS Canto (Becton Dickinson), sorting was performed
on a FACS Aria II (Becton Dickinson, Oxford, UK) and data were analysed
using FlowJo software (Treestar, Version 10, Ashland, OR, USA). Dead cells
were excluded using 40 ,6-diamidino-2-phenylindole and doublets excluded
based on FSC-H and FSC-A. For apoptosis assays, Annexin V-PE (BD
Biosciences 556422) or Annexin V-APC (BD Biosciences 550475, Oxford, UK)
was used.
Details of vectors, antibodies, cell culture/transfections and real-time
PCR provided in Supplementary Information.
Ubiquitination assay, co-immunoprecipitation and western
blotting
293 T cells transfected with described vectors were treated with 10 μM
MG-132 5 h prior to lysis where indicated. For ubiquitination assay, cells
were lysed in 1% SDS, sonicated and supernatants precleared with
Protein G Sepharose 4 fast ﬂow beads (GE Healthcare, Amersham, UK),
then incubated with C/EBPα antibody overnight. For co-immunopreci-
pitation, cells were lysed in Tris buffer (50 mM Tris pH 7.4, 150 mM NaCl,
1 mM EDTA, 0.5% NP-40, 5% glycerol, with protease and phosphatase
inhibitors) and precleared lysates were incubated with C/EBPα antibody
overnight. Whole cell proteins were isolated by RIPA lysis buffer (50 mM
Tris, pH 8.0, containing 0.5% NP-40, 0.25% sodium deoxycholate,
150 mM NaCl, 1 mM EDTA, 20 mM N-Ethylmaleimide with protease
and phosphatase inhibitors) or by direct lysis (2 × SDS sample buffer).
Details of antibodies provided in Supplementary Information. For GST-IP,
3 mg of indicated cell lysate was added to 50 μl of GSH slurry with pull-
down performed using 25 ug of GST or GST-TRIB2 (details of GST protein
production are provided in Supplementary Information). Densitometric
analysis of bands was carried out with ImageJ Software. n⩾ 3 for all
co-immunoprecipitation and ubiquitination assays.
Spot synthesis of peptides and overlay analysis
Peptide arrays were performed as previously described37,38 (n= 2) and
details are provided in Supplementary Information. Brieﬂy, peptide arrays
encompassing the C terminus of C/EBPα and the entire TRIB2 protein were
generated and incubated with GST-TRIB2 or puriﬁed C-teminal C/EBPα
(Genway, San Diego, CA, USA). Arrays were incubated with secondary
antibodies and bound protein detected using ECL or the Odyssey Infrared
Imaging System (LI-COR Biosciences, Cambridge, UK).
Statistical analysis
Statisitcal analysis and graphing was performed on GraphPad Prism
(version 5.03). When comparing two groups, an unpaired, two-tailed
Student’s t test was used. The Log-rank test was used to compare groups
on a survival curves. Statistical signiﬁcance was attained when the P value
⩽ 0.05 and was indicated in the related ﬁgure legends and graphs.
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